Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1Z)-2-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.39
(2-methylprop-2-en-1-yl)hydrazine
-
(2-phenylprop-2-en-1-yl)hydrazine
-
(2E)-2-[(1H-indol-3-yl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 43% inhibition
-
(2E)-2-[(2-chloro-3-methoxyphenyl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 17% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
0.1 mM, pH 7.4, 32% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
-
-
(2E)-2-[1-(2,4,5-trifluorophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 23% inhibition
-
(2E)-2-[1-(2,4-dihydroxy-5-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 30% inhibition
-
(2E)-2-[1-(4-chloro-3-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 13% inhibition
-
(2E)-2-[1-(4-iodophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 25% inhibition
-
(2E)-2-[1-[3-(dihydroxyamino)-4-methoxyphenyl]ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 19% inhibition
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
-
-
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
-
-
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
IC50: 0.001mM, at 0.15 mM kynuramine
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one
-
(5S)-5-(aminomethyl)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
-
(E)-5-(3-chlorostyryl)isatin
-
(E)-5-(3-fluorostyryl)isatin
-
(N-cyclopropyl-alpha-methylbenzylamine)
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
-
-
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
-
-
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methyl-4-phenylpyridinium
-
1-phenylcyclopropylamine
the inhibitor forms an irreversible flavin adduct
2,4-dichlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.92
2,4-dichlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.03
2,4-dimethoxy-5-hydroxybenzaldehyde
IC50: 0.042 mM, monoamine oxidase A
2,6-dimethoxyphenol
IC50: 0.0624 mM, monoamine oxidase A
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
-
-
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
2-(aminooxy)-1-phenylethanol
-
2-hydrazinyl-4-(3-nitrophenyl)-1,3-thiazole
0.1 mM, pH 7.4, 6% inhibition
-
2-methoxyphenol
IC50: 0.175 mM, monoamine oxidase A
2-methyl-5-methylaniline
IC50: 0.15 mM, monoamine oxidase A
2-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.45
2-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.18
3,4-dimethoxyaniline
IC50: 0.131 mM, monoamine oxidase A
3,4-dimethoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.88
3,4-dimethoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.52
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
-
-
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-methoxyphenol
IC50: 0.024 mM, monoamine oxidase A
4-(2,4-dichlorophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 25% inhibition
-
4-(2-bromophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 24% inhibition
-
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
-
-
4-chlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.42
4-chlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
IC50: 0.0134 mM, monoamine oxidase A
4-Hydroxy-3-methoxybenzylamine
IC50: 0.13 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenethyl alcohol
IC50: 0.18 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenyl acetone
IC50: 0.0302 mM, monoamine oxidase A
4-methoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.72
4-methoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.3
4-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.69
4-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.67
4-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.0
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
-
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
-
benzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
pKi: 8.14
benzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 5.92
cis-2,4,5-trimethoxypropenylbenzene
IC50: 0.142 mM, monoamine oxidase A
cis-N-benzyl-2-methoxycyclopropylamine
high inhibitory action, exhibits a poor isozyme selectivity
-
cyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 7.69
cyclopentanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
pKi: 6.85
ethyl 4-hydroxy-3-methoxycinnamate
IC50: 0.0247 mM, monoamine oxidase A
ethyl-4-hydroxy-3-methoxyphenylacetate
IC50: 0.081 mM, monoamine oxidase A
eugenol
IC50: 0.0344 mM, monoamine oxidase A
eugenol methyl ether
IC50: 0.11 mM, monoamine oxidase A
Harmane
an MAO A specific reversible inhibitor
metamphetamine
i.e. N-methyl-1-phenyl-2-propanamine
-
metanephrine
IC50: 0.252 mM, monoamine oxidase A
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
IC50: 0.09 mM, at 0.15 mM kynuramine
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
IC50: 0.0005 mM, at 0.15 mM kynuramine
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-3-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-3, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-A
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-([(5S)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-([(5S)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
N-benzyl-12-isothiocyanato-N-methyldodecan-1-amine
irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B
N-phenyl-1H-indazole-5-carboxamide
-
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
-
N1,N12-dibenzyldodecane-1,12-diamine
-
N1-(3-aminopropyl)-N4-(3-((naphthalen-2-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((pyridin-3-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((thiophen-2-ylmethyl)amino)propyl)butane-1,4-diamine
mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B
norharman
inhibition of MAO A
o-eugenol
IC50: 0.101 mM, monoamine oxidase A
p-(propylthio)-phenylisopropylamine
-
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
pirlindole
an MAO A specific reversible inhibitor
trans-2,4,5-trimethoxypropenylbenzene
IC50: 0.124 mM, monoamine oxidase A
trans-2-phenylcyclopropylamine
2-PCPA
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
(+)-amphetamine
reversible competitive inhibitor
(+/-)-6-hydroxytrypargine
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata, synthesized by reaction of 5-hydroxytryptamine hydrochloride with N-(3-[1,3]dioxolan-2-yl-propyl)-guanidine sulfate, overview
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
-
-
(1R,2R)-(-)-psi-ephedrine
(1S,2S)-(+)-psi-ephedrine
(2-methylprop-2-en-1-yl)hydrazine
-
(2-phenylprop-2-en-1-yl)hydrazine
-
(2E)-1,3-diphenylprop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
-
-
(2E)-1-(4-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
(2E)-1-[4-(benzyloxy)phenyl]-3-(4-chlorophenyl)prop-2-en-1-one
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-(3-hydroxyphenyl)ethanamide
-
-
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-phenylethanamide
-
-
(2E)-2-[(1H-indol-3-yl)methylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 10% inhibition
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
-
-
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
-
-
(2E)-2-[1-(2,4-dihydroxy-5-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 8% inhibition
-
(2E)-2-[1-(4-chloro-3-nitrophenyl)ethylidene]hydrazine-1-carboxamide
0.3% inhibition
-
(2E)-2-[1-[3-(dihydroxyamino)-4-methoxyphenyl]ethylidene]hydrazine-1-carboxamide
0.1 mM, pH 7.4, 37.2% inhibition
-
(2E)-3-(2-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
-
(2E)-3-(3-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
-
inhibits MAO-A and MAO-B
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
competitive inhibition
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
-
-
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
-
-
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
-
(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
-
i.e. safinamide, a potent selective and reversible MAO-B inhibitor, occurs in two polymorphic forms. Both forms are orthorhombic and regarded as conformational polymorphs due to the differences in the orientation of the 3-fluorobenzyloxy and propanamide groups. Both structures pack with layers in the ac plane, structure overview
(3E)-7-hydroxy-3-[(4-methoxyphenyl)methylidene]-2,3-dihydro-4H-1-benzopyran-4-one
-
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
-
-
(5E)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(3-bromobenzylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-(4-chlorobenzylidene)-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-2,5-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
-
(5E)-5-benzylidene-2-imino-1,3-thiazolidin-4-one
-
-
(5E)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5E)-5-[(3,5-dibromo-4-hydroxycyclohexa-1,4-dien-1-yl)methylidene]-1,3-thiazolidine-2,4-dione
-
-
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
L136468, binding mode, overview
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
A6355
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
L136662
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
AS605240, binding mode, overview
(aminomethyl)trimethylsilane
-
-
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-3-(2-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3,4-dimethoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(3-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(diethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-(dimethylamino)benzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-chlorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-fluorobenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(10-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(5-(1,2,3,4-tetrahydroacridin-9-ylamino)pentyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(8-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methoxybenzylidene)-7-(9-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-(4-methylbenzylidene)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-5-(3-chlorostyryl)isatin
-
(E)-5-(3-fluorostyryl)isatin
-
(E)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(3,4,5-trimethoxybenzylidene)chroman-4-one
-
(E)-7-(6-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)-3-(4-methoxybenzylidene)chroman-4-one
-
(E)-7-(8-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)3-(4-methoxybenzylidene)chroman-4-one
-
(E)-8-(3-chlorostyryl)caffeine
(E)-8-styrylcaffeine
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
-
-
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
-
-
(R)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(R)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(R)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(R)-deprenyl
i.e. selegiline, a MAO-B inhibitor
(S)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
(S)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
(S)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,2,3,4-tetrahydroacridin-9-amine
-
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3-dimethyl-5-nitro-1H-indazole
-
-
1,4-diphenyl-1,3-butadiene
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
-
-
1-(4-chlorobutyl)-5-nitro-1H-indazol-3-ol
-
-
1-(4-guanidinobutoxy)-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
1-benzyl-5-nitro-1H-indazol-3-ol
-
-
1-guanidino-6-hydroxy-3,5-dihydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
-
-
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
-
-
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
-
-
1-methyl-5-nitro-1H-indazol-3-ol
-
inhibits MAO-B by 34% at 0.015 mM
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
-
1-O-n-octyl-beta-D-glucopyranoside
-
at concentrations well below the critical micelle concentration
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
2,2'-dipyridyl disulfide
-
-
2,4-dichloro-N'-(nonan-5-yl)benzohydrazide
-
-
2,4-dimethoxy-5-hydroxybenzaldehyde
IC50: 0.39 mM
2,6-dimethoxyphenol
IC50: above 0.5 mM, monoamine oxidase B
2-(2,4-dichlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
6164872
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
6163851
2-(2-benzofuranyl)-2-imidazoline
at micromolar concentrations, to a site distinct from the active site on at least two forms of the pure enzyme, probably corresponding to oxidised and reduced enzyme states
2-(2-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-ethoxylpyridin-3-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,4,5-trimethoxyphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3,5-dimethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(3-methylphenyl)-4-(butoxycarbonylethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-(4,5-dihydroimidazol-2-yl)-isoquinoline
reversible non-competitive/mixed inhibitor
2-(4,5-dihydroimidazol-2-yl)-quinoline
reversible non-competitive/mixed inhibitor
2-(4-bromophenyl)cyclopropanamine
-
2-(4-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-ethylphenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-ethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-fluorophenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(4-methoxyphenyl)cyclopropanamine
-
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
-
-
2-(5,7-dibromobenzofuran-2-yl)-imidazoline
reversible non-competitive/mixed inhibitor
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
2-(aminooxy)-1-phenylethanol
-
2-(benzo[d][1,3]dioxol-5-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
-
-
2-(naphthalen-1-yl)cyclopropanamine
-
2-(naphthalen-2-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-(thiophen-3-yl)cyclopropanamine
-
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-ethoxy-N'-(nonan-5-yl)nicotinohydrazide
-
-
2-hydrazinyl-4-(3-nitrophenyl)-1,3-thiazole
0.1 mM, pH 7.4, 10% inhibition
-
2-methoxyphenol
IC50: above 0.5 mM, monoamine oxidase B
2-methyl-5-methylaniline
IC50: above 0.5 mM
2-oxo-2H-chromen-7-yl benzenesulfonate
-
2-oxo-N-(2,3,5,6-tetrafluoropyridin-4-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(pentafluorophenyl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(propan-2-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-[3-(trifluoromethyl)phenyl]-2H-chromene-3-carboxamide
-
-
2-oxo-N-[4-(propan-2-yl)phenyl]-2H-chromene-3-carboxamide
-
-
2-phenyl-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
2-phenylcyclopropylamine
moderate isoenzyme selectivity
2-Phenylethylamine
time-dependent, slowly reversible suicide inhibition. Addition of 2-phenylethylamine (10mM) to the enzyme results in immediate bleaching of the absorbance peak at 460 nm, a consequence of rapid reduction of the flavin cofactor by 2-phenylethylamine at steady state
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholine oxalate
-
-
2-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dien-1-yl]-3,5,7-trimethyl-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[4-(trifluoromethyl)phenyl]cyclopropanamine
-
2-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
3,4,5-trimethoxy-N'-(nonan-5-yl)benzohydrazide
-
-
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
-
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl 4-methoxybenzenesulfonate
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl benzenesulfonate
-
3,4-dimethyl-7-(2-oxo-2-phenylethoxy)-2H-chromen-2-one
-
3,4-dimethyl-7-[(3-nitrobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-[(pentafluorobenzyl)oxy]-2H-chromen-2-one
-
3,4-dimethyl-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one
-
3,5,7-trimethyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
-
-
3,5-dimethyl-N'-(nonan-5-yl)benzohydrazide
-
-
3-(2-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-naphthyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(2-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-fluorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(3-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-hydroxyphenyl)-2-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoic acid
-
-
3-(4-hydroxyphenyl)propionic acid
-
-
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
-
-
3-(4-methoxybenzyl)-7-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyloxy)chroman-4-one
-
3-(4-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(4-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
3-(5-oxo-5H-indeno[1,2-c]pyridazin-3-yl)benzonitrile
-
3-(benzyloxy)-5-nitro-1H-indazole
-
-
3-(benzyloxy)-6a,10a-dihydro-6H-benzo[c]chromen-6-one
-
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
-
-
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
-
-
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-benzyl-5-nitro-1H-indazole
-
-
3-benzyl-5H-indeno[1,2-c]pyridazin-5-one
-
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
-
-
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
-
-
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
-
-
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
3-hydroxyphenylacetic acid
-
-
3-methoxy-1-methyl-5-nitro-1H-indazole
-
inhibits MAO-B by 52% at 0.015 mM
3-methoxy-5-nitro-1H-indazole
-
-
3-methyl-5-nitro-1H-indazole
-
-
3-methyl-8-(4,4,4-trifluoro-butoxy)indeno[1.2-c]pyridazin-5-one
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
-
3-[(5E)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]propanenitrile
-
-
3-[(5E)-5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
R598127
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
-
-
3-[(E)-2-phenylvinyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-[4-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
4-(2,4-dichlorophenyl)-2-hydrazinyl-1,3-thiazole
0.1 mM, pH 7.4, 31% inhibition
-
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
-
-
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-([6-[(4-cyanophenyl)methoxy]-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
-
-
4-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
4-ethyl-N'-(nonan-5-yl)benzohydrazide
-
-
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
IC50: 0.0089 mM, monoamine oxidase B
4-Hydroxy-3-methoxybenzylamine
IC50: 0.382 mM, monoamine oxidase B
4-hydroxyphenylacetic acid
-
-
4-oxo-4H-chromene-3-carboxylic acid
-
specific for MAO-B
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
-
-
4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
-
-
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]methyl]benzonitrile
-
-
4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid
-
-
5,7-diethyl-3-methyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
5-(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
i.e. rosiglitazone
5-(4-hydroxy-3,5-dimethylbenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
-
-
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. ciglitazone
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. troglitazone
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
i.e. pioglitazone, docking of R-pioglitazone in the substrate cavity of MAO-B
5-(aminomethyl)-3-aryl-2-oxazolidinones
-
-
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
-
-
5-nitro-1-(pyridin-2-ylmethyl)-1H-indazol-3-ol
-
-
5-nitroindazole
-
inhibits MAO-B by 98.5% at 0.015 mM
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-1,3-thiazolidine-2,4-dione ammoniate (1:1)
-
-
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-2-imino-1,3-thiazolidin-4-one
-
-
6-hydroxy-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
6-nitroindazole
-
inhibits MAO-B by 89% at 0.015 mM, also inhibits MAO-A
6-[(3-iodophenyl)methoxy]-3-[(3-iodophenyl)methyl]quinazolin-4(3H)-one
-
-
6-[(3-iodophenyl)methoxy]quinazolin-4(3H)-one
-
-
6-[(4-fluorophenyl)methoxy]-3-[(4-fluorophenyl)methyl]quinazolin-4(3H)-one
-
-
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(anilinomethyl)-2H-chromen-2-one
-
7-(benzylamino)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-2H-chromen-2-one
-
7-(benzyloxy)-3,4-dimethyl-2H-chromen-2-one
-
7-(benzyloxy)-4-methyl-2H-chromen-2-one
-
7-(benzyloxy)-4-phenyl-2H-chromen-2-one
-
7-nitroindazole
-
inhibits MAO-B by 35% at 0.015 mM
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
-
8-(3-chloro)styrylcaffeine
-
-
8-(3-chlorostrylyl)caffeine
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
8-(3-chlorostyryl)caffeine
monoamine oxidase B
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
amitriptyline
competive inhibition with 2-phenylethylamine as substrate
befloxatone
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site
benzhydrylidene-prop-2-ynyl-amine
-
-
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
beta-carbolines
-
competitive reversible and potent inhibitor
Caffeine
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
cinnamyl alcohol
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
cis-2,4,5-trimethoxypropenylbenzene
IC50: 0.362 mM, monoamine oxidase B
cis-N-benzyl-2-methoxycyclopropylamine
high inhibitory action, exhibits a poor isozyme selectivity
-
cyanidin
-
competitive interaction of cyanidin with MAO A plus a mixed competitive and non-competitive mode of interaction of cyanidin with MAO B
cyanidin-3,5-diglucoside
-
-
cyanidin-3-O-beta-D-galactoside
-
-
cyanidin-3-O-beta-D-glucoside
-
mixed competitive and non-competitive mode of interaction with both enzyme isozymes
cyanidin-3-O-beta-D-rutinoside
-
-
delphinidin-3-O-beta-D-glucoside
-
-
di(2-hydroxyethyl)methyldodecylammonium
reversible competitive inhibitor
di(2-hydroxyethyl)methyldodecylammonium ion
-
a biocide, inhibits MAO-B
epigallocatechin gallate dimer
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
esuprone
-
inhibits MAO-A reversibly
ethyl 4-hydroxy-3-methoxycinnamate
IC50: 0.0057 mM, monoamine oxidase B
ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate
-
-
eugenol
IC50: 0.288 mM, monoamine oxidase B
eugenol methyl ether
IC50: 0.269 mM, monoamine oxidase B
harmalol
-
identification by HPLC-ESI-mass spectrometry
harmol
-
identification by HPLC-ESI-mass spectrometry
indol -2,3-dione
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
isoproniazid
-
inhibits MAO-A and MAO-B irreversibly
KF-17837
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
KW-6002
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
L-deprenyl
inhibition of MAO A and MAO B
lamotrigine
its in vivo MAO-B inhibiting effect might contribute in part to its antidepressant activity
LU-53439
-
inhibits MAO-B reversibly
malvidin 3-O,5-O-di-beta-D-glucoside
-
-
malvidin-3-O-beta-D-galactoside
-
-
malvidin-3-O-beta-D-glucoside
-
-
metamphetamine
i.e. N-methyl-1-phenyl-2-propanamine
-
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
-
-
N'-(2-cyanoethyl)-4-ethylbenzohydrazide
-
-
N'-(nonan-5-yl)-2-naphthohydrazide
-
-
N'-(nonan-5-yl)benzo[d][1,3]dioxole-5-carbohydrazide
-
-
N'-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carbohydrazide
-
-
N-((4-isopropylphenyl)-2-oxo-2H-chromene-3-carboxamide)-amide
-
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
i.e. ParSL-2, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-B
N-(2,3-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-difluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-4-chlorobenzamide
-
N-(2-aminoethyl)-aryl-carboxamide
-
N-(2-aminoethyl)-p-chlorobenzamide
N-(2-benzylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-chloro-6-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-1H-indol-5-yl)benzamide
-
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
-
N-(2-methyl-6-chlorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-6-chlorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide
tight-binding mechanism of inhibition
-
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
-
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
-
N-(3,4-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-8-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-8-methyl-2-oxo-7-(2-phenylethyl)-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethyl-2-oxo-2H-chromen-7-yl)benzamide
-
N-(3,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
NTZ-1441
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
-
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
NTZ-1442
N-(3-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-trifluoromethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}phenyl)acetamide
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methanesulfonylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(biphenyl-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(butan-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
-
-
N-(prop-2-ynyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-12-isothiocyanato-N-methyldodecan-1-amine
irreversible inhibition with respect to isoform MAO-A, competitive inhibition with respect to isoform MAO-B
N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methylprop-2-yn-1-amine
-
i.e. pargyline
N-benzylprop-2-yn-1-amine
-
-
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclohexyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isobutyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isopropyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-phenyl-1H-indazole-5-carboxamide
-
N-propargyl-1(R)-aminoindan
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-propargyl-l(R)-aminoindan
i.e. rasagiline. N-Propargyl-l(R)-aminoindan is well tolerated and effective in the treatment of early Parkinson's disease and as adjunctive treatment in levodopa-treated patients with Parkinson's disease experiencing motor fluctuations
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
-
i.e. clorgiline
N-[4-(methylsulfonyl)phenyl]-2-oxo-2H-chromene-3-carboxamide
-
-
N1,N12-dibenzyldodecane-1,12-diamine
-
N1-(3-aminopropyl)-N4-(3-((naphthalen-2-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((pyridin-3-ylmethyl)amino)propyl)butane-1,4-diamine
-
N1-(3-aminopropyl)-N4-(3-((thiophen-2-ylmethyl)amino)propyl)butane-1,4-diamine
mixed-type reversible inhibition with respect to isoform MAO-A and MAO-B
o-eugenol
IC50: above 0.5 mM, monoamine oxidase B
oleamide
-
inhibits MAO B
p-nitrobenzylamine
substrate for wild-type enzyme, competitive inhibitor for mutant enzyme Y435L
ParSL
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
pelargonidin 3-O,5-O-di-beta-D-glucoside
-
-
peonidin-3-O-beta-D-glucoside
-
-
phentermine
i.e. 2-methyl-1-phenyl-2-propanamine
phenylhydrazine
weak binding
rhodiocyanoside A
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rhodioloside B
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rosiridin
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
salidroside
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
tetrahydroharmine
-
identification by HPLC-ESI-mass spectrometry
tetrindole
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
trans,trans-farnesol
monoamine oxidase B
trans-2,4,5-trimethoxypropenylbenzene
IC50: 0.338 mM, monoamine oxidase B
trans-2-phenylcyclopropylamine
trans-trans-1,4-diphenyl-1,3-butadiene
-
-
triandrin
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
tyrosol
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
R598119
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
[Cu(2-[4-[bis(4-fluorophenyl)methyl]pipera-zin-1-yl]acetic acid)2(H2O)]
the complex 1 is a potent MAO-B inhibitor
-
2-phenylcyclopropylamine
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
2-phenylcyclopropylamine
moderate isoenzyme selectivity
Clorgyline
-
Clorgyline
an acetylenic inhibitor, addition of it results in the conversion of the oxidized flavin cofactors to their respective N(5) flavocyanine adducts
Clorgyline
irreversible inhibitor of isoform MAO A
Clorgyline
irreversible inhibitor of isoform MAO-A
D-amphetamine
-
D-amphetamine
competitive inhibition
D-amphetamine
a nonselective reversible MAO inhibitor, inhibits the MAO A S209E mutant with much lower affinity, 160fold and 20fold, respectively, than the wild-type enzyme
D-amphetamine
i.e. 1-phenyl-2-propanamine
harman
-
harman
inhibition of MAO A
isatin
-
isatin
competitive inhibitor
isatin
monoamine oxidase A
isatin
a nonselective reversible MAO inhibitor, inhibits the MAO A S209E mutant with much lower affinity, 160fold and 20fold, respectively, than the wild-type enzyme
methylene blue
-
moclobemide
-
moclobemide
the MAO inhibitor is promising in the therapeutic management of post-traumatic stress disorder and panic disorder
moclobemide
reversible inhibitor of isoform MAO-A
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
i.e. ParSL-1, a TEMPO-conjugated pargyline analogue
Pargyline
-
Pargyline
construction of three TEMPO-conjugated pargyline analogues ParSL-1, ParSL-2, and ParSL-3, which differ in flexibility and substituent positions of the linkers connecting the TEMPO group to the pargyline phenyl ring. The variations in conformational flexibility and substituent position have profound effects in tuning the specificities of these analogues toward the MAO isoforms, inhibitor synthesis, overview
phentermine
-
phentermine
binding to the S209E mutant is reduced by 13fold compatred to the wild-type MAO A
phentermine
i.e. 2-methyl-1-phenyl-2-propanamine
rasagiline
-
safinamide
-
tetrindole
-
tetrindole
an MAO A specific reversible inhibitor
toloxatone
-
(1R,2R)-(-)-psi-ephedrine
-
IC50 for soluble enzyme: 5.03 mM, IC50 for immobilized enzyme: 88 mM, monoamine oxidase B
(1R,2R)-(-)-psi-ephedrine
-
IC50 for soluble enzyme: 5.35 mM, IC50 for immobilized enzyme: 14.86 mM, monoamine oxidase A
(1S,2S)-(+)-psi-ephedrine
-
IC50 for soluble enzyme: 0.88 mM, IC50 for immobilized enzyme: 1.77 mM, monoamine oxidase A
(1S,2S)-(+)-psi-ephedrine
-
IC50 for soluble enzyme: 10 mM, IC50 for immobilized enzyme: 234 mM, monoamine oxidase B
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
-
(2E)-1-(4-methoxyphenyl)-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
competitive inhibition
(E)-8-(3-chlorostyryl)caffeine
a specific reversible inhibitor of MAO-B
(E)-8-(3-chlorostyryl)caffeine
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(R)-amphetamine
-
IC50 for soluble enzyme: 0.0311 mM, IC50 for immobilized enzyme: 0.0991 mM, monoamine oxidase A
(R)-amphetamine
-
IC50 for soluble enzyme: 0.246 mM, IC50 for immobilized enzyme: 4.03 mM, monoamine oxidase B
(R,S)-amphetamine
-
IC50 for soluble enzyme: 0.0031 mM, IC50 for immobilized enzyme: 0.0244 mM, monoamine oxidase A
(R,S)-amphetamine
-
IC50 for soluble enzyme: 0.0625 mM, IC50 for immobilized enzyme: 3 mM, monoamine oxidase B
1,4-diphenyl-1,3-butadiene
-
-
1,4-diphenyl-1,3-butadiene
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
1,4-diphenyl-2-butene
-
-
1,4-diphenyl-2-butene
-
inhibits by covalent binding to the flavin ring, reversible inhibitor of MAO-B
1,4-diphenyl-2-butene
monoamine oxidase B
1,4-diphenyl-2-butene
-
a component of polystyrene plasticware
amphetamine
-
-
amphetamine
-
a competitive inhibitor of MAO-A
benzylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
benzylhydrazine
the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
brofaromine
-
-
brofaromine
-
inhibitor of MAO-A
brofaromine
-
inhibits MAO-A reversibly
Clorgyline
-
Clorgyline
-
irreversible inhibitor
Clorgyline
-
IC50: 1.2 nM
Clorgyline
-
IC50: 0.000014 mM
Clorgyline
-
IC50: 0.00042 mM
Clorgyline
inhibition of MAO A and MAO B
Clorgyline
-
the irreversible MAO-A inhibitor shows anti-oncogenic and pro-differentiation effects on high grade prostate cancer cells, inhibition of MAO-A might restore differentiation and reverse the aggressive behavior of high grade prostate cancer cells, overview. The inhibitor has significant gene regulatory effects on the beta-catenin and ERBB2 pathways in vivo, overview
Clorgyline
-
inhibitor of MAO-A
Clorgyline
-
inhibits both MAO-A and MAO-B
Clorgyline
-
inhibits MAO-A irreversibly
Clorgyline
isoform MAO-A, 4.1% inhibition at 0.1 mM
D-amphetamine
-
-
D-amphetamine
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
Deprenyl
-
-
Deprenyl
-
IC50: 0.0023 mM
Deprenyl
-
IC50: 0.020 mM
Deprenyl
-
an acetylenic compound that forms covalent adducts with the N5 of the covalent FAD of MAO-B, pharmacologically inert as MAO-A inhibitor
Harmaline
-
-
Harmaline
-
identification by HPLC-ESI-mass spectrometry. Potent reversible and strong inhibition of MAO-A, poor inhibition of MAO-B, from seeds
Harmaline
-
MAOI harmaline significantly reduces 5-MeO-DMT depletion and increases bufotenine formation in human hepatocytes
harmine
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
harmine
-
identification by HPLC-ESI-mass spectrometry. Potent reversible and strong inhibition of MAO-A, poor inhibition of MAO-B, from seeds
Iproniazide
-
-
Iproniazide
-
inhibitor of MAO-A and MAO-B
Iproniazide
-
inhibits both MAO-A and MAO-B
isatin
-
-
isatin
competitive inhibitor
isatin
monoamine oxidase B
isatin
-
inhibitor of MAO-B
isatin
-
non-specific reversible inhibitor
isocarboxazide
-
-
isocarboxazide
-
inhibitor of MAO-A and MAO-B
isocarboxazide
-
inhibits MAO-A and MAO-B irreversibly
lazabemide
-
-
lazabemide
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
lazabemide
-
inhibitor of MAO-B
lazabemide
-
inhibits MAO-B reversibly
methylene blue
-
-
moclobemide
-
-
moclobemide
the MAO inhibitor is promising in the therapeutic management of post-traumatic stress disorder and panic disorder
moclobemide
-
inhibitor of MAO-A
moclobemide
-
inhibits MAO-A reversibly
moclobemide
-
specific for MAO-A
mofegiline
mechanism-based irreversible, competitive inhibition versus substrate of MAO-B with a 1:1 molar stoichiometry, also competitively inhibits MAO-A. Effects on UV absorption spectra of flavin, and inhibitor-bound enzyme structure, overview
mofegiline
-
a vinyl fluoroamine
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
i.e. ParSL-1, a TEMPO-conjugated pargyline analogue
N-(2-aminoethyl)-p-chlorobenzamide
-
-
N-(2-aminoethyl)-p-chlorobenzamide
-
inhibits by covalent binding to the flavin ring
norharman
-
-
norharman
-
competitive reversible and potent inhibitor
norharman
inhibition of MAO B
Pargyline
-
-
Pargyline
-
MAO-B sensitive
Pargyline
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
Pargyline
construction of three TEMPO-conjugated pargyline analogues ParSL-1, ParSL-2, and ParSL-3, which differ in flexibility and substituent positions of the linkers connecting the TEMPO group to the pargyline phenyl ring. The variations in conformational flexibility and substituent position have profound effects in tuning the specificities of these analogues toward the MAO isoforms, inhibitor synthesis, overview
Pargyline
-
inhibitor of MAO-A and MAO-B
Pargyline
-
inhibits MAO-A and MAO-B irreversibly
Phenelzine
-
-
Phenelzine
concentration-dependent inhibition
Phenylethylhydrazine
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
Phenylethylhydrazine
the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
R-(-)-deprenyl
-
-
R-(-)-deprenyl
-
highly active with MAO-B
R-(-)-deprenyl
-
inhibitor of MAO-B
R-(-)-deprenyl
-
inhibits both MAO-A and MAO-B
R-(-)-deprenyl
-
inhibits MAO-B irreversibly
rasagiline
-
-
rasagiline
i.e. N-propargyl-1-R-aminoindan. Irreversible MAO B inhibitor. Rasagiline is initiated at 1 mg once-daily dosage as monotherapy in early Parkinsons disease patients and at 0.5-1 mg once-daily as adjunctive to levodopa in advanced Parkinsons disease patients. Rasagiline treatment is not associated with cheese effect and up to 20 mg per day is well tolerated. In Parkinsons disease patients with hepatic impairment, rasagiline dosage should be carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and coadministration with certain antidepressants and opioids should be avoided. This drug provides an additional tool for Parkinsons disease therapy improvement in motor performance
rasagiline
-
an acetylenic compound that forms covalent adducts with the N5 of the covalent FAD of MAO-B, pharmacologically inert as MAO-A inhibitor. A rasagiline analog methylated on the amino moiety of the propargyline chain connecting the inhibitor to the flavin loses this characteristic specificity for MAO-B
rasagiline
-
inhibitor of MAO-B
rasagiline
-
inhibits MAO-B irreversibly
rasagiline
irreversible inhibitor of isoform MAO-B
safinamide
-
-
safinamide
binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
safinamide
-
a very specific MAO B non-covalent inhibitor, may function effectively as a neuroprotectant
safinamide
reversible inhibitor of isoform MAO-B
selegiline
-
-
selegiline
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
selegiline
-
an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression
selegiline
the MAO B inhibitor is efficacious in the therapeutic management of Parkinson's disease
selegiline
irreversible inhibitor of isoform MAO B
selegiline
irreversible inhibitor of isoform MAO-B
toloxatone
-
-
toloxatone
-
inhibitor of MAO-A
toloxatone
-
inhibits MAO-A reversibly
trans-2-phenylcyclopropylamine
-
inhibits by covalent binding to the flavin ring
trans-2-phenylcyclopropylamine
2-PCPA
tranylcypromine
-
-
tranylcypromine
inhibition of MAO-B
tranylcypromine
inactivation of recombinant human MAO-B with tranylcypromine results in the formation of a high affinity I2 site on the enzyme, measured as an increase in binding of 2-(2-benzofuranyl)-2-imidazoline. Inhibition by tranylcypromine results in displacement of Q206 and closure of the I199 gate
additional information
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
coffee contains compounds acting as reversible and competitive inhibitors for MAO A
-
additional information
coffee contains compounds acting as reversible and competitive inhibitors for MAO A
-
additional information
-
coffee contains compounds acting as reversible and competitive inhibitors for MAO A
-
additional information
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
-
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
-
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
-
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
successful SRY knockdown inhibits MAO A catalytic activity by 45%
-
additional information
-
successful SRY knockdown inhibits MAO A catalytic activity by 45%
-
additional information
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine
-
additional information
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine
-
additional information
-
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine
-
additional information
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
-
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
no inhibition by catechin and cyanidin
-
additional information
no inhibition by catechin and cyanidin
-
additional information
-
no inhibition by catechin and cyanidin
-
additional information
-
cigarette smoke is a potent inhibitor of MAO-A. Inhibition is partly reversible, competitive. beta-Carboline alkaloids from cigarette smoke acting as potent reversible inhibitors may contribute to the MAO reduced activity produced by tobacco smoke in smokers
-
additional information
-
cigarette smoke is a potent inhibitor of MAO-B. Inhibition is partly reversible, competitive. Veta-carboline alkaloids from cigarette smoke acting as potent reversible inhibitors may contribute to the MAO reduced activity produced by tobacco smoke in smokers
-
additional information
-
no inhibition by Mesobuthus gibbosus venom peptide
-
additional information
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
-
coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
no inhibition by 4-hydroxy-3-methoxyophenylethyl alcohol, ethyl-4-hydroxy-3-methoxyphenylacetate, metanephrine, 3,4-dimethoxy-5-hydroxybenzaldehyde and 3-methoxyphenol
-
additional information
no inhibition by 4-hydroxy-3-methoxyophenylethyl alcohol, ethyl-4-hydroxy-3-methoxyphenylacetate, metanephrine, 3,4-dimethoxy-5-hydroxybenzaldehyde and 3-methoxyphenol
-
additional information
recombinant enzyme obtained from a Baculovirus expression system is validated as convenient enzyme source for MAO B inhibitor screening
-
additional information
-
recombinant enzyme obtained from a Baculovirus expression system is validated as convenient enzyme source for MAO B inhibitor screening
-
additional information
evaluation of the application of UCSF DOCK to screen for inhibitors of MAO-B
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
-
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
inhibitors of MAO-B can be adjunctive drugs to levodopa. Neuroprotective and anti-Parkinsonian effects of A2A receptor antogonistic drugs, overview
-
additional information
Rhodiola rosea roots have potent antidepressant activity by inhibiting MAO A and may also find application in the control of senile dementia by their inhibition of MAO B, no inhibition of both isozymes by rosavin, rosarin, and rosin
-
additional information
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
-
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
-
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
-
2-arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, as monoamine oxidase inhibitors, molecular docking using crystal structures of human MAO-B, PDB ID 1S3E, and MAO-A, PDB ID 2BXS, overview
-
additional information
-
25 anthocyanidins, anthocyanidin-3-glycosides, anthocyanidin-3,5-diglucosides, proanthocyanidins, and phenolic metabolites are examined as MAO inhibitors, overview
-
additional information
-
4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains as enzyme inhibitors. Design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis, and antitumor activities against human lung cancer A-549 and human prostate cancer PC-3 cell lines, overview
-
additional information
-
cycloalkylidenhydrazothiazole derivative inhibitors derived from N1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole, molecular modeling, overview. No inhibition by 13, 42, and 44
-
additional information
design and synthesis of a series of indole and benzofuran derivatives, and evaluation as reversible inhibitors of the two MAO isozymes MAO-A and MAO-B, most compounds are selective MAO-B inhibitors, ligand docking study, overview
-
additional information
-
development and synthesis of benzylidene-prop-2-ynyl-amines analogues as monoamine oxidase inhibitors, ligand docking and molecular modelling, overview. In the active center, Ile199 is the gate residue, and two hydrophobic areas of the enzyme are implicated in the most stable binding mode. Hydrophobic pocket is delimited by Ile198, Ile199, Gln206, Phe343, and aromatic cage contains FAD, Tyr398 and Tyr435
-
additional information
-
enzyme inhibition by beta-carboline alkaloids from seeds and roots of Peganum harmala, low levels in stems and leaves, and absence in flowers, overview. Seed extracts are potent reversible and competitive inhibitors of human MAO-A with an IC50 of 0.027 mg/L whereas root extracts strongly inhibit MAO-A with an IC50 of 0.159 mg/L. In contrast, they are poor inhibitors of MAO-B. Inhibition of MAO-A by seed extracts is quantitatively attributed to harmaline and harmine whereas inhibition by root extracts came from harmine with no additional interferences
-
additional information
-
evaluation of chromone carboxylic acids as enzyme inhibitors, only chromone-3-carboxylic acid is a potent MAO-B inhibitor, with a high degree of selectivity for MAO-B compared to MAO-A, no inhibition by 4-oxo-4H-chromene-2-carboxylic acid at 0.1 mM, molecular docking, overview
-
additional information
-
extracts from Fructus crataegi and Radix polygoni multiflori plants show MAO-B inhibition by 56% and 69%, respectively. The extracts of several other plants are not inhibitory for MAO-B, overview
-
additional information
-
inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues, quantitative structure-activity relationship studies, overview
-
additional information
-
inhibitor binding affects the active site structures of MAO-A and MAO-B, overview
-
additional information
-
MAO-A is not inhibited by most of the chalcone compounds tested for MAO inhibitory activity, no inhibition of MAO-B by 5c, 5d, and 5f, overview
-
additional information
-
MAO-B and MAO-A, clinical study, in vivo inhibitory activity, detailed overview
-
additional information
-
nitroindazole isomers are good hydroxyl radical scavengers and inhibhit MPTP neurotoxin oxidation by MAO. Compounds 4, 5, 6, 7, 8, 9, 10, and 11 are poor inhibitors
-
additional information
-
synthesis and molecular modeling of selective monoamine oxidase inhibitors from a 2-thiazolylhydrazyne scaffold, structure-activity relationships, overview. No or poor activity against MAO-A with 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine, and 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine, and against MAO-B with 5, 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine, 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine, 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine, and 1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)-hydrazine
-
additional information
-
synthesis of 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives and evaluation of their monoamine oxidase inhibitory activity, ligand docking and mechanism of inhibition, molecular modelling, overview. Comparison with 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole and 2-thiazolyl hydrazones, overview. No or poor inhibition of MAO-A by all compounds tested, no inhibition of MAO-B by compounds 1-thiocarbamoyl-3-(4-fluorophenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(3-methylphenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(2-methylphenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(3-methoxyphenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(2,4-dichlorophenyl)-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(thiophen-2-yl)-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(2-methylphenyl)-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(thiophen-2-yl)-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4-methyl-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(4-fluorophenyl)-4-methyl-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4-methyl-4,5-dihydropyrazole, 1-thiocarbamoyl-3-(4-methylphenyl)-4-methyl-4,5-dihydropyrazole, 1-(N-methylthiocarbamoyl)-3-phenyl-4-methyl-4,5-dihydropyrazole, 1-thiocarbamoyl-3-phenyl-4-methyl-4,5-dihydropyrazole, and 1-thiocarbamoyl-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
additional information
-
synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins, molecular modeling, overview
-
additional information
-
isoform MAO B is not inhibited by pirlindole
-
additional information
no inhibitipon by catechin and cyanidin
-
additional information
no inhibitipon by catechin and cyanidin
-
additional information
-
no inhibitipon by catechin and cyanidin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
6,7-dihydropteridine reductase deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
6-pyruvoyltetrahydropterin synthase deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Acidosis
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Acquired Immunodeficiency Syndrome
A systematic review and meta-analysis examining the interrelationships between chemical and non-chemical stressors and inherent characteristics in children with ADHD.
Acquired Immunodeficiency Syndrome
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Acquired Immunodeficiency Syndrome
Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes.
Acute Kidney Injury
Effect of monoamine oxidase inhibitors on ischaemia/reperfusion-induced acute kidney injury in rats.
Acute Kidney Injury
Sex differences in ischaemia/reperfusion-induced acute kidney injury depends on the degradation of noradrenaline by monoamine oxidase.
Adenocarcinoma
1,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer.
Adenocarcinoma
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Adenocarcinoma of Lung
Monoamine Oxidase A Inhibits Lung Adenocarcinoma Cell Proliferation by Abrogating Aerobic Glycolysis.
Adenoma
Dissociation of thyrotropin-dependent enzyme activities, reduced iodide transport, and preserved iodide organification in nonfunctioning thyroid adenoma and multinodular goiter.
Adenoma, Islet Cell
Dopa-decarboxylase and monoamine oxidase activities in a transplantable islet cell tumor of the golden hamster.
Adrenal Hyperplasia, Congenital
Personality characteristics and platelet MAO activity in women with congenital adrenal hyperplasia (CAH).
Adrenocortical Hyperfunction
Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism.
Agranulocytosis
Medically serious adverse effects of newer antidepressants.
Airway Obstruction
Effect of exercise on serum monoamine oxidase and airway obstruction in asthmatic children.
Akathisia, Drug-Induced
SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.
Akathisia, Drug-Induced
Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Albuminuria
Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
Alcohol Withdrawal Delirium
Monoamines, monoamine oxidase and alcoholism.
Alcohol-Related Disorders
Genetic and non-genetic influences on the development of co-occurring alcohol problem use and internalizing symptomatology in adolescence: a review.
Alcohol-Related Disorders
Genetic associations with intimate partner violence in a sample of hazardous drinking men in batterer intervention programs.
Alcoholic Neuropathy
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
Alveolar Bone Loss
Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model.
Alzheimer Disease
(S)-[18F]THK5117 brain uptake is associated with A? plaques and MAO-B enzyme in a mouse model of Alzheimer's disease.
Alzheimer Disease
(±)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3? Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease.
Alzheimer Disease
1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
Alzheimer Disease
3-Aryl-1-phenyl-1H-pyrazole derivatives as new multitarget directed ligands for the treatment of Alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties.
Alzheimer Disease
3-Coumaranone derivatives as inhibitors of monoamine oxidase.
Alzheimer Disease
4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
Alzheimer Disease
A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
Alzheimer Disease
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
Alzheimer Disease
A cross-talk between A? and endothelial SSAO/VAP-1 accelerates vascular damage and A? aggregation related to CAA-AD.
Alzheimer Disease
A Hypothesis and Evidence That Mercury May be an Etiological Factor in Alzheimer's Disease.
Alzheimer Disease
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
Alzheimer Disease
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
Alzheimer Disease
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Alzheimer Disease
A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
Alzheimer Disease
A pilot study of low-dose L-deprenyl in Alzheimer's disease.
Alzheimer Disease
A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients.
Alzheimer Disease
A rapid thin-layer chromatography bioautographic method for detecting the monoamine oxidase inhibitors in plants.
Alzheimer Disease
Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death.
Alzheimer Disease
Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.
Alzheimer Disease
Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii.
Alzheimer Disease
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Alzheimer Disease
Additional acetyl cholinesterase inhibitory property of diaryl pyrazoline derivatives.
Alzheimer Disease
Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications.
Alzheimer Disease
Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.
Alzheimer Disease
Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex.
Alzheimer Disease
Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro.
Alzheimer Disease
Alzheimer's disease modifies progenitor cell expression of monoamine oxidase B in the subventricular zone.
Alzheimer Disease
Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes.
Alzheimer Disease
Antioxidant properties of eugenol, butylated hydroxylanisole, and butylated hydroxyl toluene with key biomolecules relevant to Alzheimer's diseases-In vitro.
Alzheimer Disease
Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.
Alzheimer Disease
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
Alzheimer Disease
Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant.
Alzheimer Disease
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.
Alzheimer Disease
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.
Alzheimer Disease
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Alzheimer Disease
Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology.
Alzheimer Disease
Chemotherapy of cognitive disorders in geriatric subjects.
Alzheimer Disease
Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones.
Alzheimer Disease
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Alzheimer Disease
Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites.
Alzheimer Disease
Citrus spp. essential oils improve behavioral pattern, repressed cholinesterases and monoamine oxidase activities, and production of reactive species in fruit fly (Drosophila melanogaster) model of Alzheimer's Disease.
Alzheimer Disease
Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging.
Alzheimer Disease
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Alzheimer Disease
Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
Alzheimer Disease
Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation.
Alzheimer Disease
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
Alzheimer Disease
Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease.
Alzheimer Disease
Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons.
Alzheimer Disease
Deprenyl reduces the death of motoneurons caused by axotomy.
Alzheimer Disease
Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Alzheimer Disease
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Alzheimer Disease
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-? aggregation against Alzheimer's disease.
Alzheimer Disease
Design, Synthesis, and Biological Evaluation of Pyridazinones Containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors.
Alzheimer Disease
Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Alzheimer Disease
Developing a Multi-target Model to Predict the Activity of Monoamine Oxidase A and B Drugs.
Alzheimer Disease
Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease.
Alzheimer Disease
Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia.
Alzheimer Disease
Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.
Alzheimer Disease
Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.
Alzheimer Disease
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Alzheimer Disease
Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease.
Alzheimer Disease
Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain.
Alzheimer Disease
Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.
Alzheimer Disease
Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease.
Alzheimer Disease
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
Alzheimer Disease
Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.
Alzheimer Disease
Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
Alzheimer Disease
Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer's Disease.
Alzheimer Disease
First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease.
Alzheimer Disease
From Anti-Parkinson's Drug Rasagilineto Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease.
Alzheimer Disease
G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease.
Alzheimer Disease
Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease.
Alzheimer Disease
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
Alzheimer Disease
Identifying natural compounds as multi-target directed ligands against Alzheimer's disease: an in silico approach.
Alzheimer Disease
In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid.
Alzheimer Disease
In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain.
Alzheimer Disease
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
Alzheimer Disease
In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.
Alzheimer Disease
Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence.
Alzheimer Disease
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
Alzheimer Disease
Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients.
Alzheimer Disease
Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease.
Alzheimer Disease
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Alzheimer Disease
Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants.
Alzheimer Disease
Intra- and extraneuronal monoamineoxidase-A and -B activities after central axotomy (hemisection) on rats.
Alzheimer Disease
Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.
Alzheimer Disease
Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: a 90-month longitudinal study.
Alzheimer Disease
Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia.
Alzheimer Disease
Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells.
Alzheimer Disease
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.
Alzheimer Disease
Jasonia glutinosa (L.) DC., a Traditional Herbal Tea, Exerts Antioxidant and Neuroprotective Properties in Different In Vitro and In Vivo Systems.
Alzheimer Disease
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor to Abate Alzheimer's Disease.
Alzheimer Disease
L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
Alzheimer Disease
L-deprenyl: nitric oxide production and dilation of cerebral blood vessels.
Alzheimer Disease
Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone.
Alzheimer Disease
Ladostigil prevents age-related glial activation and spatial memory deficits in rats.
Alzheimer Disease
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Alzheimer Disease
Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study.
Alzheimer Disease
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Alzheimer Disease
MAOA-VNTR Genotype Effects on Ventral Striatum-Hippocampus Network in Alzheimer's Disease: Analysis Using Structural Covariance Network and Correlation with Neurobehavior Performance.
Alzheimer Disease
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.
Alzheimer Disease
Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
Alzheimer Disease
Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.
Alzheimer Disease
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Alzheimer Disease
Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and ?-amyloid inhibitors for Alzheimer's disease.
Alzheimer Disease
Monoamine oxidase assays.
Alzheimer Disease
Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes.
Alzheimer Disease
Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study.
Alzheimer Disease
Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with ?-secretase and regulates neuronal amyloid ?-peptide levels.
Alzheimer Disease
Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients.
Alzheimer Disease
Monoamine Oxidase Inhibition and Molecular Modeling Studies of Piperidyl-thienyl and 2-Pyrazoline Derivatives of Chalcones.
Alzheimer Disease
Monoamine oxidase inhibition by Rhodiola rosea L. roots.
Alzheimer Disease
Monoamine oxidase inhibition by selected dye compounds.
Alzheimer Disease
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Alzheimer Disease
Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review).
Alzheimer Disease
Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex.
Alzheimer Disease
Monoamine oxidase-B inhibition in Alzheimer's disease.
Alzheimer Disease
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Alzheimer Disease
Monoamineoxidase-B (MAO-B) Inhibitors in theTreatment of Alzheimer's and Parkinson's Disease.
Alzheimer Disease
Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations.
Alzheimer Disease
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Alzheimer Disease
Multi-target-directed Benzylidene-indanone derivatives: Anti-? Amyloid (A?) aggregation, Antioxidant, Metal chelation and Monoamine oxidase B (MAO-B) Inhibition Properties Against Alzheimer's disease.
Alzheimer Disease
Multi-targeting aurones with monoamine oxidase and amyloid-beta inhibitory activities: Structure-activity relationship and translating multi-potency to neuroprotection.
Alzheimer Disease
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-?-amyloid (A?) aggregation and metal chelation properties against Alzheimer's disease.
Alzheimer Disease
Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Alzheimer Disease
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Alzheimer Disease
N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.
Alzheimer Disease
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Alzheimer Disease
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Alzheimer Disease
Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Alzheimer Disease
Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A?(1-42)-induced toxicity.
Alzheimer Disease
Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.
Alzheimer Disease
No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease.
Alzheimer Disease
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Alzheimer Disease
Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Alzheimer Disease
Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders.
Alzheimer Disease
Oxygen-glucose deprivation-induced changes in organotypic cultures of the rat hippocampus.
Alzheimer Disease
Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Alzheimer Disease
Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO?B inhibitors.
Alzheimer Disease
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Alzheimer Disease
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Alzheimer Disease
Platelet MAO-B activity and vitamin B12 in old age dementias.
Alzheimer Disease
Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders.
Alzheimer Disease
Platelet serotonin and monoamine oxidase in Alzheimer's disease with psychotic features.
Alzheimer Disease
Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease.
Alzheimer Disease
Platelets: Peripheral Biomarkers of Dementia?
Alzheimer Disease
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Alzheimer Disease
Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from Alternaria brassicae.
Alzheimer Disease
Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.
Alzheimer Disease
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Alzheimer Disease
Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.
Alzheimer Disease
Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
Alzheimer Disease
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Alzheimer Disease
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Alzheimer Disease
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.
Alzheimer Disease
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Alzheimer Disease
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Alzheimer Disease
Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
Alzheimer Disease
Scouting around 1,2,3,4-Tetrahydrochromeno[3,2-c]pyridin-10-ones for Single- and Multitarget Ligands Directed towards Relevant Alzheimer's Targets.
Alzheimer Disease
Selegiline as immunostimulant--a novel mechanism of action?
Alzheimer Disease
Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Alzheimer Disease
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
Alzheimer Disease
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Alzheimer Disease
Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease.
Alzheimer Disease
Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity.
Alzheimer Disease
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Alzheimer Disease
Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer's disease.
Alzheimer Disease
Substrate specificity of human platelet monoamine oxidase B activity Parkinson's and Alzheimer's disease.
Alzheimer Disease
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Alzheimer Disease
Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Alzheimer Disease
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
Alzheimer Disease
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
Alzheimer Disease
Synthesis of Amide and Ester Derivatives of Cinnamic Acid and Its Analogs: Evaluation of Their Free Radical Scavenging and Monoamine Oxidase and Cholinesterase Inhibitory Activities.
Alzheimer Disease
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.
Alzheimer Disease
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors.
Alzheimer Disease
Synthesis, biological evaluation, and molecular modeling of nitrile-containing compounds: Exploring multiple activities as anti-Alzheimer agents.
Alzheimer Disease
Synthetic polyamines as potential amine oxidase inhibitors: a preliminary study.
Alzheimer Disease
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Alzheimer Disease
The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity.
Alzheimer Disease
The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.
Alzheimer Disease
The cholinergic neurotoxin ethylcholine mustard aziridinium (AF64A) induces an increase in MAO-B activity in the rat brain.
Alzheimer Disease
The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease.
Alzheimer Disease
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Alzheimer Disease
The neuroprotective mechanism of action of the multimodal drug ladostigil.
Alzheimer Disease
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Alzheimer Disease
The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.
Alzheimer Disease
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Alzheimer Disease
The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
Alzheimer Disease
Therapeutic Potential Of Multifunctional Derivatives Of Cholinesterase Inhibitors.
Alzheimer Disease
Total monoamine oxidase (MAO) inhibition by chestnut honey, pollen and propolis.
Alzheimer Disease
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Alzheimer Disease
Type a and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
Alzheimer Disease
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Alzheimer Disease
Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Alzheimer Disease
Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study.
Alzheimer Disease
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Alzheimer Disease
[Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on the activity of monoamine oxidase A and B]
Alzheimer Disease
[Effects of Goutengsan on model of Alzheimer dementia in rats by AlCl3]
Alzheimer Disease
[Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
Amebiasis
Neurohumoral alterations and their role in amoebiasis.
Amnesia
Effect of age of habit on susceptibility to cycloheximide-induced amnesia in mice.
Amnesia
Involvement of serotonergic neuronal systems in the anti-amnesic action of naftidrofuryl oxalate.
Amnesia
Neurotransmitter Metabolic Enzymes and Antioxidant Status on Alzheimer's Disease Induced Mice Treated with Alpinia galanga (L.) Willd.
Amnesia
Recovery from amnesia induced by pre-test injections of monoamine oxidase inhibitors.
Amnesia
Role of the biogenic amines in the reversal of cycloheximide-induced amnesia.
Amnesia
Similar effects of a monoamine oxidase inhibitor and a sympathomimetic amine on memory formation.
Amnesia
Some characteristics of amnesia induced by FLA-63 an inhibitor of dopamine beta hydroxylase.
Amyotrophic Lateral Sclerosis
18F-THK5351 PET Can Identify Core Lesions in Different Amyotrophic Lateral Sclerosis Phenotypes.
Amyotrophic Lateral Sclerosis
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.
Amyotrophic Lateral Sclerosis
A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1(G93A) ALS Mice.
Amyotrophic Lateral Sclerosis
Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Monoamine oxidase-B in astrocytes.
Amyotrophic Lateral Sclerosis
Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography.
Amyotrophic Lateral Sclerosis
Monoamine oxidase-B in motor cortex: changes in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Rasagiline for Amyotrophic Lateral Sclerosis: a Randomized Controlled Trial.
Amyotrophic Lateral Sclerosis
Reactive gliosis and monoamine oxidase B.
Amyotrophic Lateral Sclerosis
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Anaphylaxis
Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline.
Anaphylaxis
[Action of reserpine and monoamine oxidase inhibitors on anaphylactic shock in mice.]
Anaphylaxis
[CRITICAL STUDIES ON THE SIGNIFICANCE OF SEROTONIN IN THE MECHANISM OF ANAPHYLAXIS. 2. CHANGES IN THE SEROTONIN CONTENT AND MONOAMINE OXIDASE ACTIVITY OF TISSUE IN ANAPHYLACTIC SHOCK.]
Anemia
Fermented Goat Milk Consumption Enhances Brain Molecular Functions during Iron Deficiency Anemia Recovery.
Anemia
Human platelet monoamine oxidase activity in health and disease: a review.
Anemia
Iron deficiency anemia and catecholamine metabolism.
Anemia
Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia.
Anemia, Iron-Deficiency
Human platelet monoamine oxidase activity in health and disease: a review.
Anemia, Iron-Deficiency
Human platelet monoamine oxidase activity in iron-deficiency anaemia.
Anemia, Iron-Deficiency
Iron deficiency anemia and catecholamine metabolism.
Anemia, Iron-Deficiency
Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia.
Anemia, Iron-Deficiency
Some properties of human platelet monoamine oxidase in iron-deficiency anaemia.
Anemia, Megaloblastic
Human platelet monoamine oxidase activity in health and disease: a review.
Anemia, Megaloblastic
Platelet monoamine oxidase activity in megaloblastic anaemia.
Anemia, Megaloblastic
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Anemia, Pernicious
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Aneurysm
Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation.
Aneurysm
Systemic reactions to ophthalmic drug preparations.
Aneurysm, Dissecting
Hypertensive emergencies. Etiology and management.
Angina Pectoris
A basis for the use of monoamine oxidase inhibitors in angina pectoris.
Angina Pectoris
A trial of a new monoamine oxidase inhibitor in angina pectoris.
Angina Pectoris
Attenuation of cardiovascular responses to exercise as a possible basis for effectiveness of monoamine oxidase inhibitors in angina pectoris.
Angina Pectoris
Clinical trials with a new monoamine oxidase inhibitor--nialamide in the treatment of angina pectoris.
Angina Pectoris
Experiences in the treatment of angina pectoris with monoamine oxidase inhibitors.
Angina Pectoris
Monoamine oxidase inhibitors and angina pectoris.
Angina Pectoris
Monoamine oxidase inhibitors in the treatment of angina pectoris.
Angina Pectoris
On the mechanism of action of monoamine oxidase inhibitors in angina pectoris.
Angina Pectoris
Present status of monoamine oxidase inhibitors in angina pectoris.
Angina Pectoris
The use of monoamine oxidase inhibitors as adjuncts in the treatment of hypertension and angina pectoris.
Angina Pectoris
Treatment of angina pectoris with a new monoamine oxidase inhibitor, pivalybenzydrazine.
Angina Pectoris
[ANGINA PECTORIS AND MONOAMINE OXIDASE INHIBITORS.]
Angina Pectoris
[Iproniazid and other inhibitors of monoamine oxidase in the treatment of angina pectoris.]
Angina Pectoris
[Iproniazid and other monoamine oxidase inhibitors in the treatment of angina pectoris.]
Angina Pectoris
[Monoamine oxidase inhibitor in the treatment of angina pectoris.]
Angina Pectoris
[Monoamine oxidase inhibitors in the treatment of angina pectoris.]
Angina Pectoris
[Notes on the treatment of angina pectoris with a new monoamine oxidase inhibitor (M.A.O.I.)]
Angina Pectoris
[On the action of monoamine oxidase inhibitors in angina pectoris.]
Angina Pectoris
[On the treatment of angina pectoris with monoamine oxidase inhibitors.]
Angina Pectoris
[SIGNIFICANCE OF MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF ANGINA PECTORIS.]
Angina Pectoris
[Thrombocyte functional resistance and histamine and serotonin metabolism in ischemic heart disease]
Angina Pectoris
[TREATMENT OF ANGINA PECTORIS WITH MONOAMINE OXIDASE INHIBITORS.]
Anhedonia
The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia.
Anthracosilicosis
[Cytochemical parameters in studying the body at peripheral hemopoiesis level]
Aortic Aneurysm
Role of the media in vascular injury: atherosclerosis and dissection.
Aortic Rupture
Beta-aminopropionitrile-induced aortic ruptures in turkeys: inhibition by reserpine and enhancement by monoamine oxidase inhibitors.
Aortic Valve Stenosis
Semicarbazide-Sensitive Amine Oxidase Increases in Calcific Aortic Valve Stenosis and Contributes to Valvular Interstitial Cell Calcification.
Aphasia
The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia.
Aphasia, Primary Progressive
Neuroinflammation is highest in areas of disease progression in semantic dementia.
Appendicitis
[Monoamine oxidase activity in the appendicitis (one cause of various post-appendectomy complaints)]
aromatic-l-amino-acid decarboxylase deficiency
A female case of aromatic l-amino acid decarboxylase deficiency responsive to MAO-B inhibition.
aromatic-l-amino-acid decarboxylase deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Arrhythmias, Cardiac
Ectopic ventricular rhythms and myocardial infarction in the domestic pig and their response to nialamide, a monoamine oxidase inhibitor.
Arrhythmias, Cardiac
Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
Arrhythmias, Cardiac
The role of monoamine oxidase inhibitors in experimental auricular arrhythmia.
Arteritis
[Action of a monoamine oxidase inhibitor (Niamid) on various experimental vascular lesions in the rabbit (allergic arteritis, myocardial necrosis caused by isoproterenol, aortic medionecrosis, venous and arterial thrombosis).]
Arthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Arthritis
[Changes in the monoamine oxidase activity in experimental myocarditis and arthritis in rats thymectomized at birth]
Arthritis
[Changes in the monoamine oxidase activity of neonatally thymectomized rats with experimental myocarditis and arthritis]
Arthritis, Rheumatoid
Monoamine oxidase inhibitors for IgA nephropathy.
Arthritis, Rheumatoid
Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors.
Arthritis, Rheumatoid
Serotonin metabolism and its enzymic activities in joint diseases.
Arthritis, Rheumatoid
The level of serum monoamine oxidase in rheumatoid arthritis.
Arthritis, Rheumatoid
Tryptophan metabolism in the joint diseases.
Arthritis, Rheumatoid
[Activity of serum monoamine oxidase in rheumatic fever and rheumatoid arthritis]
Arthritis, Rheumatoid
[Preliminary study on the clinical effects of a new monoamine oxidase antagonist in rheumatoid arthritis.]
Arthus Reaction
Serotonin metabolism in the arthus reaction.
Ascorbic Acid Deficiency
Dietary ascorbic acid deficiency in guinea pigs: no effect on ethanol preference, spiroperidol binding, or monoamine oxidase activity.
Asthma
Clinical contraindications to allergen immunotherapy: an EAACI position paper.
Asthma
Monoamine oxidase activity in serum of patients with bronchial asthma and healthy subjects.
Asthma
Personality and illness: Genetic connections?
Asthma
THE RISKS OF MONOAMINE OXIDASE INHIBITORS IN THE TREATMENT OF BRONCHIAL ASTHMA.
Asthma
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]
Asthma
[Behavior of serum monoamine oxidase (MAO) as well as the excretion of urinary 5-hydroxyindole-acetic acid (5-HIA) in healthy subjects and in children with allergic bronchial asthma]
Asthma
[Hemodynamics, serotonin and monoamine oxidase in bronchial asthma and systemic arterial hypertension]
Asthma
[Monoamine oxidase activity in serum of patients with asthma and in elderly subjects]
Asthma
[Myocardial status, hemodynamics and pressor humoral substances in patients with bronchial asthma and arterial hypertension]
Asthma
[Serum monoamine oxidase activity in patients with bronchial asthma and in healthy subjects]
Astrocytoma
Antioxidant defense against antidepressants in C6 and 1321N1 cells.
Astrocytoma
Catechol-O-methyl transferase and monoamine oxidase activity in cultured rodent astrocytoma cells.
Astrocytoma
Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene.
Astrocytoma
Monoamine oxidase B activity is increased in human gliomas.
Astrocytoma
Monoamine oxidase-B in astrocytes.
Astrocytoma
[Comparative study of the effect of inhibitors of monoamine oxidase and ftorafur on the growth of de-differentiated astrocytoma]
Astrocytoma
[Development of experimental brain tumors in modulated amine metabolism]
Atherosclerosis
Determination of human serum semicarbazide-sensitive amine oxidase activity: a possible clinical marker of atherosclerosis.
Atherosclerosis
Disruption of phactr-1 pathway triggers pro-inflammatory and pro-atherogenic factors: New insights in atherosclerosis development.
Atherosclerosis
Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover.
Atherosclerosis
Inactivation of semicarbazide-sensitive amine oxidase induces the phenotypic switch of smooth muscle cells and aggravates the development of atherosclerotic lesions.
Atherosclerosis
Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in apolipoprotein E-deficient mice.
Atherosclerosis
Inhibition of Semicarbazide-sensitive Amine Oxidase Reduces Atherosclerosis in Cholesterol-fed New Zealand White Rabbits.
Atherosclerosis
Monoamine oxidase A genotype, childhood trauma, and subclinical atherosclerosis: a twin study.
Atherosclerosis
Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure.
Atherosclerosis
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Atherosclerosis
Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis.
Atherosclerosis
Serum vascular adhesion protein-1 level is higher in smokers than non-smokers.
Atherosclerosis
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
Atherosclerosis
[Administration of monoamine oxidase inhibitors in experimental atherosclerosis]
Atherosclerosis
[Disorders of the deamination of nitrogenous compounds in the heart muscle in experimental atherosclerosis]
Atherosclerosis
[Effect of the monoamine oxidase inhibitor--Iprazid, on the functional state of the thyroid gland in healthy rabbits and in rabbits with experimental atherosclerosis]
Atherosclerosis
[Relations between catecholamines, monoamine oxidase activity and atherosclerosis in swine]
Atherosclerosis
[Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
Atrial Fibrillation
Effect of nialamide, a monoamine oxidase inhibitor, on acetylcholine-adrenaline induced atrial fibrillation in normal & reserpinized dogs.
Atrial Fibrillation
Metabolic alterations in rat myocardium in experimental acute atrial fibrillation.
Atrial Fibrillation
Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation.
Atrial Fibrillation
Plasma Catecholamine Levels on the Morning of Surgery Predict Post-Operative Atrial Fibrillation.
Atrioventricular Block
Practical considerations for the treatment of elderly patients with migraine.
Bacterial Infections
Effects of monoamine oxidase inhibitors on bacterial infections.
Bacterial Infections
[On the effect of monoamine oxidase inhibitors on bacterial infection]
Basal Ganglia Diseases
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Basal Ganglia Diseases
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
beta-Mannosidosis
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
Blister
Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema.
Bradycardia
Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor.
Brain Diseases
A direct continuous fluorometric turn-on assay for monoamine oxidase B and its inhibitor-screening based on the abnormal fluorescent behavior of silole.
Brain Diseases
Three -(pyridin-2-yl)-2-(pyridin-2-ylimino)thiazolidin-4-one as a novel inhibitor of cerebral MAO-B activity with antioxidant properties and low toxicity potential.
Brain Diseases
[Experimental studies of the pathomechanism of portal encephalopathy. I. Changes in monoamine oxidase (MAO) activity in the cerebral cortex and cerebellum of rats after portacaval shunt]
Brain Diseases
[Experimental studies of the pathomechanism of portal encephalopathy. II. Monoamine oxidase (MAO) activity in the rat brain after porta- caval shunt using 2 different methods]
Brain Edema
Quantitative evaluation of brain edema by radionuclide imaging technique.
Brain Edema
[Neuroprotective effect of monoamine oxidase monoclonal antibody against vasogenic brain edema in rats]
Brain Injuries
Attenuation of Ischemic Stroke-Caused Brain Injury by a Monoamine Oxidase Inhibitor Involves Improved Proteostasis and Reduced Neuroinflammation.
Brain Injuries
Monoamine oxidase-B activity is not involved in the neuroinflammatory response elicited by a focal freeze brain injury.
Brain Injuries
Vascular adhesion protein-1 in human ischaemic stroke.
Brain Injuries, Traumatic
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Brain Injuries, Traumatic
Prefrontal cortex lesions and MAO-A modulate aggression in penetrating traumatic brain injury.
Brain Ischemia
Chronic methamphetamine administration inhibits cerebral ischemia-induced hyperactivity in Mongolian gerbils.
Brain Ischemia
Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
Brain Ischemia
Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes.
Brain Ischemia
Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression.
Brain Ischemia
[Properties of monoamine oxidase in the brain of mongolian gerbils during cerebral ischemia]
Brain Neoplasms
Monoamine oxidase B activity is increased in human gliomas.
Brain Neoplasms
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Brain Neoplasms
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Brain Neoplasms
Site-specific expression of amine oxidases in breast cancer metastases.
Brain Neoplasms
[Histochemical demonstration of monoamine oxidase in brain tumors.]
Breast Neoplasms
Amine oxidase activities in chemically-induced mammary cancer in the rat.
Breast Neoplasms
Amine oxidase activities in rat breast cancer induced experimentally with 7,12-dimethylbenz(alpha)anthracene.
Breast Neoplasms
Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
Breast Neoplasms
Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors.
Breast Neoplasms
Mental adaptation to cancer: depression and blood platelet monoamine oxidase activity in breast cancer patients.
Breast Neoplasms
Monoamine oxidase-A activity is required for clonal tumorsphere formation by human breast tumor cells.
Breast Neoplasms
Platelet monoamine oxidase and phenolsulphotransferase M and P in cancer.
Breast Neoplasms
Psychiatric morbidity and platelet monoamine oxidase activity in cancer patients.
Breast Neoplasms
Site-specific expression of amine oxidases in breast cancer metastases.
Breast Neoplasms
The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Brief, Resolved, Unexplained Event
Serotonin transporter role in identifying similarities between SIDS and idiopathic ALTE.
Bronchiectasis
[Correlation between the changes in serotonin content, monoamine oxidase activity and the mast cell number in the lung tissue in bronchiectasis]
Bronchitis
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]
Bronchitis, Chronic
[Change in monoamine oxidase activity in chronic bronchitis]
Bruxism
Experimental aggression and bruxism in rats.
Carcinogenesis
Application of novel pH sensitive isoniazid-heptamethine carbocyanine dye conjugates against prostate cancer cells.
Carcinogenesis
Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Carcinogenesis
Induction of monoamine oxidase B by 17 beta-estradiol in the hamster kidney preceding carcinogenesis.
Carcinogenesis
Kava root extracts hinder prostate cancer development and tumorigenesis by involvement of dual inhibition of MAO-A and LSD1.
Carcinogenesis
MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
Carcinogenesis
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Carcinogenesis
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Carcinogenesis
Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane.
Carcinogenesis
The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
Carcinoid Tumor
Biochemical and ultrastructural differences between muco-epidermoid and carcinoid tumors of the bronchus.
Carcinoid Tumor
Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine.
Carcinoid Tumor
Monoamine and diamine oxidase activity in the diagnosis of carcinoid tumors.
Carcinoid Tumor
Monoamine oxidase deficiency: a cause of symptomatic hyperserotoninemia in the absence of carcinoid.
Carcinoid Tumor
[EXPERIMENTAL CONTRIBUTION TO THE STUDY OF CARCINOID SYNDROME. ON THE PARENCHYMAL LESIONS INDUCED BY PROLONGED ADMINISTRATION OF 5-HYDROXYTRYPTAMINE ASSOCIATED WITH A MONOAMINE OXIDASE INHIBITOR.]
Carcinoma
A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma.
Carcinoma
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Carcinoma
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.
Carcinoma
Cudarflavone B provides neuroprotection against glutamate-induced mouse hippocampal HT22 cell damage through the Nrf2 and PI3K/Akt signaling pathways.
Carcinoma
Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1? signaling.
Carcinoma
Effect of testosterone and 6-hydroxydopamine treatment on the metabolism of catecholamine and 5-hydroxytryptamine in methylcholanthrene-induced prostate carcinoma of rats.
Carcinoma
Histochemical studies of monoamine oxidase in carcinoma of uterine cervix.
Carcinoma
Monitoring treatment of pulmonary carcinomas by serial determination of monoamine oxidase and diamine oxidase in blood serum.
Carcinoma
Monoamine oxidase (MAO) activity and its forms in normal and pathological human thyroid tissues.
Carcinoma
Monoamine oxidase activity in the argentaffin carcinoma syndrome.
Carcinoma
Monoamine Oxidase B in Renal Cell Carcinoma.
Carcinoma
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Carcinoma
Th2 response of human peripheral monocytes involves isoform-specific induction of monoamine oxidase-A.
Carcinoma
Water-Soluble Near-Infrared Fluorescent Probes for Specific Detection of Monoamine Oxidase A in Living Biosystems.
Carcinoma, Ductal
Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
Carcinoma, Ductal
Histochemically demonstrable enzyme activities and their independence of the hormone receptor content in female breast carcinoma.
Carcinoma, Ehrlich Tumor
Monoamine oxidase activity in Ehrlich ascites tumor.
Carcinoma, Embryonal
Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells.
Carcinoma, Hepatocellular
Assignment of genes for human monoamine oxidases A and B to the X chromosome.
Carcinoma, Hepatocellular
Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene.
Carcinoma, Hepatocellular
Degradation of transplanted rat liver mitochondrial-outer-membrane proteins in hepatoma cells.
Carcinoma, Hepatocellular
Differences in the structures of monoamine oxidases A and B in rat clonal cell lines.
Carcinoma, Hepatocellular
Distinct forms of monoamine oxidase expressed in hepatoma and HeLa cells in culture.
Carcinoma, Hepatocellular
Electrophoretic characterization of monoamine oxidase by [3H]pargyline binding in rat hepatoma cells with A and B activity.
Carcinoma, Hepatocellular
Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
Carcinoma, Hepatocellular
Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain.
Carcinoma, Hepatocellular
Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
Carcinoma, Hepatocellular
SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs.
Carcinoma, Hepatocellular
Stephtetrandrine A-D, bisbenzylisoquinoline alkaloids from Stephania tetrandra.
Carcinoma, Hepatocellular
[Lipid dependence of mitochondrial monoamine oxidase from rat hepatoma 27 with the use of rat liver lipid exchange proteins]
Carcinoma, Hepatocellular
[Monoamine oxidase activity of nuclear membranes of liver and ascites hepatoma cells]
Carcinoma, Hepatocellular
[Monoamine oxidase activity of the plasma membranes of liver and ascites hepatoma cells in rats]
Carcinoma, Hepatocellular
[Use of protein-mediated lipid exchange for studies of membrane-bound enzymes. Properties of monoamine oxidase activated by phosphatidylcholine]
Carcinoma, Medullary
Serotonin metabolism and platelet monoamine oxidase activity in patients with medullary carcinoma of the thyroid and pheochromocytoma.
Carcinoma, Non-Small-Cell Lung
Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Carcinoma, Non-Small-Cell Lung
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Carcinoma, Non-Small-Cell Lung
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Carcinoma, Non-Small-Cell Lung
The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1? protein accumulation in non-small cell lung cancer cells.
Carcinoma, Renal Cell
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.
Carcinoma, Renal Cell
Monoamine Oxidase B in Renal Cell Carcinoma.
Carcinosarcoma
[Experimental data to substantiate the antitumor action of hydrazine sulfate]
Cardiomegaly
Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin.
Cardiomegaly
Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats.
Cardiomegaly
Monoamine oxidase inhibition and furazolidone-induced cardiomyopathy in turkey poults.
Cardiomegaly
Monoamine oxidase inhibitors protect against coronary heart disease in rodent rat models: A pilot study.
Cardiomyopathies
Effects of a hydrazine monoamine oxidase inhibitor (phenelzine) on isoproterenol-induced myocardiopathies in the rat.
Cardiomyopathies
Monoamine oxidase inhibition and furazolidone-induced cardiomyopathy in turkey poults.
Cardiomyopathies
Monoamine Oxidase Is Overactivated in Left and Right Ventricles from Ischemic Hearts: An Intriguing Therapeutic Target.
Cardiomyopathies
OBSERVATIONS ON HISTOCHEMICAL DIFFERENTIAL DIAGNOSIS BETWEEN PRIMARY AND SECONDARY CARDIOMYOPATHIES. BEHAVIOR OF MONOAMINE OXIDASE, PHOSPHORYLASE, AND GLYCOGEN IN HEART MUSCLE.
Cardiomyopathies
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Cardiotoxicity
A study of package inserts of potentially toxic drugs.
Cardiotoxicity
Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase.
Cardiotoxicity
Hypothermia in a combined intoxication with doxepin and moclobemide in an adolescent.
Cardiotoxicity
Interfaces of psychopharmacology and cardiology--part one.
Cardiotoxicity
Interfaces of psychopharmacology and cardiology--Part two.
Cardiotoxicity
The Determining Role of Mitochondrial Reactive Oxygen Species Generation and Monoamine Oxidase Activity in Doxorubicin-Induced Cardiotoxicity.
Cardiotoxicity
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.
Cardiotoxicity
[Effects on the micro-electrocardiogram of a monoamine oxidase inhibitor. Study of the cardiotoxicity of phenelzine in the chick embryo "in situ". Possible therapeutic repercussions in patients with coronary disease]
Cardiovascular Diseases
Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: Pathophysiological and therapeutic implications (Review).
Cardiovascular Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Cardiovascular Diseases
Antiglycation, radical scavenging, and semicarbazide-sensitive amine oxidase inhibitory activities of acetohydroxamic acid in vitro.
Cardiovascular Diseases
Clinical application of the monoamine oxidase inhibitors in cardiovascular disease.
Cardiovascular Diseases
Clinical contraindications to allergen immunotherapy: an EAACI position paper.
Cardiovascular Diseases
Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
Cardiovascular Diseases
Monoamine oxidase A genotype, childhood trauma, and subclinical atherosclerosis: a twin study.
Cardiovascular Diseases
Multifunctional compounds in the extract from mature seeds of Vicia faba var. minor: Phytochemical profiling, antioxidant activity and cellular safety in human selected blood cells in in vitro trials.
Cardiovascular Diseases
The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients.
Cardiovascular Diseases
The importance of the monoamine oxidase inhibitors in cardiovascular disease.
Cardiovascular Diseases
[Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome]
Cardiovascular Diseases
[The therapeutic effect of monoamine oxidase inhibitors in cardiovascular diseases.]
Carotid Artery Diseases
Inactivation of Semicarbazide-Sensitive Amine Oxidase Stabilizes the Established Atherosclerotic Lesions via Inducing the Phenotypic Switch of Smooth Muscle Cells.
Carotid Artery Diseases
Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis.
Catalepsy
Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic.
Catalepsy
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Catalepsy
Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease.
Catalepsy
[ Anticataleptic effect of delta sleep-inducing peptide and its action on brain monoamine oxidase in rats genetically predisposed to catalepsy]
Catalepsy
[Brain monoamine oxidase and the predisposition for catalepsy in tame and aggressive Norway rats]
Cataplexy
Cataplexy and monoamine oxidase deficiency in Norrie disease.
Catatonia
Genetic predisposition to catatonic behaviour and methylphenidate sensitivity in rats.
Catatonia
The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.
Central Nervous System Diseases
Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson's disease: Synthesis, in vitro and in vivo studies.
Central Nervous System Diseases
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Central Nervous System Diseases
Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B.
Central Nervous System Infections
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Cerebellar Ataxia
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Cerebral Amyloid Angiopathy
A cross-talk between A? and endothelial SSAO/VAP-1 accelerates vascular damage and A? aggregation related to CAA-AD.
Cerebral Amyloid Angiopathy
The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease.
Cerebral Hemorrhage
[Report on a intracerebral hemorrhage after long term treatment with a monoamine oxidase inhibitor (MAO)]
Cerebrovascular Disorders
Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.
Cerebrovascular Disorders
The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity.
Chemical and Drug Induced Liver Injury
Tyramine oxidase activity in needle biopsy of normal livers and diseased livers.
Cholangiocarcinoma
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
Cholangiocarcinoma
Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events.
Cholangiocarcinoma
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.
Cholestasis
Metabolic changes in rat brain histaminergic neurons during subhepatic cholestasis.
Cholestasis
[Metabolic changes in rat brain histaminergic neurons in dynamics of subhepatic cholestasis]
Chorea
Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.
Choriocarcinoma
Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat.
Choriocarcinoma
Monoamine oxidase in rat placenta, human placenta, and cultured choriocarcinoma.
Cluster Headache
Concentration and uptake of 5-hydroxytryptamine in platelets from cluster headache and migraine patients.
Cluster Headache
Kinetics and thermolability of platelet monoamine oxidase in cluster headache and migraine.
Cluster Headache
Low platelet monoamine oxidase activity in headache: no correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking.
Cluster Headache
Migraine and cluster headache: links between platelet monoamine oxidase activity, smoking and personality.
Cluster Headache
Monoamine oxidase activities in patients with migraine or with cluster headache during the acute phases and after treatment with L-5-hydroxytryptophan.
Collagen Diseases
[1. ON SKIN TESTS. SKIN TESTS AND CLINICAL EFFECTIVENESS IN PATIENTS WITH ALLERGIC AND COLLAGEN DISEASES. 2. INFLUENCE OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN ANTAGONISTS. 3. RELATION TO CATECHOLAMINES.]
Collagen Diseases
[Clinical significances of monoamine oxidase (MAO) activities in various collagen diseases (author's transl)]
Colonic Neoplasms
Reliability, decision rules, and the value of repeated tests.
Colorectal Neoplasms
Antidepressants and colorectal cancer: A population-based nested case-control study.
Colorectal Neoplasms
Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures.
Coma
Hypothermia in a combined intoxication with doxepin and moclobemide in an adolescent.
Coma
Phenelzine toxicity responsive to dantrolene.
Coma
Ping Pong gaze in reversible coma due to overdose of monoamine oxidase inhibitor.
Coma
Similarity between tyramine-induced neurotoxicity and the coma of Reye's syndrome.
Confusion
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Confusion
90 years of monoamine oxidase: some progress and some confusion.
Confusion
Associations between platelet monoamine oxidase-B activity and acquired colour vision loss in a fish-eating population.
Confusion
Monoamine oxidase inhibitors and anaesthesia. A review.
Connective Tissue Diseases
Evaluation of serum monoamine oxidase in patients with connective tissue diseases.
Connective Tissue Diseases
[Activity of serum monoamine oxidase (SMAO) in patients with connective tissue diseases : preliminary results]
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Coronary Artery Disease
Coronary artery disease: the use of monoamine oxidase inhibitors in the treatment of the anginal syndrome.
Coronary Disease
Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease.
Coronary Disease
MONOAMINE OXIDASE INHIBITOR (TERSAVID) IN CORONARY HEART DISEASE.
Coronary Disease
Monoamine oxidase inhibitors protect against coronary heart disease in rodent rat models: A pilot study.
Coronary Disease
[Effects on the micro-electrocardiogram of a monoamine oxidase inhibitor. Study of the cardiotoxicity of phenelzine in the chick embryo "in situ". Possible therapeutic repercussions in patients with coronary disease]
Coronary Disease
[Preliminary clinical observations on treatment with a monoamine oxidase antagonist in coronary diseases and in other disease states.]
Coronary Occlusion
Myocardial interstitial levels of serotonin and its major metabolite 5-hydroxyindole acetic acid during ischemia-reperfusion.
Cough
Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.
Cough
Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Cough
Modulation of capsaicin induced airway reflexes in humans: effect of monoamine oxidase inhibition.
Cough
New recombinant cyclohexylamine oxidase variants for deracemization of secondary amines by orthogonally assaying designed mutants with structurally diverse substrates.
COVID-19
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.
Craniocerebral Trauma
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Craniocerebral Trauma
Drug therapy of hypertensive crises.
Craniocerebral Trauma
Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.
Craniocerebral Trauma
[Brain monoamine oxidase in craniocerebral trauma]
Crohn Disease
Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.
Crohn Disease
Monoamine oxidase inhibitors for IgA nephropathy.
Cysts
On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals.
Deafness
Isolation of a candidate gene for Norrie disease by positional cloning.
Dehydration
Phytochemicals and Enzyme Inhibitory Capacities of the Methanolic Extracts from the Italian Apple Cultivar Mela Rosa dei Monti Sibillini.
Dehydration
Studies of the in vitro oxidation of 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine by human monoamine oxidases A and B.
Dehydration
Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.
Dehydration
[Effect of hydration and dehydration of the bodies of animals on bioenergetic and mediator processes in the neurosecretory cells of the anterior hypothalamus]
Delirium
Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection.
Delirium
Withdrawal phenomena associated with antidepressant and antipsychotic agents.
Dementia
A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Dementia
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
Dementia
Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.
Dementia
Ameliorative Effect of Trans-sinapic Acid and its Protective Role in Cerebral Hypoxia of Aluminium Chloride Induced Dementia of Alzheimers Type
Dementia
Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study.
Dementia
Bamboo leaf extract improves spatial learning ability in a rat model with senile dementia.
Dementia
Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.
Dementia
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Dementia
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Dementia
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Dementia
Depression and senile dementia of the Alzheimer type: a role for moclobemide.
Dementia
Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia.
Dementia
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
Dementia
Effects of selegiline alone or with donepezil on memory impairment in rats.
Dementia
Expression of monoamine oxidase B activity in astrocytes of senile plaques.
Dementia
Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type.
Dementia
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Dementia
Maintenance therapies for late-life recurrent major depression: research and review circa 1995.
Dementia
Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease).
Dementia
Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
Dementia
N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.
Dementia
New Frontiers in Selective Human MAO-B Inhibitors.
Dementia
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Dementia
Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease.
Dementia
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Dementia
Platelet MAO-B activity and vitamin B12 in old age dementias.
Dementia
Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders.
Dementia
Platelet monoamine oxidase B activity and vitamin B12 in dementia.
Dementia
Platelet monoamine oxidase B activity in dementia. A 4-year follow-up.
Dementia
Platelet monoamine oxidase, plasma dopamine beta-hydroxylase activity, dementia and family history of alcoholism in chronic alcoholics.
Dementia
Platelets: Peripheral Biomarkers of Dementia?
Dementia
Recognition and treatment of depression in Alzheimer's disease.
Dementia
Selegiline in the treatment of mild to moderate Alzheimer-type dementia.
Dementia
The management of coexisting depression in patients with dementia: potential of calcium channel antagonists.
Dementia
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Dementia
Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study.
Dementia
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.
Dementia, Multi-Infarct
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Dementia, Vascular
Drugs and vascular dementia.
Dementia, Vascular
Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia.
Dementia, Vascular
Platelet MAO-B activity and vitamin B12 in old age dementias.
Demyelinating Diseases
Five decades of cuprizone, an updated model to replicate demyelinating diseases.
Dengue
Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections.
Depression, Postpartum
Abnormal platelet 5-hydroxytryptamine uptake and imipramine binding in postnatal dysphoria.
Depression, Postpartum
Elevated brain monoamine oxidase A binding in the early postpartum period.
Depression, Postpartum
Relationship of monoamine oxidase-A distribution volume to postpartum depression and postpartum crying.
Dermatitis, Atopic
Cofactor levels of mono- and diamine oxidase in atopic eczema.
Dermatitis, Atopic
Monoamine and diamine oxidase activities in atopic eczema.
Dermatitis, Atopic
Pathological changes in platelet histamine oxidases in atopic eczema.
Dermatitis, Atopic
[Histamine degrading enzymes in atopic eczema]
Dermatitis, Atopic
[Monoamine oxidase activity of the skin in patients with disseminated neurodermatitis]
Diabetes Complications
Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications.
Diabetes Complications
Antiglycation, radical scavenging, and semicarbazide-sensitive amine oxidase inhibitory activities of acetohydroxamic acid in vitro.
Diabetes Complications
Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet.
Diabetes Complications
Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia.
Diabetes Complications
Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats.
Diabetes Complications
Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications.
Diabetes Complications
Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.
Diabetes Insipidus
[Age-dependent changes in brain monoamine oxidase in Brattleboro rats with genetically determined diabetes insipidus]
Diabetes Mellitus
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Diabetes Mellitus
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Diabetes Mellitus
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis.
Diabetes Mellitus
Effects of diabetes mellitus and chemical sympathectomy on tissue monoamine oxidase activity and norepinephrine concentration in the golden hamster.
Diabetes Mellitus
Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy.
Diabetes Mellitus
Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus.
Diabetes Mellitus
Increased activity of serum amine oxidases in granuloma annulare, necrobiosis lipoidica and diabetes.
Diabetes Mellitus
Patient selection in ambulatory anesthesia - an evidence-based review: part II.
Diabetes Mellitus
Physiological and pathological influences on serum monoamine oxidase level. Effect of age, sex, contraceptive steroids and diabetes mellitus.
Diabetes Mellitus
Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin.
Diabetes Mellitus
Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus.
Diabetes Mellitus
Production of a truncated soluble human semicarbazide-sensitive amine oxidase mediated by a GST-fusion protein secreted from HEK293 cells.
Diabetes Mellitus
Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases.
Diabetes Mellitus
Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice.
Diabetes Mellitus
The effect of diabetes mellitus on the morphology and physiology of monoamine oxidase in the pancreas.
Diabetes Mellitus
The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1.
Diabetes Mellitus
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
Diabetes Mellitus
[Blood serum monoamine oxidase and ceruloplasmin activity in diabetes mellitus]
Diabetes Mellitus
[Value of the use of monoamine oxidase inhibitors in the treatment of diabetes mellitus]
Diabetes Mellitus, Experimental
Changes in monoamine oxidase activity in rat brain during alloxan diabetes.
Diabetes Mellitus, Experimental
The effects of anxiogenic stress on glucocorticoid sensitivity, glucose tolerance, and alloxan resistance in rats.
Diabetes Mellitus, Type 1
A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes.
Diabetes Mellitus, Type 1
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride.
Diabetes Mellitus, Type 1
Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes.
Diabetes Mellitus, Type 1
Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes and Depression.
Diabetes Mellitus, Type 1
Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia.
Diabetes Mellitus, Type 1
Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin.
Diabetes Mellitus, Type 1
The effects of type 1 diabetes mellitus and of tobacco smoke on dissipation of catecholamines in pulmonary endothelial cells--a non-neuronal site of uptake1.
Diabetes Mellitus, Type 2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Diabetes Mellitus, Type 2
Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Bioactive and functional properties of sour cherry juice (Prunus cerasus).
Diabetes Mellitus, Type 2
Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Cytotoxic, Antioxidant, and Enzyme Inhibitory Properties of the Traditional Medicinal Plant Matthiola incana (L.) R. Br.
Diabetes Mellitus, Type 2
Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy.
Diabetes Mellitus, Type 2
Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride.
Diabetes Mellitus, Type 2
Evaluation of the inhibition of monoamine oxidase A by bioactive coffee compounds protecting serotonin degradation.
Diabetes Mellitus, Type 2
Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Islet-specific monoamine oxidase A and B expression depends on MafA transcriptional activity and is compromised in type 2 diabetes.
Diabetes Mellitus, Type 2
Monoamine oxidase and semicarbazide-sensitive amine oxidase kinetic analysis in mesenteric arteries of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 activity exerts an antidiabetic action in Goto-Kakizaki rats.
Diabetic Angiopathies
Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats.
Diabetic Cardiomyopathies
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: Implications in heart failure.
Diabetic Cardiomyopathies
Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy.
Diabetic Foot
Linezolid-Associated Serotonin Syndrome. A Report of Two Cases.
Diabetic Nephropathies
Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
Diabetic Nephropathies
The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity.
Diabetic Retinopathy
Soluble Vascular Adhesion Protein-1 Mediates Spermine Oxidation as Semicarbazide-Sensitive Amine Oxidase: Possible Role in Proliferative Diabetic Retinopathy.
Diabetic Retinopathy
[Determination of serum semicarbazide-sensitive amine oxidase activity in diabetic retinopathy in type-2 diabetes]
Disorders of Excessive Somnolence
Pharmacologic safety concerns in Parkinson's disease: facts and insights.
Disorders of Excessive Somnolence
Selegiline reduces daytime sleepiness in patients with Parkinson's disease.
Disseminated Intravascular Coagulation
Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction.
Down Syndrome
Diminished activity of platelet monoamine oxidase in Down's syndrome.
Down Syndrome
Mitochondrial enzyme deficiencies in Down's syndrome.
Down Syndrome
Platelet monoamine oxidase activity in Down's syndrome.
Drug-Related Side Effects and Adverse Reactions
Adverse drug reaction following treatment with monoamine oxidase inhibitors and imipramine and similar drugs: report of two cases--one successfully treated with chlorpromazine.
Drug-Related Side Effects and Adverse Reactions
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.
Drug-Related Side Effects and Adverse Reactions
Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.
Drug-Related Side Effects and Adverse Reactions
Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
Drug-Related Side Effects and Adverse Reactions
The medical consequences of the selection of an antidepressant.
Drug-Related Side Effects and Adverse Reactions
[Adverse drug reactions in combined treatment with tricyclic antidepressants and monoamine oxidase inhibitors]
Duodenal Ulcer
A study of the effects of monoamine oxidase inhibitors on the experimental gastric and duodenal ulcers.
Duodenal Ulcer
Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Duodenal Ulcer
Effect of furazolidone on gut catecholamine in cysteamine-induced duodenal ulcer in the rat.
Duodenal Ulcer
Evidence for the involvement of dopamine agonists and antagonists in duodenal ulcer disease.
Duodenal Ulcer
MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine.
Dysautonomia, Familial
Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia.
Dyskinesias
A biochemical study of tardive dyskinesia in young male patients.
Dyskinesias
Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Dyskinesias
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
Dyskinesias
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Dyskinesias
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
Dyskinesias
Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.
Dyskinesias
Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Dyskinesias
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Dyskinesias
Garcinol, a multifaceted sword for the treatment of Parkinson's disease.
Dyskinesias
Influence of Single Nucleotide Polymorphisms in COMT , MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease.
Dyskinesias
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Dyskinesias
Monoamine oxidase B inhibitors for early Parkinson's disease.
Dyskinesias
Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
Dyskinesias
Parkinson disease: an update.
Dyskinesias
Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors.
Dyskinesias
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.
Dyskinesias
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Dyskinesias
Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia.
Dyskinesias
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Dyskinesias
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Dyskinesias
The therapy of the motor symptoms in the advanced stage of Parkinson's disease.
Dyskinesias
Treatment of levodopa-induced motor complications.
Dyskinesias
[Medical and surgical treatment of Parkinson's disease].
Dystonia
Catechol-O-methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans.
Eclampsia
Drug therapy of hypertensive crises.
Eclampsia
Hypertensive emergencies. Etiology and management.
Encephalomyelitis
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Encephalomyelitis
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Encephalomyelitis, Autoimmune, Experimental
Monoamine oxidase and acetylcholinesterase activity in animals with experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Encephalomyelitis, Autoimmune, Experimental
[ Serotonin and monoamine oxidase activity in the dynamics of experimental neuroallergy]
Encephalomyelitis, Autoimmune, Experimental
[Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis]
End Stage Liver Disease
Hepatic encephalopathy: An update of pathophysiologic mechanisms.
Endometrial Neoplasms
miR-522 facilitates the prosperities of endometrial carcinoma cells by directly binding to monoamine oxidase B.
Epilepsies, Partial
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Epilepsy
Bupropion SR for smoking cessation.
Epilepsy
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Epilepsy
Epilepsy and Serotonin (5HT): Variations of 5HT Related Genes in Temporal Lobe Epilepsy.
Epilepsy
Flumazenil and seizures: analysis of 43 cases.
Epilepsy
Higher transcription alleles of the MAOA-uVNTR polymorphism are associated with higher seizure frequency in temporal lobe epilepsy.
Epilepsy
Human monoamine oxidase. Lack of brain and platelet correlation.
Epilepsy
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
Epilepsy
Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Epilepsy
L-deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice.
Epilepsy
Monoamine oxidase activity in blood platelets of migraine patients.
Epilepsy
Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.
Epilepsy
Monoamine oxidases A and B gene polymorphisms in migraine patients.
Epilepsy
New directions in monoamine oxidase A and B selective inhibitors and substrates.
Epilepsy
Platelet monoamine oxidase activity in epilepsy.
Epilepsy
Safinamide (Newron Pharmaceuticals).
Epilepsy
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Epilepsy
Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl--analysis of kinetic data.
Epilepsy
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.
Epilepsy
Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
Epilepsy
[ELECTROENCEPHALOGRAPHIC CONTRIBUTION TO THE STUDY OF MONOAMINE OXIDASE INHIBITING DRUGS: CHANGES INDUCED IN EXPERIMENTAL EPILEPSY IN RABBITS.]
Epilepsy, Generalized
Association analysis between a regulatory-promoter polymorphism of the human monoamine oxidase A gene and idiopathic generalized epilepsy.
Epilepsy, Reflex
[Change in the catalytic properties of mitochondrial monoamine oxidase in experimental audiogenic epilepsy]
Epilepsy, Temporal Lobe
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Epilepsy, Temporal Lobe
Epilepsy and Serotonin (5HT): Variations of 5HT Related Genes in Temporal Lobe Epilepsy.
Epilepsy, Temporal Lobe
Higher transcription alleles of the MAOA-uVNTR polymorphism are associated with higher seizure frequency in temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.
Erectile Dysfunction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Erectile Dysfunction
Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction.
Erectile Dysfunction
Moringa oleifera leaf and seed inclusive diets influenced the restoration of biochemicals associated with erectile dysfunction in the penile tissue of STZ-induced diabetic male rats treated with/without Acarbose drug.
Erectile Dysfunction
Naringin regulates erectile dysfunction by abolition of apoptosis and inflammation through NOS/cGMP/PKG signalling pathway on exposure to Bisphenol-A in hypertensive rat model.
Erectile Dysfunction
Three cases of female anorgasmia associated with MAOIs.
Esophageal Neoplasms
Decreased monoamine oxidase (MAO) activity and MAO-A expression as diagnostic indicators of human esophageal cancers.
Essential Hypertension
Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension.
Exfoliation Syndrome
Lysyl oxidase-like protein 1 (LOXL1) gene polymorphisms and exfoliation glaucoma in a Central European population.
Familial Primary Pulmonary Hypertension
MAO-A promoter polymorphism and idiopathic pulmonary arterial hypertension.
Fatigue Syndrome, Chronic
A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.
Fibromyalgia
Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Fibromyalgia
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome.
Fibromyalgia
MONOAMINE OXIDASE INHIBITORS (MAOIs) FOR FIBROMYALGIA SYNDROME.
Fibromyalgia
Protective Effect of Esculetin, Natural Coumarin in Mice Model of Fibromyalgia: Targeting Pro-Inflammatory Cytokines and MAO-A.
Fibromyalgia
The association between fibromyalgia and polymorphism of monoamine oxidase A and interleukin-4.
Fibromyalgia
Which genotype of MAO gene that the patients have are likely to be most susceptible to the symptoms of fibromyalgia?
Fragile X Syndrome
Testing for association of the monoamine oxidase A promoter polymorphism with brain structure volumes in both autism and the fragile X syndrome.
Frontotemporal Dementia
Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide.
Frontotemporal Dementia
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.
Galactorrhea
[Treatment of extra-puerperal galactorrhea with the MAO-B inhibitor selegiline]
Ganglion Cysts
The novel phytocomponent asiaticoside-D isolated from Centella asiatica exhibits monoamine oxidase-B inhibiting potential in the rotenone degenerated cerebral ganglions of Lumbricus terrestris.
Gastritis
[Intravital histopathological changes in the gastric mucosa and the activity of certain cytoplasmic enzymes (cholinesterase, monoamine oxidase, histaminase) and acetylcholine in peptic ulcer and chronic gastritis]
Gastritis, Atrophic
Enzyme activities in human gastric mucosa in gastritis and resected stomachs.
Gastroesophageal Reflux
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Genetic Diseases, Inborn
Anesthetic management in MAO-A and MAO-B deficiency: a case report.
Genetic Diseases, Inborn
Use of a monoclonal antibody for comparative studies of monoamine oxidase B in mitochondrial extracts of human brain and peripheral tissues.
Glaucoma
Drug-induced secondary glaucoma.
Glaucoma
Human platelet monoamine oxidase activity in glaucoma.
Glaucoma
Identification of pathogenic genes and transcription factors in glaucoma.
Glaucoma
Ocular hypotensive effects of monoamine oxidase-A inhibitors in rabbit.
Glaucoma
[Changes of monoamine oxidase (MAO) activity in patients with glaucoma (author's transl)]
Glaucoma
[Monoamine oxidase activity in women with glaucoma]
Glaucoma, Angle-Closure
3. Phenylephrine hydrochloride.
Glaucoma, Angle-Closure
Drug-induced secondary glaucoma.
Glaucoma, Angle-Closure
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.
Glaucoma, Angle-Closure
[Drug-induced glaucoma].
Glioblastoma
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.
Glioblastoma
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1.
Glioblastoma
Monoamine oxidase B activity is increased in human gliomas.
Glioblastoma
Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case.
Glioblastoma
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.
Glioblastoma
Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study.
Glioblastoma
Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.
Glioblastoma
The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
Glioblastoma
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Glioblastoma
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Glioblastoma
[Development of experimental brain tumors in modulated amine metabolism]
Glioma
Antioxidant defense against antidepressants in C6 and 1321N1 cells.
Glioma
Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay.
Glioma
Densities of I2-imidazoline receptors, imidazoline receptor proteins, and MAO-B sites in human gliomas and pituitary adenomas.
Glioma
Design and Synthesis of a MAO-B-Selectively Activated Prodrug Based on MPTP: A Mitochondria-Targeting Chemotherapeutic Agent for Treatment of Human Malignant Gliomas.
Glioma
Differences in the structures of monoamine oxidases A and B in rat clonal cell lines.
Glioma
Expression of A and B types of monoamine oxidase in differentiated neuroblastoma hybrid cells.
Glioma
Expression of A and B types of monoamine oxidase in neuroblastoma hybrid cells.
Glioma
Expression of differentiated activities in reaggregated brain cell cultures.
Glioma
Glioma cell antioxidant capacity relative to reactive oxygen species produced by dopamine.
Glioma
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Glioma
Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R-(-)-deprenyl.
Glioma
Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells.
Glioma
Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro.
Glioma
Metabolism of biogenic amines in neuroblastoma and glioma cells in culture.
Glioma
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Glioma
Monoamine oxidase B activity is increased in human gliomas.
Glioma
Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1? and with transcription factors Sp1 and Sp3.
Glioma
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Glioma
Near-Infrared Monoamine Oxidase Inhibitor Biodistribution in a Glioma Mouse Model.
Glioma
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.
Glioma
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Glioma
Rational Design of a Two-Photon Fluorogenic Probe for Visualizing Monoamine Oxidase?A Activity in Human Glioma Tissues.
Glioma
Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells.
Glioma
The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
Glioma
[Effect of monoamine oxidase inhibitor on the differentiation of malignant glioma cell].
Glomerulonephritis
Drug therapy of hypertensive crises.
Glomerulonephritis, IGA
Monoamine oxidase inhibitors for IgA nephropathy.
Glucose Intolerance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Goiter
Dissociation of thyrotropin-dependent enzyme activities, reduced iodide transport, and preserved iodide organification in nonfunctioning thyroid adenoma and multinodular goiter.
Goiter
[Acetylcholine and monoamine oxidase content of blood serum in patients with toxic goiter]
Goiter
[Monoamine oxidase activity in diffuse toxic goiter and primary hypothyroidism]
Gout
Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress.
Gout
Monoamine oxidase A gene polymorphisms and enzyme activity associated with risk of gout in Taiwan aborigines.
Granuloma Annulare
Increased activity of serum amine oxidases in granuloma annulare, necrobiosis lipoidica and diabetes.
Graves Disease
Monoamine oxidase (MAO) activity and its forms in normal and pathological human thyroid tissues.
Gynecomastia
[Gynecomastia induced by a monoamine oxidase inhibitor]
Hallucinations
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Hallucinations
Ayahuasca: Uses, Phytochemical and Biological Activities.
Hallucinations
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.
Hallucinations
Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients.
Hallucinations
THE EFFECT OF D-LYSERGIC ACID DIETHYLAMIDE TARTRATE (LSD-25) AND D-2-BROMO LYSERGIC ACID TARTRATE (BOL-148) ON SPECIFIC CHOLINESTERASE AND MONOAMINE OXIDASE OF RAT LIVER AS POSSIBLE FACTORS IN THE MECHANISM OF HALLUCINATION. A HISTOCHEMICAL STUDY.
Hallucinations
THE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE TARTRATE (LSD-25) ON THE CHOLINESTERASES AND MONOAMINE OXIDASE IN THE SPINAL CORD: A POSSIBLE FACTOR IN THE MECHANISM OF HALLUCINATION.
Hallucinations
Withdrawal phenomena associated with antidepressant and antipsychotic agents.
Head Injuries, Closed
Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.
Headache Disorders
Prophylactic pharmacological treatment of chronic daily headache.
Headache Disorders
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Heart Arrest
Could monoamine oxidase inhibitors promote asystole in electroconvulsive therapy patients?
Heart Arrest
Inhibition of monoamine oxidase A increases recovery after experimental cardiac arrest.
Heart Diseases
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction.
Heart Diseases
Cardiac disorders and antidepressant medications.
Heart Diseases
Histochemically demonstrable monoamine oxidase activity in the adult human heart in various cardiac diseases.
Heart Diseases
Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet.
Heart Diseases
Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts.
Heart Diseases
Monoamine oxidase-A, serotonin and norepinephrine: synergistic players in cardiac physiology and pathology.
Heart Diseases
Monoamine Oxidases, Oxidative Stress, and Altered Mitochondrial Dynamics in Cardiac Ageing.
Heart Diseases
Safe use of epinephrine with halothane anesthesia.
Heart Diseases
Serum monoamine oxidase in the heart diseases.
Heart Failure
ABNORMALITIES OF SERUM MONOAMINE OXIDASE IN CHRONIC CONGESTIVE HEART FAILURE.
Heart Failure
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction.
Heart Failure
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Heart Failure
Cardiac catechol O-methyltransferase and monoamine oxidase activity in congestive heart failure.
Heart Failure
Effect of ibopamine and the active metabolite epinine on the catecholamine content of rat hypothalamus and brainstem in vitro.
Heart Failure
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: Implications in heart failure.
Heart Failure
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Heart Failure
Major depression and heart failure: Interest of monoamine oxidase inhibitors.
Heart Failure
Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload.
Heart Failure
Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts.
Heart Failure
Monoamine Oxidase Is Overactivated in Left and Right Ventricles from Ischemic Hearts: An Intriguing Therapeutic Target.
Heart Failure
Oxidative stress by monoamine oxidase-A impairs transcription factor-EB activation and autophagosome clearance leading to cardiomyocyte necrosis and heart failure.
Heart Failure
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Heart Failure
Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure.
Heart Failure
Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure.
Heart Failure
Practical considerations for the treatment of elderly patients with migraine.
Heart Failure
Production of a truncated soluble human semicarbazide-sensitive amine oxidase mediated by a GST-fusion protein secreted from HEK293 cells.
Heart Failure
Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2.
Heart Failure
Semicarbazide-sensitive amine oxidase and mortality in chronic heart failure.
Hemiplegia
[RECURRING LEFT HEMIPLEGIA SECONDARY TO A MEDICAMENTOUS ORTHOSTATIC HYPOTENSION CAUSED BY A MONOAMINE OXIDASE INHIBITOR IN A PATIENT WITH STENOSIS OF THE INTERNAL CAROTID AT ITS ORIGIN. CURE BY ENDARTERIECTOMY AND CESSATION OF THE MAOI.]
Hemochromatosis
Isoenzyme composition of human plasma monoamine oxidase in normal subjects and in fibrotic liver disease.
Hemorrhagic Fever with Renal Syndrome
[Inactivation of serotonin in patients with hemorrhagic fever with kidney syndrome]
Hepatic Encephalopathy
Analysis of the effect of the polyprenol preparation ropren and the choline alphoscerate preparation gliatilin on the membrane-bound and soluble forms of cholinesterases and monoamine oxidase of rat brain and serum in the tetrachloromethane model system of hepatic encephalopathy.
Hepatic Encephalopathy
Hepatic encephalopathy: An update of pathophysiologic mechanisms.
Hepatic Encephalopathy
Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy.
Hepatitis
Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B.
Hepatitis
The diagnostic potential of the combined determination of serum monoamine oxidase and N-acetyl-beta-D-glucosaminidase for fibroproliferative liver diseases.
Hepatitis
[Prognostic value of monoamine oxidase (MAO) in the serum in correlation to the activity of AspAt and AlAt in viral hepatitis]
Hepatitis
[Serum monoamine oxidase (MAO) as a prognostic indicator in chronic active hepatitis. II]
Hepatitis, Chronic
[Preliminary results of the studies of serum monoamine oxidase and ceruloplasmin activities in patients with chronic hepatitis and liver cirrhosis]
Hepatitis, Chronic
[Serum monoamine oxidase (MAO) as a prognostic indicator in chronic active hepatitis. II]
Herpes Zoster
Histochemical localization of monoamine oxidase types A and B in the adrenal gland.
Herpes Zoster
Identification of imidazoline-receptor binding sites in cortex and medulla of the bovine adrenal gland. Colocalization with MAO-A and MAO-B.
Herpes Zoster
In vivo voltammetric monitoring of noradrenaline release and catecholamine metabolism in the hypothalamic paraventricular nucleus.
Hirschsprung Disease
Cholinesterases and monoamine oxidase in congenital megacolon.
Histiocytoma, Malignant Fibrous
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer.
HIV Infections
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Hodgkin Disease
Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.
Hodgkin Disease
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Huntington Disease
Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.
Huntington Disease
Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.
Huntington Disease
Intra- and extraneuronal monoamineoxidase-A and -B activities after central axotomy (hemisection) on rats.
Huntington Disease
Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion.
Huntington Disease
Platelet monoamine oxidase activity in Huntington's chorea.
Huntington Disease
Platelet monoamine oxidase activity in patients with Huntington's disease.
Huntington Disease
Platelet monoamine oxidase activity in subjects tested for Huntington's disease gene mutation.
Huntington Disease
Treatment of depression in Huntington's disease with monoamine oxidase inhibitors.
Huntington Disease
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Huntington Disease
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
Huntington Disease
[Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)]
Hydrocephalus
Acute hydrocephalus upregulates monoamine oxidase mRNA in neonatal rat brain.
Hyperalgesia
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Hyperalgesia
Fisetin exerts antihyperalgesic effect in a mouse model of neuropathic pain: engagement of spinal serotonergic system.
Hyperalgesia
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
Hypercholesterolemia
Influence of experimental hypercholesterolemia on the monoamine oxidase activity in rabbit arteries.
Hyperemia
Changes in the plethysmogram patterns of finger reactive hyperemia in nutritional (alcoholic) liver disease patients with increased serum monoamine oxidase activities.
Hyperglycemia
Effect of experimental diabetes on the catecholamine metabolism in rat brain.
Hyperglycemia
Treatment of depression in patients with diabetes mellitus.
Hyperinsulinism
Plasma semicarbazide-sensitive amine oxidase is moderately decreased by pronounced exogenous hyperinsulinemia but is not associated with insulin sensitivity and body fat.
Hyperkalemia
Peaked "T" waves with tranylcypromine (parnate) overdose.
Hyperkinesis
Locomotor stimulation by L-dopa: relative importance of noradrenaline receptor activation.
Hyperlipidemias
Hyperlipidemia Downregulate Brain Antioxidant Defense Enzymes and Neurotrophins in Rats: Assessment of the Modulatory Potential of EPA+DHA and Zerumbone.
Hyperlipoproteinemias
Chiral inversion of drugs: coincidence or principle?
Hyperparathyroidism, Secondary
Effect of chronic renal failure with and without secondary hyperparathyroidism on the activities of synaptosomal tyrosine hydroxylase and monoamine oxidase.
Hyperprolactinemia
Pharmacological causes of hyperprolactinemia.
Hypersensitivity
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Hypersensitivity
Bupropion SR for smoking cessation.
Hypersensitivity
Iproclozide fulminant hepatitis. Possible role of enzyme induction.
Hypersensitivity
Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.
Hypersensitivity
Vascular hypersensitivity and potentiation of catecholamines induced by monoamine oxidase inhibition.
Hypersensitivity
[Dynamics of the activity of mitochondrial monoamine oxidase of the liver in allergic reactions of the direct type]
Hypersensitivity
[Role of monoamine oxidase inhibition in the formation of delayed-type hypersensitivity]
Hypertension
"Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity.
Hypertension
A case of MAO inhibitor/MDMA interaction: agony after ecstasy.
Hypertension
A method for measurement of monoamine oxidase inhibition in man: application to studies on hypertension.
Hypertension
Acute myocarditis after massive phenelzine overdose.
Hypertension
Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors.
Hypertension
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Hypertension
Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study.
Hypertension
Aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, monoamine oxidase, malondialdehyde, and acid phosphatase in rat brain capillaries and kidney glomeruli in experimental hypertension.
Hypertension
Brain and vascular monoamine oxidase activity in the deoxycorticosterone-salt hypertensive rat.
Hypertension
Cardiac hypertrophy in spontaneously hypertensive rats.
Hypertension
Clinical and pharmacologic observations on a monoamine oxidase inhibitor (pargyline hydrochloride) in hypertension.
Hypertension
CLINICAL EXPERIENCE WITH THE MONOAMINE OXIDASE INHIBITOR, DL-SERINE-N-ISOPROPYLHYDRAZIDE (RO 4-1038), IN THE TREATMENT OF HYPERTENSION.
Hypertension
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Hypertension
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Hypertension
Drug-induced hypertension. Recognition and management in older patients.
Hypertension
Evaluation of 2 monoamine oxidase inhibitors (iproniazid and JB 516) in the therapy of arterial hypertension.
Hypertension
Hemodynamics and monoamine oxidase activity in spontaneously hypertensive rats (SHR).
Hypertension
Hypertension during anaesthesia with monoamine oxidase inhibitors.
Hypertension
HYPERTENSION WITH MONOAMINE OXIDASE INHIBITORS.
Hypertension
Hypertensive emergencies. Etiology and management.
Hypertension
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Hypertension
MAO-A promoter polymorphism and idiopathic pulmonary arterial hypertension.
Hypertension
Monoamine oxidase defect in essential arterial hypertension. A single dose pargyline test.
Hypertension
Monoamine oxidase inhibitors in hypertension.
Hypertension
Monoamine oxidase inhibitors in hypertension: preliminary observations on nialamide.
Hypertension
Perioperative management of drug therapy, clinical considerations.
Hypertension
Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs.
Hypertension
Proceedings: Monoamine oxidase defect in essential arterial hypertension: 'a single dose pargyline test'.
Hypertension
Safe use of epinephrine with halothane anesthesia.
Hypertension
Safety and tolerability of linezolid.
Hypertension
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.
Hypertension
Systemic reactions to ophthalmic drug preparations.
Hypertension
The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.
Hypertension
The use of monoamine oxidase inhibitors as adjuncts in the treatment of hypertension and angina pectoris.
Hypertension
Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines.
Hypertension
Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.
Hypertension
[5 years treatment of arterial hypertension with a monoamine oxidase inhibiter (Marsilid)]
Hypertension
[ACUTE HYPERTENSION DUE TO MONOAMINE OXIDASE INHIBITORS AND THE EATING OF CHEESE.]
Hypertension
[Ambulatory treatment of hypertension with a monoamine oxidase inhibitor]
Hypertension
[Antidepressive agents and hypertension: A case/no-case study in French pharmacovigilance database].
Hypertension
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]
Hypertension
[Blood phenolsulfotransferase and monoamine oxidase-B activity in essential arterial hypertension]
Hypertension
[Clinical experiences with monoamine oxidase inhibitor (niamid) in the treatment of hypertension.]
Hypertension
[Disorder of monoamine oxidase activity in essential arterial hypertension]
Hypertension
[Effect of several drugs on hypertension and cerebral monoamine oxidase activity in old rats exposed to environmental stress]
Hypertension
[Hemodynamics, serotonin and monoamine oxidase in bronchial asthma and systemic arterial hypertension]
Hypertension
[Monoamine oxidase activity in rheumatic heart disease associated with symptomatic hypertension]
Hypertension
[Monoamine oxidase and essential arterial hypertension]
Hypertension
[Myocardial status, hemodynamics and pressor humoral substances in patients with bronchial asthma and arterial hypertension]
Hypertension
[On the treatment of arterial hypertension with a drug inhibiting monoamine oxidase (DL-serine-N2-isopropylhydrazide).]
Hypertension
[Results obtained with a new monoamine oxidase inhibitor in the treatment of arterial hypertension.]
Hypertension
[Studies on mode of action of monoamine oxidase inhibitors on the experimental hypertension of the rat]
Hypertension
[Treatment of certain refractory arterial hypertensions with a monoamine oxidase inhibitor]
Hypertension, Malignant
Hypertensive emergencies. Etiology and management.
Hypertension, Portal
Cardiovascular responses to serotonin in experimental liver disease.
Hypertension, Portal
Serum monoamine oxidase (MAO) levels in portal hypertension.
Hypertension, Pregnancy-Induced
Dopamine in the Pathophysiology of Preeclampsia and Gestational Hypertension: Monoamine Oxidase (MAO) and Catechol-O-methyl Transferase (COMT) as Possible Mechanisms.
Hypertension, Renovascular
Drug therapy of hypertensive crises.
Hypertensive Encephalopathy
Hypertensive emergencies. Etiology and management.
Hypertensive Encephalopathy
Posterior Reversible Encephalopathy Syndrome Secondary to Hypertensive Encephalopathy Brought on by a MAO Inhibitor: A Case Report.
Hyperthyroidism
Biogenic amines and thyrotoxicosis.
Hyperthyroidism
Effect of hyper- and hypothyroidism on platelet monoamine oxidase activity and serotonin metabolism.
Hyperthyroidism
Influence of hypo- and hyperthyroidism on noradrenaline metabolism in brown adipose tissue of the developing rat.
Hyperthyroidism
Influence of neonatal and adult hyperthyroidism on behavior and biosynthetic capacity for norepinephrine, dopamine and 5-hydroxytryptamine in rat brain.
Hyperthyroidism
Metabolism of monoamines and diamines in hyperthyroid and hypothyroid rats.
Hyperthyroidism
The activities of antioxidant enzymes and monoamine oxidase and uncoupling protein 1 content in brown fat of hypo- and hyperthyroid rats.
Hypertrophy, Left Ventricular
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Hypoglycemia
Effect of experimental diabetes on the catecholamine metabolism in rat brain.
Hypoglycemia
Treatment of depression in patients with diabetes mellitus.
Hypoglycemia
Weight gain with antidepressants and lithium.
Hypokinesia
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Hypokinesia
Future directions in the treatment of Parkinson's disease.
Hypokinesia
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
Hypokinesia
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Hypokinesia
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Hyponatremia
Medically serious adverse effects of newer antidepressants.
Hypophosphatemia, Familial
Role of Chronic Inhibition of Dopamine-Metabolizing Enzymes in the Regulation of Renal Sodium and Phosphate Excretion in the Rat Remnant Kidney.
Hypotension
2-bromoethylamine, a suicide inhibitor of semicarbazide-sensitive amine oxidase, increases hydralazine hypotension in rats.
Hypotension
Biochemical and physiological effects of chlordimeform.
Hypotension
Blood pressure effects of monoamine oxidase inhibitors--the highs and lows.
Hypotension
Catecholamines and monoamine oxidase activity in turkeys with high or low blood pressure.
Hypotension
Controlling monoamine oxidase inhibitor hypotension with 9-alpha-fluoro-hydrocortisone.
Hypotension
Enhancement of hydralazine hypotension by low doses of isoniazid. Possible role of semicarbazide-sensitive amine oxidase inhibition.
Hypotension
Hypotension following use of monoamine oxidase inhibitor.
Hypotension
MAO inhibitors and coronary artery surgery: a patient death.
Hypotension
Phenelzine toxicity responsive to dantrolene.
Hypotension
Practical considerations for the treatment of elderly patients with migraine.
Hypotension
Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide.
Hypotension
[Pharmacological aspect of the treatment of hypotension induced by phenothiazine neuroleptics and monoamine oxidase inhibitors]
Hypotension, Orthostatic
Acute psychosis following phenelzine discontinuation.
Hypotension, Orthostatic
Antidepressants and falls in the elderly.
Hypotension, Orthostatic
Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.
Hypotension, Orthostatic
Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure.
Hypotension, Orthostatic
Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
Hypotension, Orthostatic
Drug-induced orthostatic hypotension.
Hypotension, Orthostatic
Evaluating dysfunction of the autonomic nervous system.
Hypotension, Orthostatic
Idiopathic orthostatic hypotension controlled with a monoamine oxidase inhibitor and 9-alpha-fluorohydrocortisone.
Hypotension, Orthostatic
Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.
Hypotension, Orthostatic
Recent advances in geriatric psychopharmacology.
Hypotension, Orthostatic
St. John's wort: a new alternative for depression?
Hypotension, Orthostatic
Systemic reactions to ophthalmic drug preparations.
Hypotension, Orthostatic
The cardiovascular effects of antidepressants.
Hypotension, Orthostatic
The use of newer antidepressants for panic disorder.
Hypotension, Orthostatic
Tranylcypromine compared with L-deprenyl in Alzheimer's disease.
Hypotension, Orthostatic
Treatment of Depression in Patients with Concomitant Cardiac Disease.
Hypotension, Orthostatic
Treatment of neurogenic orthostatic hypotension with a monoamine oxidase inhibitor and tyramine.
Hypotension, Orthostatic
[Hypertension en orthostatic hypotension during use of monoamine oxidase (MAO) inhibitors].
Hypotension, Orthostatic
[RECURRING LEFT HEMIPLEGIA SECONDARY TO A MEDICAMENTOUS ORTHOSTATIC HYPOTENSION CAUSED BY A MONOAMINE OXIDASE INHIBITOR IN A PATIENT WITH STENOSIS OF THE INTERNAL CAROTID AT ITS ORIGIN. CURE BY ENDARTERIECTOMY AND CESSATION OF THE MAOI.]
Hypotension, Orthostatic
[Treatment of neurogenic orthostatic hypotension by an association of tyramine and a monoamine oxidase inhibitor (author's transl)]
Hypothyroidism
Effect of hyper- and hypothyroidism on platelet monoamine oxidase activity and serotonin metabolism.
Hypothyroidism
Presence of kynurenine hydroxylase in developing rat brain.
Hypothyroidism
Selective effects of neonatal hypothyroidism on monoamine oxidase activities in the rat brain.
Hypothyroidism
[Monoamine oxidase activity in diffuse toxic goiter and primary hypothyroidism]
Hypothyroidism
[The effect of hyper- and hypothyroidism on serotonin and noradrenaline concentration and monoamine oxidase activity in the nerve endings of the brains of rats]
Illusions
Correlation between platelet monoamine oxidase activity and the strength of a visual illusion.
Infarction, Middle Cerebral Artery
Lack of protection from ischemic injury of monoamine oxidase B-deficient mice following middle cerebral artery occlusion.
Infections
Aberrations in cerebral vascular functions due to Plasmodium yoelii nigeriensis infection in mice.
Infections
Alteration of free radical metabolism in the brain of mice infected with scrapie agent.
Infections
Brugia malayi: status of host during different stages of infection.
Infections
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Infections
Linezolid-Associated Serotonin Syndrome. A Report of Two Cases.
Infections
Monoamine oxidase inhibition and CNS immunodeficiency infection.
Infections
Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Infections
Patient selection in ambulatory anesthesia - an evidence-based review: part II.
Infections
Serum enzyme tests in hepatosplenic schistosomiasis.
Infections
The response of histamine degrading enzymes to nematode infection.
Infections
Toxicity of derivatives from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine against Toxoplasma gondii after infection of differentiated 3T3-L1 cells.
Infections
Tryptamine and sakuranetin accumulation in Sekiguchi lesions associated with the light-enhanced resistance of the lesion mimic mutant of rice to Magnaporthe oryzae
Infections
[Monoamine oxidase (MAO) activity in the blood and homogenates of the spleen, mesenteric lymph node and small intestine of mice with experimental Trichinella spiralis infection]
Infections
[Monoamine oxidase (MAO) activity in the blood, spleen, mesenteric lymph node and small intestine of mice with Trichinella pseudospiralis infection]
Infections
[Separate and combined action of antibiotics and vitamins on monoamine oxidase activity of the rabbit liver in staphylococcal infection]
Infectious Mononucleosis
Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections.
Infertility
The effect of R-(-)-deprenyl administration on reproductive parameters of rat males.
Infertility
[Monoamine oxidase activity in women treated with clomide for functional sterility]
Influenza, Human
Amantadine as augmentation therapy in the management of treatment-resistant depression.
Influenza, Human
Presence of specific antigen and alterations in enzyme activity in the chorio-allantoic membrane of embryonate hen eggs infected with influenza A2 or B virus.
Insulin Resistance
A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ''Harmine''.
Insulin Resistance
Plasma semicarbazide-sensitive amine oxidase is moderately decreased by pronounced exogenous hyperinsulinemia but is not associated with insulin sensitivity and body fat.
Insulinoma
Comparison of monoamine oxidase in golden hamster islets and insulinoma.
Insulinoma
Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas.
Intellectual Disability
A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression.
Intellectual Disability
Association of monoamine oxidase A and serotonin transporter gene functional variants with intellectual disability related behavioral problems.
Intellectual Disability
Catecholamine metabolism and psychiatric or behavioral disorders.
Intellectual Disability
Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis.
Intellectual Disability
Monoamine oxidase activity of blood platelets and their ability to store 5-hydroxytryptamine in some mental deficiencies.
Intellectual Disability
Relationship between monoamine oxidase (MAO) A specific activity and proportion of human skin fibroblasts which express the enzyme in culture.
Intellectual Disability
Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.
Intellectual Disability
The promoter of the human monoamine oxidase A gene.
Intellectual Disability
[Discovery of monoamine oxidase forms A and B]
Intracranial Aneurysm
Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation.
Intracranial Arteriosclerosis
[MONOAMINE OXIDASE INHIBITORS IN PSYCHOSES DUE TO CEREBRAL ARTERIOSCLEROSIS.]
Intracranial Hemorrhages
Hypertensive emergencies. Etiology and management.
Iron Deficiencies
Fetal iron deficiency and genotype influence emotionality in infant rhesus monkeys.
Iron Deficiencies
Influence of prenatal iron deficiency and MAOA genotype on response to social challenge in rhesus monkey infants.
Iron Deficiencies
Iron deficiency in the rat: biochemical studies of brain metabolism.
Iron Deficiencies
Prenatal iron deficiency and monoamine oxidase A (MAOA) polymorphisms: combined risk for later cognitive performance in rhesus monkeys.
Iron Deficiencies
[Characterization of rat monoamine oxidase and the alteration of their activities in iron deficiency]
Irritable Bowel Syndrome
Correlation of serotonin and monoamine oxidase levels with anxiety level in diarrhea-predominant irritable bowel syndrome.
Ischemic Stroke
Change in platelet monoamine oxidase activity in the acutest period of ischemic stroke is associated with the degree of neurological recovery.
Ischemic Stroke
Mass spectrometry-based urinary metabolomics for the investigation on the mechanism of action of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. leaves against ischemic stroke in rats.
Ischemic Stroke
[Role of semicarbazide-sensitive amine oxidase in disturbances of endogenic detoxication in ischemic stroke patients].
Joint Diseases
[Monoamine oxidase activity in the synovial fluid in joint diseases]
Kidney Diseases
Semicarbazide-sensitive amine oxidase and kidney disease.
Kidney Failure, Chronic
Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure.
Kidney Failure, Chronic
Effect of chronic renal failure with and without secondary hyperparathyroidism on the activities of synaptosomal tyrosine hydroxylase and monoamine oxidase.
Kidney Failure, Chronic
Identification, expression and tissue distribution of a renalase homologue from mouse.
Kidney Failure, Chronic
[Monoamine oxidase activity in patients with chronic renal failure and in experimental uremia in rats]
Kidney Neoplasms
Monoamine Oxidase B in Renal Cell Carcinoma.
Learning Disabilities
[Genetic polymorphism of COMT in mental disorders]
Leprosy
Chiral inversion of drugs: coincidence or principle?
Lesch-Nyhan Syndrome
Monoamine oxidase activity decreased in cells lacking hypoxanthine phosphoribosyltransferase activity.
Lesch-Nyhan Syndrome
Monoamine oxidase and catechol-o-methyltransferase activity in cultured fibroblasts from patients with maple syrup urine disease, Lesch-Nyhan syndrome and healthy controls.
Leukemia
An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins.
Leukemia
Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent.
Leukemia
Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells.
Leukemia
[The vehaviour of monoaminooxydase (MAO) activity in tumours. I. MAO activity measurement in experimental tumours (author's transl)]
Leukoencephalopathies
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Leukoencephalopathy, Progressive Multifocal
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Leukopenia
A case report of leukopenia associated with phenelzine.
Lewy Body Disease
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
Lewy Body Disease
The neuroprotective mechanism of action of the multimodal drug ladostigil.
Lewy Body Disease
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Lichen Planus
Measurement of Serum Monoamine Oxidase in Lichen Planus and its Clinical Significance.
Lipoma
Prediction of cell type-specific gene modules: identification and initial characterization of a core set of smooth muscle-specific genes.
Liver Cirrhosis
Bupropion SR for smoking cessation.
Liver Cirrhosis
Rapid Two-Photon Fluorescence Imaging of Monoamine Oxidase B for Diagnosis of Early-Stage Liver Fibrosis in Mice.
Liver Cirrhosis
Validity of monoamine oxidase in serum for diagnosis of liver cirrhosis: estimation of predictive values, sensitivities and specificities.
Liver Cirrhosis
[Determination of serum monoamine oxidase (MAO) --diagnosis of liver fibrosis]
Liver Cirrhosis
[Preliminary results of the studies of serum monoamine oxidase and ceruloplasmin activities in patients with chronic hepatitis and liver cirrhosis]
Liver Diseases
Abnormalities of serum monoamine oxidase in chronic liver disease.
Liver Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Liver Diseases
Association of gene polymorphisms encoding dopaminergic system components and platelet MAO-B activity with alcohol dependence and alcohol dependence-related phenotypes.
Liver Diseases
Changes in the plethysmogram patterns of finger reactive hyperemia in nutritional (alcoholic) liver disease patients with increased serum monoamine oxidase activities.
Liver Diseases
Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease.
Liver Diseases
Clinical study of serum monoamine oxidase in liver diseases. Colorimetric method with p-benzylamino-azo-beta-naphthol as substrate.
Liver Diseases
Comparative studies on human plasma monoamine oxidase in normal subjects and in fibrotic liver disease.
Liver Diseases
Isoenzyme composition of human plasma monoamine oxidase in normal subjects and in fibrotic liver disease.
Liver Diseases
Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.
Liver Diseases
Monoamine oxidase activity and kinetic properties in platelet-rich plasma from controls, chronic alcoholics, and patients with nonalcoholic liver disease.
Liver Diseases
Quantitative evaluation of brain edema by radionuclide imaging technique.
Liver Diseases
The diagnostic potential of the combined determination of serum monoamine oxidase and N-acetyl-beta-D-glucosaminidase for fibroproliferative liver diseases.
Liver Diseases
Validity of monoamine oxidase in serum for diagnosis of liver cirrhosis: estimation of predictive values, sensitivities and specificities.
Liver Diseases
[Serum monoamine oxidase (MAO) in the differential diagnosis of chronic liver disease. I]
Liver Diseases
[Serum monoamine oxidase activity in liver diseases]
Liver Neoplasms, Experimental
Association of monoamine oxidase with lipid--a comparative study mitochondria from Novikoff hepatoma and rat liver.
Lordosis
Effects of monoamine oxidase inhibition on female sexual behavior, serotonin levels and type A and B monoamine oxidase activity.
Lordosis
Inhibition of lordosis behavior by intrahypothalamic implants of pargyline.
Lordosis
Pargyline-induced increase in serotonin levels: correlation with inhibition of lordosis in rats.
Lung Injury
Xanthine oxidase-induced lung injury inhibits removal of 5-hydroxytryptamine from the pulmonary circulation.
Lung Neoplasms
Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.
Lung Neoplasms
Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer.
Lung Neoplasms
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Lung Neoplasms
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell.
Lung Neoplasms
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Lung Neoplasms
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Lung Neoplasms
Repurposing of a monoamine oxidase A inhibitor?heptamethine carbocyanine dye conjugate for paclitaxel?resistant non?small cell lung cancer.
Lung Neoplasms
Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.
Lung Neoplasms
The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1? protein accumulation in non-small cell lung cancer cells.
Lung Neoplasms
[Serum monoamine oxidase activity and serotoninopectic properties in lung cancer patients]
Lymphadenopathy
Lymphadenopathy associated with monoamine oxidase inhibitors.
Lymphoma
[Effect of Monoamine Oxidase Inhibitor Phenelzine on Proliferation of Mantle Cell Lymphoma and Its Mechanism].
Lymphoma, Mantle-Cell
[Effect of Monoamine Oxidase Inhibitor Phenelzine on Proliferation of Mantle Cell Lymphoma and Its Mechanism].
Macular Edema
Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.
Malaria
Topological polar surface area: a useful descriptor in 2D-QSAR.
Malnutrition
Effects of nutritional stress on brain tyramine concentration and dopamine turnover.
Malnutrition
Maintenance of central and peripheral monoamine oxidase activity in developing rats subjected to disturbed alimentary rhythms and undernutrition.
Mania
Acute psychosis following phenelzine discontinuation.
Mania
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
Mania
Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Mania
Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis.
Mania
Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials.
Mania
Clinical herbal interactions with conventional drugs: from molecules to maladies.
Mania
Drug-induced mania.
Mania
Implications of monoamine oxidase inhibitor-induced hypomania.
Mania
Managing bipolar depression.
Mania
Mania after withdrawal of isocarboxazid.
Mania
Mania associated with high percentage of inhibition of monoamine oxidase.
Mania
Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor.
Mania
Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients.
Mania
Platelet serotonin and serum lipids in psychotic mania.
Mania
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.
Mania
Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor.
Maple Syrup Urine Disease
Monoamine oxidase and catechol-o-methyltransferase activity in cultured fibroblasts from patients with maple syrup urine disease, Lesch-Nyhan syndrome and healthy controls.
Massive Hepatic Necrosis
Iproclozide fulminant hepatitis. Possible role of enzyme induction.
Massive Hepatic Necrosis
[Fatal fulminant hepatitis in 2 women taking toloxatone (Humoryl)]
Melanoma
Cudarflavone B provides neuroprotection against glutamate-induced mouse hippocampal HT22 cell damage through the Nrf2 and PI3K/Akt signaling pathways.
Melanoma
Current status of symptomatic medical therapy in Parkinson's disease.
Melanoma
The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Memory Disorders
Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: prevention by ladostigil.
Memory Disorders
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Memory Disorders
Extract of Yi Zhi Fang improves learning and memory behaviours of mice and its possible mechanisms.
Memory Disorders
Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats.
Memory Disorders
Positive Modulation of Pink Nelumbo nucifera Flowers on Memory Impairment, Brain Damage, and Biochemical Profiles in Restraint Rats.
Meningioma
Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl.
Meningioma
Monoamine oxidase B activity is increased in human gliomas.
Menkes Kinky Hair Syndrome
[Histochemical and biochemical investigations of monoamine oxidase activity level in the brain of the brindled mouse]
Methemoglobinemia
Serotonin syndrome after cardiopulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors.
Migraine Disorders
A close look at fenfluramine and dexfenfluramine.
Migraine Disorders
A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach.
Migraine Disorders
A study of the activity of platelet monoamine oxidase in patients with migraine headaches or with 'cluster headaches'.
Migraine Disorders
Anti-migraine and anti-depression activities of Tianshu capsule by mediating Monoamine oxidase.
Migraine Disorders
Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine.
Migraine Disorders
Association Between Polymorphisms of DRD2, COMT, DBH, and MAO-A Genes and Migraine Susceptibility: A Meta-Analysis.
Migraine Disorders
Changes in monoamine oxidase (MAO) activity in migraine.
Migraine Disorders
Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression.
Migraine Disorders
Enterococci in milk and milk products.
Migraine Disorders
Human platelet monoamine oxidase activity in health and disease: a review.
Migraine Disorders
Implications of the platelet monoamine oxidase deficit during migraine attacks.
Migraine Disorders
Investigation of some biological trait markers in migraine: deuterated tyramine challenge test, monoamine oxidase, phenolsulfotransferase and plasma and urinary biogenic amine and acid metabolite levels.
Migraine Disorders
Kinetics and thermolability of platelet monoamine oxidase in cluster headache and migraine.
Migraine Disorders
Letter: Monoamine oxidase and migraine.
Migraine Disorders
MAO activity, serotonin metabolism and aggregation of platelets from migraine patients. A preliminary study.
Migraine Disorders
MAOA, MTHFR, and TNF-? genes polymorphisms and personality traits in the pathogenesis of migraine.
Migraine Disorders
Migraine and cluster headache: links between platelet monoamine oxidase activity, smoking and personality.
Migraine Disorders
Migraine and depression: biological aspects.
Migraine Disorders
Migraine headache: epidemiologic perspectives.
Migraine Disorders
Monoamine oxidase activities in patients with migraine or with cluster headache during the acute phases and after treatment with L-5-hydroxytryptophan.
Migraine Disorders
Monoamine oxidase activity in blood platelets of migraine patients.
Migraine Disorders
Monoamine oxidase inhibition in the treatment of migraine.
Migraine Disorders
Monoamine oxidase inhibitors in the control of migraine.
Migraine Disorders
Monoamine oxidases A and B gene polymorphisms in migraine patients.
Migraine Disorders
New Frontiers in Selective Human MAO-B Inhibitors.
Migraine Disorders
Platelet monoamine oxidase activity and headache.
Migraine Disorders
Platelet monoamine oxidase activity in female migraine patients.
Migraine Disorders
Platelet monoamine oxidase in migraine.
Migraine Disorders
Platelet serotonin measures in migraine.
Migraine Disorders
Platelet size: no correlation with migraine or monoamine oxidase activity.
Migraine Disorders
Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Migraine Disorders
Selegeline, a MAO B inhibitor, is not effective in the prophylaxis of migraine without aura--an open study.
Migraine Disorders
Serotonin metabolism in migraine.
Migraine Disorders
The potential effectiveness of moclobemide, the new monoamine oxidase inhibitor, in the prophylaxis of migraine.
Migraine Disorders
Transitory platelet monoamine oxidase deficit in migraine: some reflections.
Migraine Disorders
Urinary output of endogenous monoamine oxidase inhibitor and isatin during acute migraine attacks.
Migraine Disorders
[Severe migraine, monoamine oxidase inhibitors and methysergide.]
Migraine with Aura
Monoamine oxidases A and B gene polymorphisms in migraine patients.
Migraine with Aura
Platelet monoamine oxidase activity and headache.
Migraine without Aura
Monoamine oxidases A and B gene polymorphisms in migraine patients.
monoamine oxidase deficiency
Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline.
monoamine oxidase deficiency
Anesthetic management in MAO-A and MAO-B deficiency: a case report.
monoamine oxidase deficiency
Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon?
monoamine oxidase deficiency
Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the iNTD registry.
monoamine oxidase deficiency
Behavioral Disinhibition and Reduced Anxiety-like Behaviors in Monoamine Oxidase B-Deficient Mice.
monoamine oxidase deficiency
Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.
monoamine oxidase deficiency
Cataplexy and monoamine oxidase deficiency in Norrie disease.
monoamine oxidase deficiency
CSF acid monoamine metabolites in psychotic syndromes: what might they signify?
monoamine oxidase deficiency
Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements.
monoamine oxidase deficiency
Early postnatal inhibition of serotonin synthesis results in long-term reductions of perseverative behaviors, but not aggression, in MAO A-deficient mice.
monoamine oxidase deficiency
Effect of MAO A deficiency on different kinds of aggression and social investigation in mice.
monoamine oxidase deficiency
From aggression to autism: new perspectives on the behavioral sequelae of monoamine oxidase deficiency.
monoamine oxidase deficiency
Hepatic monoamine oxidase deficiency in Reye syndrome.
monoamine oxidase deficiency
Migraine headache: epidemiologic perspectives.
monoamine oxidase deficiency
Mild learning difficulties and offending behaviour--is there a link with monoamine oxidase A deficiency?
monoamine oxidase deficiency
Monoamine oxidase A deficiency: biogenic amine metabolites in random urine samples.
monoamine oxidase deficiency
Monoamine Oxidase Deficiency Causes Prostate Atrophy and Reduces Prostate Progenitor Cell Activity.
monoamine oxidase deficiency
Monoamine oxidase deficiency in males with an X chromosome deletion.
monoamine oxidase deficiency
Monoamine oxidase deficiency: a cause of flushing and attention-deficit/ hyperactivity disorder?
monoamine oxidase deficiency
Monoamine oxidase deficiency: a cause of symptomatic hyperserotoninemia in the absence of carcinoid.
monoamine oxidase deficiency
Monoaminergic control of vasopressin and VIP expression in the mouse suprachiasmatic nucleus.
monoamine oxidase deficiency
Novel monoamine oxidase A knock out mice with human-like spontaneous mutation.
monoamine oxidase deficiency
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
monoamine oxidase deficiency
Relationship between monoamine oxidase (MAO) A specific activity and proportion of human skin fibroblasts which express the enzyme in culture.
monoamine oxidase deficiency
Screen for MAOA mutations in target human groups.
monoamine oxidase deficiency
Social Deficits and Perseverative Behaviors, but not Overt Aggression, in MAO-A Hypomorphic Mice.
monoamine oxidase deficiency
Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.
monoamine oxidase deficiency
The aggression and behavioral abnormalities associated with monoamine oxidase A deficiency are rescued by acute inhibition of serotonin reuptake.
monoamine oxidase deficiency
Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia.
monoamine oxidase deficiency
[Characteristics of behavior of knockout mice with genetic monoamine oxidase A deficiency]
monoamine oxidase deficiency
[Development of serotonergic neurons of dorsal raphe nuclei in mice with knockout of monoamine oxidase A and 5-HT1A and 5-HT1B autoreceptor]
Motor Neuron Disease
Medical Management of Frontotemporal Dementias: The Importance of the Caregiver in Symptom Assessment and Guidance of Treatment Strategies.
Motor Neuron Disease
Monoamine oxidase (MAO), 5-hydroxyindole acetic acid (5 HIAA) and homovanillic acid (HVA) in motor neuron disease.
Motor Neuron Disease
Neurotransmitter abnormalities in patients with motor neuron disease.
Movement Disorders
A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
Movement Disorders
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
Movement Disorders
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study.
Movement Disorders
The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases.
MPTP Poisoning
1-Methyl-4-phenylpyridinium (MPP+) binds with high affinity to a beta-carboline binding site located on monoamine oxidase type A in rat brain.
MPTP Poisoning
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
MPTP Poisoning
MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine.
MPTP Poisoning
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.
MPTP Poisoning
The hypothalamus in MPTP-induced parkinsonism.
Multiple Sclerosis
Platelet monoamine oxidase and plasma dopamine-beta-hydroxylase activities in patients with multiple sclerosis.
Multiple System Atrophy
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Multiple System Atrophy
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Multiple System Atrophy
Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Muscle Hypotonia
Autonomic nervous system function in narcolepsy.
Muscle Hypotonia
De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: A genomics approach to personalized medicine.
Muscle Hypotonia
Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements.
Muscle Rigidity
Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.
Muscle Rigidity
Phenelzine toxicity responsive to dantrolene.
Muscle Rigidity
[Acute toloxatone poisoning. Apropos of 122 cases]
Muscular Diseases
Catecholamine-induced muscle weakness.
Muscular Diseases
Monoamine oxidase inhibition prevents mitochondrial dysfunction and apoptosis in myoblasts from patients with collagen VI myopathies.
Muscular Diseases
Overexpression of semicarbazide-sensitive amine oxidase in human myopathies.
Muscular Dystrophies
Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients.
Muscular Dystrophies
[Adrenergic structures and monoamine oxidase activity in dystrophic skeletal muscles]
Muscular Dystrophy, Duchenne
Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients.
Muscular Dystrophy, Duchenne
Turner syndrome and Xp deletions: clinical and molecular studies in 47 patients.
Muscular Dystrophy, Duchenne
[Mitochondrial monoamine oxidase in progressive Duchenne muscular dystrophy]
Mutism
Phenomenology and treatment of selective mutism.
Mutism
The use of medication in selective mutism: a systematic review.
Myasthenia Gravis
Platelet monoamine oxidase-B activity in Parkinson's disease.
Mycoses
[The histamine-serotonin-monoamine oxidase system in patients with foot mycosis during treatment]
Mydriasis
Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Myocardial Infarction
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Myocardial Infarction
Cardiomyocytes-specific deletion of monoamine oxidase B reduces irreversible myocardial ischemia/reperfusion injury.
Myocardial Infarction
Ectopic ventricular rhythms and myocardial infarction in the domestic pig and their response to nialamide, a monoamine oxidase inhibitor.
Myocardial Infarction
Histochemical studies of monoamine oxidase in experimental myocardial infarctions.
Myocardial Infarction
[Biogenic amines (catecholamines, serotonin) in the blood and serum monoamine oxidase activity in acute myocardial infarct and some of its complications]
Myocardial Infarction
[Clinical studies on the changes of serum monoamine oxidase activities in myocardial infarction (author's transl)]
Myocardial Infarction
[Role of lysosomes in experimental myocardial infarct lesions and in protecte action of monoamine oxidase inhitors]
Myocardial Infarction
[Thrombocyte functional resistance and histamine and serotonin metabolism in ischemic heart disease]
Myocarditis
[Changes in the monoamine oxidase activity in experimental myocarditis and arthritis in rats thymectomized at birth]
Myocarditis
[Changes in the monoamine oxidase activity of neonatally thymectomized rats with experimental myocarditis and arthritis]
Myoclonus
Beneficial effects of serotonin precursors in postanoxic action myoclonus.
Myoclonus
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
Myoclonus
Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?
Myoclonus
Myoclonus in the rat induced by p,p'-DDT and the role of altered monoamine function.
Myoclonus
Observations on chloralose-induced myoclonus in guinea-pigs.
Myoclonus
Tryptamine-induced myoclonus in guinea-pigs pretreated with a monoamine oxidase inhibitor indicates pre- and post-synaptic actions of tryptamine upon central indoleamine systems.
Narcolepsy
Analysis of the monoamine oxidase genes and the Norrie disease gene locus in narcolepsy.
Narcolepsy
MAO-A and COMT polymorphisms and gene effects in narcolepsy.
Narcolepsy
Selegiline in narcolepsy.
Narcolepsy
Selegiline in the treatment of narcolepsy.
Narcolepsy
Treatment of intractable narcolepsy with a monoamine oxidase inhibitor.
Narcolepsy
Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine-a pilot study.
Nasopharyngeal Carcinoma
Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma.
Necrobiosis Lipoidica
Increased activity of serum amine oxidases in granuloma annulare, necrobiosis lipoidica and diabetes.
Neoplasm Metastasis
Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer.
Neoplasm Metastasis
Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
Neoplasm Metastasis
MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.
Neoplasm Metastasis
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Neoplasm Metastasis
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Neoplasm Metastasis
Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
Neoplasm Metastasis
Monoamine oxidase-A targeting probe for prostate cancer imaging and inhibition of metastasis.
Neoplasm Metastasis
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Neoplasm Metastasis
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Neoplasm Metastasis
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Neoplasm Metastasis
Repurposing antitubercular agent isoniazid for treatment of prostate cancer.
Neoplasm Metastasis
Site-specific expression of amine oxidases in breast cancer metastases.
Neoplasms
A comparison of cell proliferation in normal and neoplastic intestinal epithelia following either biogenic amine depletion or monoamine oxidase inhibition.
Neoplasms
A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
Neoplasms
Amine oxidase activities in chemically-induced mammary cancer in the rat.
Neoplasms
Amine oxidase activities in rat breast cancer induced experimentally with 7,12-dimethylbenz(alpha)anthracene.
Neoplasms
An indicator of cancer: downregulation of Monoamine Oxidase-A in multiple organs and species.
Neoplasms
An integrated approach for identifying priority contaminant in the Great Lakes Basin - Investigations in the Lower Green Bay/Fox River and Milwaukee Estuary areas of concern.
Neoplasms
Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.
Neoplasms
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Neoplasms
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.
Neoplasms
Biochemical and ultrastructural differences between muco-epidermoid and carcinoid tumors of the bronchus.
Neoplasms
Biochemical composition of edge and center of malignant hamster insulinoma.
Neoplasms
Biochemical studies on mitochondria isolated from Normal and Neoplastic Tissues of the Mouse Mammary Gland.
Neoplasms
Biodistribution and radiation dosimetry of 11C-harmine in baboons.
Neoplasms
Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways.
Neoplasms
Clinical contraindications to allergen immunotherapy: an EAACI position paper.
Neoplasms
Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.
Neoplasms
Conjugation with polyamines enhances the antitumor activity of naphthoquinones against human glioblastoma cells.
Neoplasms
Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Neoplasms
Decreased monoamine oxidase (MAO) activity and MAO-A expression as diagnostic indicators of human esophageal cancers.
Neoplasms
Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine.
Neoplasms
Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
Neoplasms
Distribution of cyclic 3',5'-phosphodiesterase, monoamine oxidase & beta-glucuronidase in liver tumours induced by technical grade hexachlorocyclohexane in inbred swiss mice.
Neoplasms
Dopa-decarboxylase and monoamine oxidase activities in a transplantable islet cell tumor of the golden hamster.
Neoplasms
Drug therapy of hypertensive crises.
Neoplasms
Dual inhibitors of LSD1 and spermine oxidase.
Neoplasms
Effect of metastatic cancer on platelet monoamine oxidase activity and serotonin metabolism.
Neoplasms
Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells.
Neoplasms
Effects of various synthetic retinoids on proliferation and immunophenotype of human melanoma cells in vitro.
Neoplasms
Enzyme inhibition of dopamine metabolism alters 6-[18 F]FDOPA uptake in orthotopic pancreatic adenocarcinoma.
Neoplasms
Exploration of phytochemicals for inhibition of monoamine oxidase-A induced cancer using molecular docking studies.
Neoplasms
Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes.
Neoplasms
Histochemical observations of monoamine oxidase activity in human tumors.
Neoplasms
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer.
Neoplasms
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Neoplasms
In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain.
Neoplasms
Increased 3-nitrotyrosine levels in mitochondrial membranes and impaired respiratory chain activity in brain regions of adult female rats submitted to daily vitamin A supplementation for 2 months.
Neoplasms
Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo.
Neoplasms
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
Neoplasms
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells.
Neoplasms
Inhibitor structure-guided design and synthesis of near-infrared fluorescent probes for monoamine oxidase A (MAO-A) and its application in living cells and in vivo.
Neoplasms
Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.
Neoplasms
L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.
Neoplasms
Loxl2 is dispensable for dermal development, homeostasis and tumour stroma formation.
Neoplasms
MAOA and TNF-? gene polymorphisms are associated with photophobia but not osmophobia in patients with migraine.
Neoplasms
MAOA, MTHFR, and TNF-? genes polymorphisms and personality traits in the pathogenesis of migraine.
Neoplasms
Mental adaptation to cancer: depression and blood platelet monoamine oxidase activity in breast cancer patients.
Neoplasms
Metabolism and storage of catecholamines in rats with pheochromocytoma implants.
Neoplasms
Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.
Neoplasms
Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.
Neoplasms
Monoamine and diamine oxidase activity in the diagnosis of carcinoid tumors.
Neoplasms
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Neoplasms
Monoamine oxidase a inhibitor-near-infrared dye conjugate reduces prostate tumor growth.
Neoplasms
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Neoplasms
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Neoplasms
Monoamine oxidase activity in Ehrlich ascites tumor.
Neoplasms
Monoamine oxidase B activity is increased in human gliomas.
Neoplasms
Monoamine Oxidase B in Renal Cell Carcinoma.
Neoplasms
Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane.
Neoplasms
Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1? and with transcription factors Sp1 and Sp3.
Neoplasms
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Neoplasms
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.
Neoplasms
Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction.
Neoplasms
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell.
Neoplasms
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Neoplasms
Platelet monoamine oxidase and phenolsulphotransferase M and P in cancer.
Neoplasms
Positron emission tomography in acromegaly and other pituitary adenoma patients.
Neoplasms
Prevention of Mammary Tumor Development through Neuroimmunomodulation in the Spleen and Lymph Nodes of Old Female Sprague-Dawley Rats by L-Deprenyl.
Neoplasms
Prophylactic neuroprotective efficiency of co-administration of Ginkgo biloba and Trifolium pretense against sodium arsenite-induced neurotoxicity and dementia in different regions of brain and spinal cord of rats.
Neoplasms
Psychiatric morbidity and platelet monoamine oxidase activity in cancer patients.
Neoplasms
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Neoplasms
Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity.
Neoplasms
Regulation of semicarbazide-sensitive amine oxidase expression by tumor necrosis factor-alpha in adipocytes: functional consequences on glucose transport.
Neoplasms
Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.
Neoplasms
Resorufin Enters the Photodynamic Therapy Arena: A Monoamine Oxidase Activatable Agent for Selective Cytotoxicity.
Neoplasms
Role of Plant-Derived Flavonoids and Their Mechanism in Attenuation of Alzheimer's and Parkinson's Diseases: An Update of Recent Data.
Neoplasms
Secretory, enzymatic, and morphological characterization of rat pancreatic endocrine tumours induced by streptozotocin and nicotinamide.
Neoplasms
Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies.
Neoplasms
Serum vascular adhesion protein-1 level is higher in smokers than non-smokers.
Neoplasms
Single nucleotide polymorphisms in obesity-related genes and all-cause and cause-specific mortality: a prospective cohort study.
Neoplasms
Synthesis and biological evaluation of 2-phenoxyacetamide analogues, a novel class of potent and selective monoamine oxidase inhibitors.
Neoplasms
Targeting monoamine oxidase A for T cell-based cancer immunotherapy.
Neoplasms
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
Neoplasms
The effects of vitamin A supplementation for 3 months on adult rat nigrostriatal axis: Increased monoamine oxidase enzyme activity, mitochondrial redox dysfunction, increased ?-amyloid(1-40) peptide and TNF-? contents, and susceptibility of mitochondria to an in vitro H(2)O(2) challenge.
Neoplasms
The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Neoplasms
The neurotoxicity of ?-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin.
Neoplasms
The significance of monoamine oxidase-A expression in high grade prostate cancer.
Neoplasms
Topological polar surface area: a useful descriptor in 2D-QSAR.
Neoplasms
Type B monoamine oxidase activity in human brain malignant tumors.
Neoplasms
Using Molecular Docking Analysis to Discovery Dregea sinensis Hemsl. Potential Mechanism of Anticancer, Antidepression, and Immunoregulation.
Neoplasms
[Comparative study of the effect of inhibitors of monoamine oxidase and ftorafur on the growth of de-differentiated astrocytoma]
Neoplasms
[Development of experimental brain tumors in modulated amine metabolism]
Neoplasms
[Effect of flavonoids from Sophora flavescens in aging mice induced by D-galactos].
Neoplasms
[Effects of berberine on learning and memory ability in vascular cognitive impairment rats].
Neoplasms
[Histochemical studies on the monoamine oxidase activity of human neoplasms. (Preliminary note)]
Neoplasms
[Monoamine oxidase activity in tumors of the neural crest]
Neoplasms
[Monoamine oxidase activity of cell nuclei from the liver of mice with transplanted malignant neoplasms]
Neoplasms
[Monoamine oxidase and diamine oxidase activities in patients with primary bronchial cancer]
Neoplasms
[Role of R-(-)-deprenyl in adhesion of neuronal and non-neuronal cells]
Neoplasms
[The modification of the catalytic activity of mitochondrial monoaminoxidase and the suppression of the growth of experimental brain tumors]
Neoplasms
[The vehaviour of monoaminooxydase (MAO) activity in tumours. I. MAO activity measurement in experimental tumours (author's transl)]
Nervous System Diseases
An update on amine oxidase inhibitors: Multifaceted drugs.
Nervous System Diseases
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.
Nervous System Diseases
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Nervous System Diseases
Characterization of Three Extracellular ?-Glucosidases Produced by a Fungal Isolate Aspergillus sp. YDJ14 and Their Hydrolyzing Activity for a Flavone Glycoside.
Nervous System Diseases
Clinical applications of MAO-inhibitors.
Nervous System Diseases
Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane.
Nervous System Diseases
Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B.
Nervous System Diseases
Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.
Nervous System Diseases
Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
Nervous System Diseases
Effect of neurocatin on the activity of monoamine oxidase B in rat brain synaptosomes.
Nervous System Diseases
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Nervous System Diseases
Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders.
Nervous System Diseases
Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders.
Nervous System Diseases
Hybrid caffeic acid derivatives as monoamine oxidases inhibitors: synthesis, radical scavenging activity, molecular docking studies and in silico ADMET analysis.
Nervous System Diseases
In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid.
Nervous System Diseases
Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.
Nervous System Diseases
Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Nervous System Diseases
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.
Nervous System Diseases
Iron-Restricted Diet Affects Brain Ferritin Levels, Dopamine Metabolism and Cellular Prion Protein in a Region-Specific Manner.
Nervous System Diseases
Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.
Nervous System Diseases
Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study.
Nervous System Diseases
MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study, and docking calculations.
Nervous System Diseases
Metal- and Solvent-Free Multicomponent Decarboxylative A3-Coupling for the Synthesis of Propargylamines: Experimental, Computational, and Biological Investigations.
Nervous System Diseases
Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.
Nervous System Diseases
Monoamine oxidase inhibitors, their structural analogues, and neuroprotection.
Nervous System Diseases
Myoclonic seizures after abrupt withdrawal from phenelzine and alprazolam.
Nervous System Diseases
Perspectives on MAO-B in aging and neurological disease: where do we go from here?
Nervous System Diseases
Piperazine multi-substituted triarylphosphine oxide compound as an instant "light-up" fluorescent probe for monoamine oxidase.
Nervous System Diseases
Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders.
Nervous System Diseases
Platelet monoamine oxidase activity is related to MAOB intron 13 genotype.
Nervous System Diseases
Radiosynthesis and in vivo evaluation of [11C]-labelled pyrrole-2-carboxamide derivates as novel radioligands for PET imaging of monoamine oxidase A.
Nervous System Diseases
Recent Updates on Pyrazolines Derivatives as Promising Candidates for Neuropsychiartic and Neurodegenerative disorders.
Nervous System Diseases
Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity.
Nervous System Diseases
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Nervous System Diseases
Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition.
Nervous System Diseases
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Nervous System Diseases
Sensitive and Selective Ratiometric Fluorescence Probes for Detection of Intracellular Endogenous Monoamine Oxidase A.
Nervous System Diseases
Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.
Nervous System Diseases
Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review.
Nervous System Diseases
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders.
Nervous System Diseases
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors.
Nervous System Diseases
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
Nervous System Diseases
Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
Nervous System Diseases
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
Nervous System Diseases
The role of monoamine oxidase enzymes in the pathophysiology of neurological disorders.
Nervous System Diseases
Upregulation of serotonin transporter by alcohol in human dendritic cells: possible implication in neuroimmune deregulation.
Nervous System Diseases
What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase?B Towards Histamine and N-Methylhistamine.
Neuralgia
5-HT1A receptor-mediated attenuation of heat hyperalgesia and mechanical allodynia by chrysin in mice with experimental mononeuropathy.
Neuralgia
CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Neuralgia
Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain.
Neuralgia
Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice.
Neuralgia
Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.
Neuralgia
Moclobemide in chronic neuropathic pain: preliminary case reports.
Neuralgia
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
Neuralgia
The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model.
Neuritis
[Toxic neuritis caused by monoamine oxidase inhibitors]
Neurobehavioral Manifestations
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Neuroblastoma
A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells.
Neuroblastoma
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.
Neuroblastoma
Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro.
Neuroblastoma
Assignment of genes for human monoamine oxidases A and B to the X chromosome.
Neuroblastoma
Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat.
Neuroblastoma
Beta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression.
Neuroblastoma
Biotransformation of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetra- hydropyridine to a fluorescent pyridinium metabolite by intact neuroblastoma cells.
Neuroblastoma
Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons.
Neuroblastoma
Cellular uptake of quercetin and luteolin and their effects on monoamine oxidase-A in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells.
Neuroblastoma
Estrogen modulation of catecholamine synthesis and monoamine oxidase A activity in the human neuroblastoma cell line SK-ER3.
Neuroblastoma
Estrogenic control of monoamine oxidase A activity in human neuroblastoma cells expressing physiological concentrations of estrogen receptor.
Neuroblastoma
Expression of A and B types of monoamine oxidase in differentiated neuroblastoma hybrid cells.
Neuroblastoma
Expression of A and B types of monoamine oxidase in neuroblastoma hybrid cells.
Neuroblastoma
Expression of differentiated activities in reaggregated brain cell cultures.
Neuroblastoma
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1.
Neuroblastoma
Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/?-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.
Neuroblastoma
Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R-(-)-deprenyl.
Neuroblastoma
Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
Neuroblastoma
Inhibition of monoamine oxidase activity by repetitive transcranial magnetic stimulation: implications for inter-train interval and frequency.
Neuroblastoma
Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells.
Neuroblastoma
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
Neuroblastoma
L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells.
Neuroblastoma
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Neuroblastoma
Measurement of mitochondrial respiration in permeabilized murine neuroblastoma (N-2alpha) cells, a simple and rapid in situ assay to investigate mitochondrial toxins.
Neuroblastoma
Metabolism of biogenic amines in neuroblastoma and glioma cells in culture.
Neuroblastoma
Monoamine oxidase A variants are associated with heavy betel quid use.
Neuroblastoma
Monoamine oxidase activity decreased in cells lacking hypoxanthine phosphoribosyltransferase activity.
Neuroblastoma
Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins.
Neuroblastoma
Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells.
Neuroblastoma
Monoamine oxidase-A promotes protective autophagy in human SH-SY5Y neuroblastoma cells through Bcl-2 phosphorylation.
Neuroblastoma
Monoamine Oxidase-B Inhibition Facilitates ?-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.
Neuroblastoma
Parkin suppresses the expression of monoamine oxidases.
Neuroblastoma
Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells.
Neuroblastoma
R1, a novel repressor of the human monoamine oxidase A.
Neuroblastoma
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Neuroblastoma
Resorufin Enters the Photodynamic Therapy Arena: A Monoamine Oxidase Activatable Agent for Selective Cytotoxicity.
Neuroblastoma
Retinoic acid activates monoamine oxidase B promoter in human neuronal cells.
Neuroblastoma
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Neuroblastoma
The human testis-determining factor SRY localizes in midbrain dopamine neurons and regulates multiple components of catecholamine synthesis and metabolism.
Neuroblastoma
The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.
Neuroblastoma
Thyroid hormone binding and regulation of adrenergic enzymes in two neuroblastoma cell lines.
Neuroblastoma
Toxicity of MPTP and structural analogs in clonal cell lines of neuronal origin expressing B type monoamine oxidase activity.
Neuroblastoma
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Neuroblastoma
Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Neuroblastoma
Tyrosine hydroxylase and monoamine oxidase-A activity increases in differentiating human neuroblastoma after elimination of dividing cells.
Neurodegenerative Diseases
''70th Birthday Professor Riederer'' Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
Neurodegenerative Diseases
(-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo.
Neurodegenerative Diseases
(Hetero-)(arylidene)arylhydrazides as Multitarget-Directed Monoamine Oxidase Inhibitors.
Neurodegenerative Diseases
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
Neurodegenerative Diseases
2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.
Neurodegenerative Diseases
3D-QSAR and in-silico studies of natural products and related derivatives as monoamine oxidase inhibitors.
Neurodegenerative Diseases
4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis.
Neurodegenerative Diseases
A rational approach to elucidate human monoamine oxidase molecular selectivity.
Neurodegenerative Diseases
A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression.
Neurodegenerative Diseases
Activation of monoamine oxidase type-B by aluminum in rat brain homogenate.
Neurodegenerative Diseases
Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's disease.
Neurodegenerative Diseases
An update on amine oxidase inhibitors: Multifaceted drugs.
Neurodegenerative Diseases
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.
Neurodegenerative Diseases
Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors.
Neurodegenerative Diseases
Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis.
Neurodegenerative Diseases
Bacopa monnieri and L-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF-?B pathways in the spleen of female wistar rats.
Neurodegenerative Diseases
Basic cell physiological activities (cell adhesion, chemotaxis and proliferation) induced by selegiline and its derivatives in Mono Mac 6 human monocytes.
Neurodegenerative Diseases
Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach.
Neurodegenerative Diseases
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Neurodegenerative Diseases
Binding models of reversible inhibitors to type-B monoamine oxidase.
Neurodegenerative Diseases
Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
Neurodegenerative Diseases
Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Neurodegenerative Diseases
Chemical characterization of small-molecule inhibitors of monoamine oxidase B synthesized from the Acanthopanax senticosus root with affinity ultrafiltration mass spectrometry.
Neurodegenerative Diseases
Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases.
Neurodegenerative Diseases
Click-Reaction-Triggered SERS Signals for Specific Detection of Monoamine Oxidase B Activity.
Neurodegenerative Diseases
Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies.
Neurodegenerative Diseases
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.
Neurodegenerative Diseases
Deciphering the detailed structure-activity relationship of coumarins as Monoamine oxidase enzyme inhibitors-An updated review.
Neurodegenerative Diseases
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Neurodegenerative Diseases
Design, Synthesis, and Biological Evaluation of Pyridazinones Containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors.
Neurodegenerative Diseases
Development of 2D, 3D-QSAR and Pharmacophore Modeling of Chalcones for the Inhibition of Monoamine Oxidase B.
Neurodegenerative Diseases
Differential increases in catecholamine metabolizing enzymes in amyotrophic lateral sclerosis.
Neurodegenerative Diseases
Discovery of two new classes of potent monoamine oxidase-B inhibitors by tricky chemistry.
Neurodegenerative Diseases
Docking of Natural Products against Neurodegenerative Diseases: General Concepts.
Neurodegenerative Diseases
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Neurodegenerative Diseases
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Neurodegenerative Diseases
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
Neurodegenerative Diseases
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.
Neurodegenerative Diseases
Emodin Derivatives as Multi-Target-Directed Ligands Inhibiting Monoamine Oxidase and Antagonizing Vasopressin V1A Receptors.
Neurodegenerative Diseases
Exploration of a Library of 3,4-(Methylenedioxy)aniline-Derived Semicarbazones as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase: Design, Synthesis, and Evaluation.
Neurodegenerative Diseases
Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
Neurodegenerative Diseases
Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells.
Neurodegenerative Diseases
Glyceraldehyde-3-Phosphate Dehydrogenase-Monoamine Oxidase B-Mediated Cell Death-Induced by Ethanol is Prevented by Rasagiline and 1-R-Aminoindan.
Neurodegenerative Diseases
High throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors.
Neurodegenerative Diseases
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
Neurodegenerative Diseases
In silico identification of novel and selective monoamine oxidase B inhibitors.
Neurodegenerative Diseases
In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases.
Neurodegenerative Diseases
In vitro anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida).
Neurodegenerative Diseases
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
Neurodegenerative Diseases
Indole Alkaloids And Semisynthetic Indole Derivatives As Multifunctional Scaffolds Aiming The Inhibition Of Enzymes Related To Neurodegenerative Diseases - A Focus On Psychotria L. Genus.
Neurodegenerative Diseases
Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors.
Neurodegenerative Diseases
Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells.
Neurodegenerative Diseases
Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl.
Neurodegenerative Diseases
Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants.
Neurodegenerative Diseases
Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines.
Neurodegenerative Diseases
Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Neurodegenerative Diseases
Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
Neurodegenerative Diseases
Integrated Binary QSAR-Driven Virtual Screening and In Vitro Studies for Finding Novel hMAO-B-Selective Inhibitors.
Neurodegenerative Diseases
Investigation of pyrazolo[1,5-a]quinoxalin-4-ones as novel monoamine oxidase inhibitors.
Neurodegenerative Diseases
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
Neurodegenerative Diseases
Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT.
Neurodegenerative Diseases
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.
Neurodegenerative Diseases
Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.
Neurodegenerative Diseases
Ligand based screening of chemical constituents from African medicinal plants for the identification of MAOB inhibitors.
Neurodegenerative Diseases
Link between monoamine oxidase and nitric oxide.
Neurodegenerative Diseases
Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome.
Neurodegenerative Diseases
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Neurodegenerative Diseases
Maintenance therapies for late-life recurrent major depression: research and review circa 1995.
Neurodegenerative Diseases
MAO inhibitors and their wider applications: a patent review.
Neurodegenerative Diseases
Marine natural products with monoamine oxidase (MAO) inhibitory activity.
Neurodegenerative Diseases
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Neurodegenerative Diseases
Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor.
Neurodegenerative Diseases
Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
Neurodegenerative Diseases
Monoamine oxidase (MAO) inhibitory activity: 3-phenylcoumarins versus 4-hydroxy-3-phenylcoumarins.
Neurodegenerative Diseases
Monoamine oxidase and agitation in psychiatric patients.
Neurodegenerative Diseases
Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes.
Neurodegenerative Diseases
Monoamine oxidase inhibition by selected dye compounds.
Neurodegenerative Diseases
Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Neurodegenerative Diseases
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Neurodegenerative Diseases
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Neurodegenerative Diseases
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
Neurodegenerative Diseases
Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography.
Neurodegenerative Diseases
Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
Neurodegenerative Diseases
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Neurodegenerative Diseases
Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice.
Neurodegenerative Diseases
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
Neurodegenerative Diseases
Multiscale Modeling of Two-Photon Probes for Parkinson's Diagnostics Based on Monoamine Oxidase B Biomarker.
Neurodegenerative Diseases
Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3 R Antagonism for Neurodegenerative Diseases.
Neurodegenerative Diseases
Natural based piperine derivatives as potent monoamine oxidase inhibitors: an in silico ADMET analysis and molecular docking studies.
Neurodegenerative Diseases
Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties.
Neurodegenerative Diseases
Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
Neurodegenerative Diseases
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Neurodegenerative Diseases
Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A?(1-42)-induced toxicity.
Neurodegenerative Diseases
Neuroprotective Potential of Verbascoside Isolated from Acanthus mollis L. Leaves through Its Enzymatic Inhibition and Free Radical Scavenging Ability.
Neurodegenerative Diseases
New indane derivatives containing 2-hydrazinothiazole as potential acetylcholinesterase and monoamine oxidase-B inhibitors.
Neurodegenerative Diseases
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Neurodegenerative Diseases
Novel Diels-Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Neurodegenerative Diseases
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Neurodegenerative Diseases
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Neurodegenerative Diseases
Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B.
Neurodegenerative Diseases
On the functions of monoamine oxidase, the emotions, and adaptation to stress.
Neurodegenerative Diseases
Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders.
Neurodegenerative Diseases
Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO?B inhibitors.
Neurodegenerative Diseases
Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B.
Neurodegenerative Diseases
Pharmacophore-Based 3D-QSAR Analysis of Thienyl Chalcones as a New Class of Human MAO-B Inhibitors: Investigation of Combined Quantum Chemical and Molecular Dynamics Approach.
Neurodegenerative Diseases
Plant secondary metabolites- potent inhibitors of monoamine oxidase isoforms.
Neurodegenerative Diseases
Potent and Selective Monoamine Oxidase-B Inhibitory Activity: Fluoro- vs. Trifluoromethyl-4-hydroxylated Chalcone Derivatives.
Neurodegenerative Diseases
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Neurodegenerative Diseases
Promising selective MAO-B inhibition by sesamin, a lignan from Zanthoxylum flavum stems.
Neurodegenerative Diseases
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Neurodegenerative Diseases
Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Neurodegenerative Diseases
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
Neurodegenerative Diseases
Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders.
Neurodegenerative Diseases
Quinolinyl-Thienyl Chalcones as Monoamine Oxidase Inhibitors and their In Silico Modeling Studies.
Neurodegenerative Diseases
Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Neurodegenerative Diseases
Rasagiline improves learning and memory in young healthy rats.
Neurodegenerative Diseases
Ratiometric Near-Infrared Fluorescent Probe for Synergistic Detection of Monoamine Oxidase B and Its Contribution to Oxidative Stress in Cell and Mice Aging Models.
Neurodegenerative Diseases
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Neurodegenerative Diseases
Recent Updates on Pyrazolines Derivatives as Promising Candidates for Neuropsychiartic and Neurodegenerative disorders.
Neurodegenerative Diseases
Revealing the role of fluorine pharmacophore in chalcone scaffold for shifting the MAO-B selectivity: investigation of a detailed molecular dynamics and quantum chemical study.
Neurodegenerative Diseases
Selected chromone derivatives as inhibitors of monoamine oxidase.
Neurodegenerative Diseases
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Neurodegenerative Diseases
Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana).
Neurodegenerative Diseases
Selective MAO-B inhibitors: a lesson from natural products.
Neurodegenerative Diseases
Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies.
Neurodegenerative Diseases
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Neurodegenerative Diseases
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Neurodegenerative Diseases
Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis.
Neurodegenerative Diseases
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B.
Neurodegenerative Diseases
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Neurodegenerative Diseases
Synthesis and Evaluation of 2-benzylidene-1-tetralone Derivatives for Monoamine Oxidase Inhibitory Activity.
Neurodegenerative Diseases
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Neurodegenerative Diseases
Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors.
Neurodegenerative Diseases
Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl--analysis of kinetic data.
Neurodegenerative Diseases
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Neurodegenerative Diseases
The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.
Neurodegenerative Diseases
The MAO Inhibitor Tranylcypromine Alters LPS- and A?-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD.
Neurodegenerative Diseases
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Neurodegenerative Diseases
The perspective of caffeine and caffeine derived compounds in therapy.
Neurodegenerative Diseases
The use of chemometrics to study multifunctional indole alkaloids from Psychotria nemorosa (Palicourea comb. nov.). Part II: Indication of peaks related to the inhibition of butyrylcholinesterase and monoamine oxidase-A.
Neurodegenerative Diseases
The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes.
Neurodegenerative Diseases
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Neurodegenerative Diseases
Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders.
Neurodegenerative Diseases
Type a and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
Neurodegenerative Diseases
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Neurodegenerative Diseases
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Neurodegenerative Diseases
Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Neurodegenerative Diseases
Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Neurodegenerative Diseases
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.
Neurodegenerative Diseases
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release.
Neurodermatitis
A follow-up study on the chemotherapy of neurodermatitis with a monoamine oxidase inhibitor.
Neurodermatitis
On the treatment of neurodermatitis with a monoamine oxidase inhibitor. The chemotherapy of psychosomatic illness through A-REM suppression.
Neuroendocrine Tumors
Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.
Neuroinflammatory Diseases
(E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) Phenol Ameliorates MPTP-Induced Dopaminergic Neurodegeneration by Inhibiting the STAT3 Pathway.
Neuroinflammatory Diseases
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Neuroinflammatory Diseases
Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.
Neuroinflammatory Diseases
Attenuation of Ischemic Stroke-Caused Brain Injury by a Monoamine Oxidase Inhibitor Involves Improved Proteostasis and Reduced Neuroinflammation.
Neuroinflammatory Diseases
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
Neuroinflammatory Diseases
Elevated brain monoamine oxidase activity in SIV and HIV neurological disease.
Neuroinflammatory Diseases
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.
Neuroinflammatory Diseases
In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.
Neuroinflammatory Diseases
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and ?-amyloid in aging and Alzheimer's disease.
Neuroinflammatory Diseases
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Neuroinflammatory Diseases
Preclinical Evaluation of TSPO and MAO-B PET Radiotracers in an LPS Model of Neuroinflammation.
Neuroinflammatory Diseases
Recurrent Lobar Hemorrhages and Multiple Cortical Superficial Siderosis in a Patient of Alzheimer's Disease With Homozygous APOE ?2 Allele Presenting Hypobetalipoproteinemia and Pathological Findings of 18F-THK5351 Positron Emission Tomography: A Case Report.
Neuroinflammatory Diseases
The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6.
Neuroinflammatory Diseases
The MAO Inhibitor Tranylcypromine Alters LPS- and A?-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD.
Neuromuscular Diseases
Early changes of muscle mitochondria in Duchenne dystrophy. Partition and activity of mitochondrial enzymes in fractionated muscle of unaffected boys and adults and patients.
Non-alcoholic Fatty Liver Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Nutrition Disorders
[ADJUNCTION OF A MONOAMINE OXIDASE INHIBITOR TO CLASSIC TREATMENTS OF DISEASES OF THE DIGESTIVE TRACT AND NUTRITION DISORDERS.]
Obesity
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Obesity
Cytotoxic, Antioxidant, and Enzyme Inhibitory Properties of the Traditional Medicinal Plant Matthiola incana (L.) R. Br.
Obesity
Family-based association study between the monoamine oxidase A gene and obesity: implications for psychopharmacogenetic studies.
Obesity
Hypoxia inhibits semicarbazide-sensitive amine oxidase activity in adipocytes.
Obesity
Personality and illness: Genetic connections?
Obesity
Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats.
Obesity
Two functional serotonin polymorphisms moderate the effect of food reinforcement on BMI.
Obesity
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
Obesity
[Effect of different dietary programs on serum monoamine oxidase activity in patients with obesity]
Obesity
[Monoamine oxidase activity of the blood in metabolic-alimentary obesity]
Obesity
[Serum monoamine oxidase activity in alimentary obesity]
Obesity, Abdominal
Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase.
Obesity, Morbid
Patient selection in ambulatory anesthesia - an evidence-based review: part II.
Obstetric Labor, Premature
Changes in serum calcium, magnesium, cyclic AMP and monoamine oxidase levels during pregnancy and under prolonged ritodrine treatment for preterm labor.
Optic Neuritis
[Bilateral optic neuritis with sudden onset occurring in an atherosclerotic subject, a heavy smoker, poisoned by an monoamine oxidase inhibitor (MAOI)]
Optic Neuritis
[Optic neuritis caused by monoamine oxidase inhibitors]
Osteoarthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Osteoarthritis
Chondrocytic monoamine oxidase activity in the development of natural murine osteoarthritis.
Osteoarthritis
Tryptophan metabolism in the joint diseases.
Osteogenesis Imperfecta
Influence of age, sex and osteogenesis imperfecta on count, protein content, and monoamine oxidase activity of human thrombocytes.
Overweight
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Overweight
Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO.
Pancreatic Neoplasms
11C-harmine as a potential PET tracer for ductal pancreas cancer: in vitro studies.
Paralysis
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Paralysis
Central serotonin receptor sensitivity in rats with experimental allergic encephalomyelitis.
Paralysis
Jasonia glutinosa (L.) DC., a Traditional Herbal Tea, Exerts Antioxidant and Neuroprotective Properties in Different In Vitro and In Vivo Systems.
Paralysis
Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I.
Paralysis
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Paralysis
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.
Paralysis
Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal.
Paralysis
Viola cornuta and Viola x wittrockiana: Phenolic compounds, antioxidant and neuroprotective activities on Caenorhabditis elegans.
Parkinson Disease
'Bad guys' among the antiparkinsonian drugs.
Parkinson Disease
(-)-Deprenyl fails to promote axonal regeneration of retinal ganglion cells in vitro and in vivo.
Parkinson Disease
(-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats.
Parkinson Disease
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
Parkinson Disease
1-N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors.
Parkinson Disease
1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
Parkinson Disease
2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.
Parkinson Disease
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Parkinson Disease
3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter?
Parkinson Disease
3-Coumaranone derivatives as inhibitors of monoamine oxidase.
Parkinson Disease
? Safinamide for Parkinson's disease.
Parkinson Disease
?-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
Parkinson Disease
A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
Parkinson Disease
A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
Parkinson Disease
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Parkinson Disease
A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Parkinson Disease
A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease.
Parkinson Disease
A meta-analysis on relationship of MAOB intron 13 polymorphisms, interactions with smoking/COMT H158L polymorphisms with the risk of PD.
Parkinson Disease
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Parkinson Disease
A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Parkinson Disease
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
Parkinson Disease
A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
Parkinson Disease
A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
Parkinson Disease
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Disease
A rapid thin-layer chromatography bioautographic method for detecting the monoamine oxidase inhibitors in plants.
Parkinson Disease
A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
Parkinson Disease
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Parkinson Disease
A scaffold hopping approach to identify novel monoamine oxidase B inhibitors.
Parkinson Disease
A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.
Parkinson Disease
Activation of monoamine oxidase type-B by aluminum in rat brain homogenate.
Parkinson Disease
Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
Parkinson Disease
Adjuvant potential of selegiline in treating acute toxicity of aluminium phosphide in rats.
Parkinson Disease
Advances in the pharmacologic management of early Parkinson disease.
Parkinson Disease
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.
Parkinson Disease
Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's disease.
Parkinson Disease
Age-related memory decline and longevity under treatment with selegiline.
Parkinson Disease
Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson's disease.
Parkinson Disease
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced ?-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Parkinson Disease
Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson's Disease.
Parkinson Disease
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.
Parkinson Disease
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Parkinson Disease
An allelic association study of monoamine oxidase B in Parkinson's disease.
Parkinson Disease
An expert opinion on safinamide in Parkinson's disease.
Parkinson Disease
An inducible MAO-B mouse model of Parkinson's disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics.
Parkinson Disease
An integrated approach to patient management in Parkinson's disease.
Parkinson Disease
An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Parkinson Disease
An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
Parkinson Disease
An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
Parkinson Disease
An update on amine oxidase inhibitors: Multifaceted drugs.
Parkinson Disease
An update on pharmacological approaches to neurodegenerative diseases.
Parkinson Disease
Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP(+)-treated SH-SY5Y human dopaminergic cells.
Parkinson Disease
Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.
Parkinson Disease
Antioxidant therapy in Parkinson's disease.
Parkinson Disease
Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma.
Parkinson Disease
Association analysis of a polymorphism of the monoamine oxidase B gene with Parkinson's disease in a Japanese population.
Parkinson Disease
Association between monoamine oxidase B A644G polymorphism and Parkinson's disease risk: a meta-analysis in the Chinese population.
Parkinson Disease
Association of a monoamine oxidase B allele with Parkinson's disease.
Parkinson Disease
Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease.
Parkinson Disease
Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
Parkinson Disease
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
Parkinson Disease
Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant.
Parkinson Disease
Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis.
Parkinson Disease
Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson's disease in an Iranian population.
Parkinson Disease
Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups.
Parkinson Disease
Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface.
Parkinson Disease
Binding mechanism of naringenin with monoamine oxidase - B enzyme: QM/MM and molecular dynamics perspective.
Parkinson Disease
Biochemical actions of l-deprenyl (selegiline).
Parkinson Disease
Boosting Drug Discovery for Parkinson's: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles.
Parkinson Disease
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Parkinson Disease
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Parkinson Disease
Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease.
Parkinson Disease
Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects.
Parkinson Disease
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Parkinson Disease
Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
Parkinson Disease
Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
Parkinson Disease
Carnisone increases efficiency of DOPA therapy of Parkinson's disease: a pilot study.
Parkinson Disease
Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease.
Parkinson Disease
Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population.
Parkinson Disease
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Parkinson Disease
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.
Parkinson Disease
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Parkinson Disease
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Parkinson Disease
Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.
Parkinson Disease
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells.
Parkinson Disease
Chronic alterations in jejunal myoelectric activity in rats due to MPTP.
Parkinson Disease
Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites.
Parkinson Disease
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
Parkinson Disease
Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway.
Parkinson Disease
Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
Parkinson Disease
Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset.
Parkinson Disease
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.
Parkinson Disease
Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Parkinson Disease
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline.
Parkinson Disease
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
Parkinson Disease
Clinical trials with rasagiline: evidence for short-term and long-term effects.
Parkinson Disease
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
Parkinson Disease
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Parkinson Disease
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Parkinson Disease
Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors.
Parkinson Disease
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Parkinson Disease
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Parkinson Disease
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
Parkinson Disease
Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Parkinson Disease
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Parkinson Disease
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Parkinson Disease
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Parkinson Disease
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.
Parkinson Disease
Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
Parkinson Disease
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Parkinson Disease
Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl.
Parkinson Disease
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.
Parkinson Disease
Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons.
Parkinson Disease
Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
Parkinson Disease
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Parkinson Disease
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Parkinson Disease
Deprenyl reduces the death of motoneurons caused by axotomy.
Parkinson Disease
Deprenyl, a therapeutic agent for Parkinson's disease, inhibits arsenic toxicity potentiated by GSH depletion via inhibition of JNK activation.
Parkinson Disease
Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors.
Parkinson Disease
Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease.
Parkinson Disease
Design Expert(®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease.
Parkinson Disease
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Parkinson Disease
Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
Parkinson Disease
Design, Synthesis and Evaluation of 8-Thiosubstituted 1,3,7-Trimethylxanthine Hydrazones with In Vitro Neuroprotective and MAO-B Inhibitory Activities.
Parkinson Disease
Design, Synthesis and Inhibitory Activities of 8-(Substituted styrol-formamido)phenyl-xanthine Derivatives on Monoamine Oxidase B.
Parkinson Disease
Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Parkinson Disease
Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease.
Parkinson Disease
Detection of l-Methamphetamine and l-Amphetamine as Selegiline Metabolites.
Parkinson Disease
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Parkinson Disease
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Parkinson Disease
Developing a Multi-target Model to Predict the Activity of Monoamine Oxidase A and B Drugs.
Parkinson Disease
Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil.
Parkinson Disease
Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease.
Parkinson Disease
Different generations of type-B monoamine oxidase inhibitors in Parkinson's disease: from bench to bedside.
Parkinson Disease
Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies.
Parkinson Disease
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
Parkinson Disease
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
Parkinson Disease
Discovery, Biological Evaluation, and Structure-Activity and -Selectivity Relationships of 6'-Substituted (E)-2-(Benzofuran-3(2H)-ylidene)-N-methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors.
Parkinson Disease
DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson's disease cases and unrelated controls.
Parkinson Disease
Does phenylethylamine act as an endogenous amphetamine in some patients?
Parkinson Disease
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
Parkinson Disease
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
Parkinson Disease
Drug treatment of Parkinson's disease: current concepts.
Parkinson Disease
Dual monoamine oxidase and cholinesterase Inhibitors with different heterocyclic scaffolds.
Parkinson Disease
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
Parkinson Disease
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Parkinson Disease
Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Parkinson Disease
Dysregulation of astrocytic mitochondrial function following exposure to a dopamine metabolite: Implications for Parkinson's disease.
Parkinson Disease
Early diagnosis of Parkinson's disease and initiation of treatment.
Parkinson Disease
Early therapy for Parkinson's disease.
Parkinson Disease
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Parkinson Disease
Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
Parkinson Disease
Effect of selegiline on cognitive functions in Parkinson's disease.
Parkinson Disease
Effects of 1-cyclohexyl- and 1-cyclohexyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline on dopaminergic spontaneous discharge in nigral neurons of rats.
Parkinson Disease
Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.
Parkinson Disease
Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.
Parkinson Disease
Effects of Mitochondrial Antioxidant SkQ1 on Biochemical and Behavioral Parameters in a Parkinsonism Model in Mice.
Parkinson Disease
Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells.
Parkinson Disease
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Parkinson Disease
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Parkinson Disease
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Parkinson Disease
Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study.
Parkinson Disease
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Parkinson Disease
Efficacy and tolerability of rasagiline in daily clinical use - a post-marketing observational study in patients with Parkinson's disease.
Parkinson Disease
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Parkinson Disease
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Parkinson Disease
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.
Parkinson Disease
Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Parkinson Disease
Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders.
Parkinson Disease
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Parkinson Disease
Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele.
Parkinson Disease
Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation.
Parkinson Disease
Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage.
Parkinson Disease
Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.
Parkinson Disease
Evaluation of the inhibitory effects of eckol and dieckol isolated from edible brown alga Eisenia bicyclis on human monoamine oxidases A and B.
Parkinson Disease
Evaluation of the overall system precision of the Welch-Allyn transtelephonic home blood pressure monitor in adults with Parkinson's disease.
Parkinson Disease
Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Parkinson Disease
Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
Parkinson Disease
Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
Parkinson Disease
Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease.
Parkinson Disease
Exposing the Interplay Between Enzyme Turnover, Protein Dynamics, and the Membrane Environment in Monoamine Oxidase B.
Parkinson Disease
Fluoxetine and selegiline--lack of significant interaction.
Parkinson Disease
Free radicals in Alzheimer's dementia: currently available therapeutic strategies.
Parkinson Disease
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
Parkinson Disease
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.
Parkinson Disease
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Parkinson Disease
Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
Parkinson Disease
Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands.
Parkinson Disease
G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease.
Parkinson Disease
Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug.
Parkinson Disease
GAPDH as a sensor of NO stress.
Parkinson Disease
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Parkinson Disease
Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease.
Parkinson Disease
Gene-gene interaction between FGF20 and MAOB in Parkinson disease.
Parkinson Disease
Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism.
Parkinson Disease
Genetic polymorphism of monoamine oxidase B and susceptibility of Parkinson's disease.
Parkinson Disease
Genetics and Parkinson's disease.
Parkinson Disease
Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.
Parkinson Disease
Herbal natural products as a source of monoamine oxidase inhibitors: a review.
Parkinson Disease
Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease.
Parkinson Disease
Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease.
Parkinson Disease
High throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors.
Parkinson Disease
Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine.
Parkinson Disease
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
Parkinson Disease
Hydroxytyrosol as anti-parkinsonian molecule: Assessment using in-silico and MPTP-induced Parkinson's disease model.
Parkinson Disease
Hydroxytyrosol inhibits MAO isoforms and prevents neurotoxicity inducible by MPP+ invivo.
Parkinson Disease
I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
Parkinson Disease
Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach.
Parkinson Disease
Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects.
Parkinson Disease
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Parkinson Disease
Improvement of mouse brain mitochondrial function after deprenyl treatment.
Parkinson Disease
In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid.
Parkinson Disease
In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain.
Parkinson Disease
Increased L-dopa-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Parkinson Disease
Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
Parkinson Disease
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Parkinson Disease
Influence of Single Nucleotide Polymorphisms in COMT , MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease.
Parkinson Disease
Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration.
Parkinson Disease
Inhibition of monoamine oxidase by benzoxathiolone analogues.
Parkinson Disease
Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease.
Parkinson Disease
Inhibition of monoamine oxidase by indole and benzofuran derivatives.
Parkinson Disease
Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives.
Parkinson Disease
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Parkinson Disease
Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP+ Parkinson's disease models.
Parkinson Disease
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.
Parkinson Disease
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
Parkinson Disease
Inhibitory effect of drugs used in the treatment of Parkinson's disease on plasma monoamine oxidase activity.
Parkinson Disease
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Parkinson Disease
Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors.
Parkinson Disease
Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.
Parkinson Disease
Involvement of Bcl-2-associated athanogene (BAG)-family proteins in the neuroprotection by rasagiline.
Parkinson Disease
Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells.
Parkinson Disease
Is selegiline neuroprotective in Parkinson's disease?
Parkinson Disease
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
Parkinson Disease
Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.
Parkinson Disease
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
Parkinson Disease
L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
Parkinson Disease
L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.
Parkinson Disease
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Parkinson Disease
L-deprenyl: nitric oxide production and dilation of cerebral blood vessels.
Parkinson Disease
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Parkinson Disease
Lack of protective effect of R(-)-deprenyl on programmed cell death of mouse thymocytes induced by dexamethasone.
Parkinson Disease
Laser modification of the blood in vitro and in vivo in patients with Parkinson's disease.
Parkinson Disease
Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study.
Parkinson Disease
Ligand based screening of chemical constituents from African medicinal plants for the identification of MAOB inhibitors.
Parkinson Disease
Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2A Adenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors.
Parkinson Disease
Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
Parkinson Disease
Lisuride plus selegiline in the treatment of early Parkinson's disease.
Parkinson Disease
Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
Parkinson Disease
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Parkinson Disease
Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson's Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance.
Parkinson Disease
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Parkinson Disease
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
Parkinson Disease
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Parkinson Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
Parkinson Disease
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Parkinson Disease
Low Dosage of Rasagiline and Epigallocatechin Gallate Synergistically Restored the Nigrostriatal Axis in MPTP-Induced Parkinsonism.
Parkinson Disease
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Parkinson Disease
M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
Parkinson Disease
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Parkinson Disease
MAO-B and Parkinson's disease.
Parkinson Disease
MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology.
Parkinson Disease
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([
Parkinson Disease
MAO-B inhibitors for the treatment of Parkinson's disease.
Parkinson Disease
MAO-B inhibitors in Parkinson's disease.
Parkinson Disease
MAO-inhibitors in Parkinson's Disease.
Parkinson Disease
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
Parkinson Disease
MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
Parkinson Disease
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Parkinson Disease
Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson's Disease.
Parkinson Disease
Metabolic transformation of deprenyl enantiomers in rats.
Parkinson Disease
Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
Parkinson Disease
Methamphetamine and amphetamine derived from the metabolism of selegiline.
Parkinson Disease
Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.
Parkinson Disease
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
Parkinson Disease
Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey.
Parkinson Disease
Milestones in Parkinson's disease therapeutics.
Parkinson Disease
Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.
Parkinson Disease
Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.
Parkinson Disease
Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Parkinson Disease
Molecular characterization of monoamine oxidases A and B.
Parkinson Disease
Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease.
Parkinson Disease
Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Parkinson Disease
Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Parkinson Disease
Monoamine oxidase A and B inhibitors in Parkinson's disease.
Parkinson Disease
Monoamine oxidase A inhibition and Parkinson's disease.
Parkinson Disease
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Parkinson Disease
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Parkinson Disease
Monoamine oxidase and ?-synuclein as targets in Parkinson's disease therapy.
Parkinson Disease
Monoamine Oxidase and Dopamine ?-Hydroxylase Inhibitors from the Fruits of Gardenia jasminoides.
Parkinson Disease
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
Parkinson Disease
Monoamine oxidase B and Parkinson's disease.
Parkinson Disease
Monoamine oxidase B inhibitors for early Parkinson's disease.
Parkinson Disease
Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
Parkinson Disease
Monoamine oxidase B inhibitors in Parkinson's disease.
Parkinson Disease
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Parkinson Disease
Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: a study in an Asian population.
Parkinson Disease
Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease.
Parkinson Disease
Monoamine oxidase B, smoking, and Parkinson's disease.
Parkinson Disease
Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
Parkinson Disease
Monoamine oxidase inhibition by selected dye compounds.
Parkinson Disease
Monoamine oxidase inhibitors and their pharmacological significance.
Parkinson Disease
Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.
Parkinson Disease
Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Parkinson Disease
Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson's Disease.
Parkinson Disease
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Parkinson Disease
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
Parkinson Disease
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Parkinson Disease
Monoamine oxidase inhibitors. An update on drug interactions.
Parkinson Disease
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
Parkinson Disease
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
Parkinson Disease
Monoamine oxidase substrates in Parkinson's disease.
Parkinson Disease
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Parkinson Disease
Monoamine oxidase type B inhibitors in the treatment of Parkinson's disease.
Parkinson Disease
Monoamine oxidase, dopamine and Parkinson's disease.
Parkinson Disease
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Parkinson Disease
Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
Parkinson Disease
Monoamine oxidase-A promotes protective autophagy in human SH-SY5Y neuroblastoma cells through Bcl-2 phosphorylation.
Parkinson Disease
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.
Parkinson Disease
Monoamine Oxidase-B Inhibition Facilitates ?-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.
Parkinson Disease
Monoamine oxidase-B inhibition in Alzheimer's disease.
Parkinson Disease
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Parkinson Disease
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Parkinson Disease
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Parkinson Disease
Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
Parkinson Disease
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Parkinson Disease
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Parkinson Disease
Monoamine Oxidases.
Parkinson Disease
Monoamineoxidase-B (MAO-B) Inhibitors in theTreatment of Alzheimer's and Parkinson's Disease.
Parkinson Disease
Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences.
Parkinson Disease
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Parkinson Disease
Multicenter trial of L-Deprenyl in Parkinson disease.
Parkinson Disease
Multiscale Modeling of Two-Photon Probes for Parkinson's Diagnostics Based on Monoamine Oxidase B Biomarker.
Parkinson Disease
My love with monoamine oxidase, iron and Parkinson's disease.
Parkinson Disease
Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors.
Parkinson Disease
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
Parkinson Disease
Neurochemical perspectives to the function of monoamine oxidase.
Parkinson Disease
Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration.
Parkinson Disease
Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition.
Parkinson Disease
Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Parkinson Disease
Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.
Parkinson Disease
Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1? signaling pathway and mitochondrial uncoupling protein -2(UCP-2).
Parkinson Disease
Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
Parkinson Disease
Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
Parkinson Disease
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Parkinson Disease
Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an in vivo model of excitotoxicity.
Parkinson Disease
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Parkinson Disease
Neurorescuing effects of the GAPDH ligand CGP 3466B.
Parkinson Disease
Neurotoxins and monoamine oxidase inhibition: new aspects.
Parkinson Disease
New directions in monoamine oxidase A and B selective inhibitors and substrates.
Parkinson Disease
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Parkinson Disease
New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling.
Parkinson Disease
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
Parkinson Disease
No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms.
Parkinson Disease
Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.
Parkinson Disease
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
Parkinson Disease
Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?
Parkinson Disease
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Parkinson Disease
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Parkinson Disease
Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
Parkinson Disease
Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.
Parkinson Disease
Novel Diels-Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases.
Parkinson Disease
Novel Food Supplement "CP1" Improves Motor Deficit, Cognitive Function, and Neurodegeneration in Animal Model of Parkinson's Disease.
Parkinson Disease
Novel MAO-B inhibitors potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Parkinson Disease
Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility.
Parkinson Disease
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Parkinson Disease
On the functions of monoamine oxidase, the emotions, and adaptation to stress.
Parkinson Disease
Orally disintegrating selegiline for the treatment of Parkinson's disease.
Parkinson Disease
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Parkinson Disease
Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Parkinson Disease
Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease.
Parkinson Disease
Oxidative stress and antioxidant therapy in Parkinson's disease.
Parkinson Disease
Oxidative Stress Indices in Parkinson's Disease : Biochemical Determination.
Parkinson Disease
Oxy-radical toxicity in catecholamine neurons.
Parkinson Disease
Pain in Parkinson's disease: new concepts in pathogenesis and treatment.
Parkinson Disease
Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.
Parkinson Disease
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.
Parkinson Disease
Parkinson's Disease Management. Part II- Discovery of MAO-B Inhibitors Based on Nitrogen Heterocycles and Analogues.
Parkinson Disease
Parkinson's disease.
Parkinson Disease
Parkinson's disease: clinical and therapeutic aspects.
Parkinson Disease
Parkinson's disease: diagnosis and treatment.
Parkinson Disease
Parkinson's disease: fewer treatment withdrawals with levodopa.
Parkinson Disease
Parkinson's disease: focus on management alternatives.
Parkinson Disease
Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics.
Parkinson Disease
Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.
Parkinson Disease
Perspectives on MAO-B in aging and neurological disease: where do we go from here?
Parkinson Disease
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Parkinson Disease
PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
Parkinson Disease
Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine.
Parkinson Disease
Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease.
Parkinson Disease
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Parkinson Disease
Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Parkinson Disease
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Parkinson Disease
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Parkinson Disease
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Parkinson Disease
Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status.
Parkinson Disease
Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.
Parkinson Disease
Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors.
Parkinson Disease
Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
Parkinson Disease
Pharmacological and clinical implications of MAO-B inhibitors.
Parkinson Disease
Pharmacological aspects of (-)-deprenyl.
Parkinson Disease
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Parkinson Disease
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
Parkinson Disease
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Parkinson Disease
Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Parkinson Disease
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Parkinson Disease
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.
Parkinson Disease
Pharmacology of selegiline.
Parkinson Disease
Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO?B inhibitors.
Parkinson Disease
Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B.
Parkinson Disease
Phytochemical investigation of some traditional chinese medicines and endophyte cultures.
Parkinson Disease
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
Parkinson Disease
Platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls.
Parkinson Disease
Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.
Parkinson Disease
Platelet monoamine oxidase B activity in "de novo" and l-dopa treated parkinsonian patients and controls.
Parkinson Disease
Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation.
Parkinson Disease
Platelet monoamine oxidase B activity in parkinsonian patients.
Parkinson Disease
Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
Parkinson Disease
Platelet monoamine oxidase-B activity in Parkinson's disease.
Parkinson Disease
Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease.
Parkinson Disease
Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
Parkinson Disease
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
Parkinson Disease
Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from Alternaria brassicae.
Parkinson Disease
Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.
Parkinson Disease
Practical considerations for the treatment of elderly patients with migraine.
Parkinson Disease
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Parkinson Disease
Preclinical Herb-Drug Pharmacokinetic Interaction of Panax ginseng Extract and Selegiline in Freely Moving Rats.
Parkinson Disease
Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease.
Parkinson Disease
Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
Parkinson Disease
Progress in monoamine oxidase (MAO) research in relation to genetic engineering.
Parkinson Disease
Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.
Parkinson Disease
Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
Parkinson Disease
Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Parkinson Disease
Protein aggregation in retinal cells and approaches to cell protection.
Parkinson Disease
Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease.
Parkinson Disease
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Parkinson Disease
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Parkinson Disease
R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Parkinson Disease
Rapid onset of efficacy of rasagiline in early Parkinson's disease.
Parkinson Disease
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Parkinson Disease
Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.
Parkinson Disease
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Parkinson Disease
Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.
Parkinson Disease
Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Parkinson Disease
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Parkinson Disease
Rasagiline derivatives combined with histamine H3 receptor properties.
Parkinson Disease
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia.
Parkinson Disease
Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study.
Parkinson Disease
Rasagiline in Parkinson's disease.
Parkinson Disease
Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Parkinson Disease
Rasagiline in the pharmacotherapy of Parkinson's disease - a review.
Parkinson Disease
Rasagiline in treatment of Parkinson's disease.
Parkinson Disease
Rasagiline induced hypersexuality in Parkinson's disease.
Parkinson Disease
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Parkinson Disease
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Parkinson Disease
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
Parkinson Disease
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.
Parkinson Disease
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Parkinson Disease
Rasagiline, a Suicide Inhibitor of Monoamine Oxidases, Binds Reversibly to ?-Synuclein.
Parkinson Disease
Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content.
Parkinson Disease
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Parkinson Disease
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Parkinson Disease
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Parkinson Disease
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Parkinson Disease
Rationally designed multi-targeted agents against neurodegenerative diseases.
Parkinson Disease
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Parkinson Disease
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Parkinson Disease
Recent advances in pharmacological therapy of Parkinson's disease.
Parkinson Disease
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Parkinson Disease
Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis.
Parkinson Disease
Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl.
Parkinson Disease
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Parkinson Disease
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Parkinson Disease
Ring opening of pymisyl-protected aziridines with organocuprates.
Parkinson Disease
Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
Parkinson Disease
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Parkinson Disease
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Parkinson Disease
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Parkinson Disease
Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
Parkinson Disease
Safinamide (Newron Pharmaceuticals).
Parkinson Disease
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Parkinson Disease
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Parkinson Disease
Safinamide in the treatment of Parkinson's disease.
Parkinson Disease
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Parkinson Disease
Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-?B signaling.
Parkinson Disease
Selected chromone derivatives as inhibitors of monoamine oxidase.
Parkinson Disease
Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana).
Parkinson Disease
Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.
Parkinson Disease
Selective inhibitors of monoamine oxidase type B and the "cheese effect".
Parkinson Disease
Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease.
Parkinson Disease
Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Parkinson Disease
Selegiline and cognitive function in Parkinson's disease.
Parkinson Disease
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Parkinson Disease
Selegiline as immunostimulant--a novel mechanism of action?
Parkinson Disease
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
Parkinson Disease
Selegiline for Parkinson's disease.
Parkinson Disease
Selegiline in Parkinson's disease.
Parkinson Disease
Selegiline in the treatment of narcolepsy.
Parkinson Disease
Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms.
Parkinson Disease
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Parkinson Disease
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Parkinson Disease
Selegiline transdermal system: in the treatment of major depressive disorder.
Parkinson Disease
Selegiline treatment facilitates recovery after stroke.
Parkinson Disease
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
Parkinson Disease
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
Parkinson Disease
Selegiline: a molecule with innovative potential.
Parkinson Disease
Selegiline: a reappraisal of its role in Parkinson disease.
Parkinson Disease
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.
Parkinson Disease
Seligiline transdermal system in depression.
Parkinson Disease
Sex-dependent monoamine oxidase isoforms expression patterns during human brain ageing.
Parkinson Disease
Short review on monoamine oxidase and its inhibitors.
Parkinson Disease
Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
Parkinson Disease
Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC-MS/MS: Application to a clinical pharmacokinetic study.
Parkinson Disease
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Parkinson Disease
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Parkinson Disease
Single heterocyclic compounds as Monoamine Oxidase Inhibitors: From past to present.
Parkinson Disease
Sizes and ligands tuned gold nanocluster acting as a new type of monoamine oxidase B inhibitor.
Parkinson Disease
Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal.
Parkinson Disease
SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.
Parkinson Disease
Steered molecular dynamics simulations reveal important mechanisms in reversible monoamine oxidase B inhibition.
Parkinson Disease
Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.
Parkinson Disease
Structure-based design and analysis of MAO-B inhibitors for Parkinson's disease: using in silico approaches.
Parkinson Disease
Successful use of rasagiline in combination with two antidepressants: a case report.
Parkinson Disease
Suicide inhibition of monoamine oxidases A and B by (-)-deprenyl. A computer-aided solution for determining inhibition specificity.
Parkinson Disease
Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis.
Parkinson Disease
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Parkinson Disease
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35).
Parkinson Disease
Synthesis and Evaluation of 2-benzylidene-1-tetralone Derivatives for Monoamine Oxidase Inhibitory Activity.
Parkinson Disease
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
Parkinson Disease
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Parkinson Disease
Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase.
Parkinson Disease
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors.
Parkinson Disease
Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
Parkinson Disease
Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.
Parkinson Disease
The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
Parkinson Disease
The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells.
Parkinson Disease
The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.
Parkinson Disease
The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
Parkinson Disease
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Parkinson Disease
The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.
Parkinson Disease
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Parkinson Disease
The effect of deprenyl washout in patients with long-standing Parkinson's disease.
Parkinson Disease
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Parkinson Disease
The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials.
Parkinson Disease
The effects of pyridinium salts, structurally related compounds of 1-methyl-4-phenylpyridinium ion (MPP+), on tyrosine hydroxylation in rat striatal tissue slices.
Parkinson Disease
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study.
Parkinson Disease
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
Parkinson Disease
The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.
Parkinson Disease
The hypothalamus in MPTP-induced parkinsonism.
Parkinson Disease
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
Parkinson Disease
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
Parkinson Disease
The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
Parkinson Disease
The molecular pharmacology of L-deprenyl.
Parkinson Disease
The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population.
Parkinson Disease
The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone.
Parkinson Disease
The monoamine oxidase inhibitory activity of essential oils obtained from Eryngium species and their chemical composition.
Parkinson Disease
The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
Parkinson Disease
The new generation of monoamine oxidase inhibitors.
Parkinson Disease
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Parkinson Disease
The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB.
Parkinson Disease
The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue.
Parkinson Disease
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Parkinson Disease
The pharmacology of selegiline.
Parkinson Disease
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
Parkinson Disease
The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis.
Parkinson Disease
The relationship of early studies of monoamine oxidase to present concepts.
Parkinson Disease
The relationship of negative schizophrenia to parkinsonism.
Parkinson Disease
The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
Parkinson Disease
The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
Parkinson Disease
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Parkinson Disease
The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease.
Parkinson Disease
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Parkinson Disease
The Synthesis and Evaluation of C7-Substituted ?-Tetralone Derivatives as Inhibitors of Monoamine Oxidase.
Parkinson Disease
The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase.
Parkinson Disease
The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
Parkinson Disease
The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
Parkinson Disease
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Parkinson Disease
The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes.
Parkinson Disease
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Parkinson Disease
Theoretical Study of Monoamine Oxidase B Inhibitors as Drug Candidates for Treatment of Parkinson's Disease.
Parkinson Disease
Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
Parkinson Disease
Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib.
Parkinson Disease
Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis.
Parkinson Disease
Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?
Parkinson Disease
Total monoamine oxidase (MAO) inhibition by chestnut honey, pollen and propolis.
Parkinson Disease
Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Parkinson Disease
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Parkinson Disease
Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response.
Parkinson Disease
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future challenges - A Mini-Review.
Parkinson Disease
Treatment of Parkinson's disease.
Parkinson Disease
Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells.
Parkinson Disease
Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Parkinson Disease
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Parkinson Disease
Type B monoamine oxidase and neurotoxins.
Parkinson Disease
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release.
Parkinson Disease
Using monoamine oxidase type B inhibitors in Parkinson's disease.
Parkinson Disease
Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease.
Parkinson Disease
Virtual screening and drug repurposing experiments to identify potential novel selective MAO-B inhibitors for Parkinson's disease treatment.
Parkinson Disease
What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase?B Towards Histamine and N-Methylhistamine.
Parkinson Disease
Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients.
Parkinson Disease
X-LRT: a likelihood approach to estimate genetic risks and test association with X-linked markers using a case-parents design.
Parkinson Disease
Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease.
Parkinson Disease
Zhichan powder regulates nigrostriatal dopamine synthesis and metabolism in Parkinson's disease rats.
Parkinson Disease
Zonisamide: a new drug for Parkinson's disease.
Parkinson Disease
Zydis selegiline in the management of Parkinson's disease.
Parkinson Disease
[Application of the common marmoset to pharmacological studies]
Parkinson Disease
[Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution]
Parkinson Disease
[Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
Parkinson Disease
[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies]
Parkinson Disease
[Do monoamine oxidase B inhibitors represent hope for Parkinson's disease patients?]
Parkinson Disease
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Parkinson Disease
[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
Parkinson Disease
[Impact of rhythmic transcranial magnetic stimulation on the dynamics of motor and non-motor manifestations of Parkinson's disease].
Parkinson Disease
[Inhibitory monoamine oxidases of the new generation]
Parkinson Disease
[Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease]
Parkinson Disease
[Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]
Parkinson Disease
[Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)]
Parkinson Disease
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]
Parkinson Disease
[Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect®)].
Parkinson Disease
[Pharmacological treatments of Parkinson's disease]
Parkinson Disease
[Plasma levels of mediator amino acids in patients with Parkinson disease]
Parkinson Disease
[Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson's disease]
Parkinson Disease
[Polymorphisms of catechol-O-methyltransferase and monoamine oxidase B genes among Chinese patients with Parkinson's disease].
Parkinson Disease
[Positron emission tomography of C-11-labelled selegiline]
Parkinson Disease
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
Parkinson Disease
[Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals]
Parkinson Disease
[Relationship between the Fnu4HI site polymorphism of monoamine oxidase A gene and Parkinson's disease]
Parkinson Disease
[Role of gene polymorphism of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), cytochrome P450 2D6 (CYP2D6) and N-acetyltransferase 2 (NAT2) in pathogenesis of Parkinson's disease]
Parkinson Disease
[Safinamide Mesilate (Equfina® TABLETS 50?mg): preclinical and clinical pharmacodynamics, efficacy, and safety].
Parkinson Disease
[Severe therapy refractory depression as initial manifestation of Parkinson disease]
Parkinson Disease
[The EcoR V polymorphism of human monoamine oxidase A is not associated with idiopathic Parkinson's disease in a Shanghai Han population]
Parkinson Disease
[The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease].
Parkinson Disease
[The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
Parkinson Disease
[The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].
Parkinson Disease
[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease]
Parkinson Disease
[Tobacco--once a medicinal plant. Does it contain substances with medicinal properties?].
Parkinsonian Disorders
1-Methyl-4-phenylpyridinium (MPP+) binds with high affinity to a beta-carboline binding site located on monoamine oxidase type A in rat brain.
Parkinsonian Disorders
1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs.
Parkinsonian Disorders
A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Parkinsonian Disorders
A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
Parkinsonian Disorders
Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice.
Parkinsonian Disorders
Ameliorative effect of ethoxylated chalcone-based MAO-B inhibitor on behavioural predictors of haloperidol-induced Parkinsonism in mice: evidence of its antioxidative role against Parkinson's diseases.
Parkinsonian Disorders
Antiparkinsonian Effects of Aqueous Methanolic Extract of Hyoscyamus niger Seeds Result From its Monoamine Oxidase Inhibitory and Hydroxyl Radical Scavenging Potency.
Parkinsonian Disorders
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Parkinsonian Disorders
Biochemical actions of l-deprenyl (selegiline).
Parkinsonian Disorders
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Parkinsonian Disorders
Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys.
Parkinsonian Disorders
Cytotoxicity of 1-amino-4-phenyl-1,2,3,6-tetrahydropyridine and 1-amino-4-phenylpyridinium ion, 1-amino analogues of MPTP and MPP+, to clonal pheochromocytoma PC12 cells.
Parkinsonian Disorders
Deprenyl in Parkinson disease.
Parkinsonian Disorders
Deprenyl monotherapy improves visuo-motor control in early parkinsonism.
Parkinsonian Disorders
Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
Parkinsonian Disorders
Dopamine efflux by MPTP and hydroxyl radical generation.
Parkinsonian Disorders
Drug treatment of Parkinson's disease: current concepts.
Parkinsonian Disorders
Early idiopathic parkinsonism: initiation and optimization of treatment.
Parkinsonian Disorders
Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review.
Parkinsonian Disorders
Fracture risk associated with parkinsonism and anti-Parkinson drugs.
Parkinsonian Disorders
Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease.
Parkinsonian Disorders
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Parkinsonian Disorders
Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.
Parkinsonian Disorders
Inhibition of type A monoamine oxidase by 1-methyl-4-phenylpyridine.
Parkinsonian Disorders
Isoquinoline neurotoxins in the brain and Parkinson's disease.
Parkinsonian Disorders
Medical Management of Frontotemporal Dementias: The Importance of the Caregiver in Symptom Assessment and Guidance of Treatment Strategies.
Parkinsonian Disorders
Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase.
Parkinsonian Disorders
Molecular characterization of monoamine oxidases A and B.
Parkinsonian Disorders
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Parkinsonian Disorders
Neurotoxicity of MPTP.
Parkinsonian Disorders
Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
Parkinsonian Disorders
Parkinson's disease: past, present, and future.
Parkinsonian Disorders
Parkinsonian side effects induced by a monoamine oxidase inhibitor.
Parkinsonian Disorders
Parkinsonism induced by a monoamine oxidase inhibitor.
Parkinsonian Disorders
Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.
Parkinsonian Disorders
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Parkinsonian Disorders
Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.
Parkinsonian Disorders
Platelet monoamine oxidase B activity in parkinsonian patients.
Parkinsonian Disorders
Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.
Parkinsonian Disorders
Prevalence of parkinsonism estimated using the drug prescription archive: a possible method to estimate the prevalence of a chronic neurological disease?
Parkinsonian Disorders
Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping.
Parkinsonian Disorders
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Parkinsonian Disorders
Short review on monoamine oxidase and its inhibitors.
Parkinsonian Disorders
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
Parkinsonian Disorders
The effect of deprenyl treatment on directional and velocity control of arm movement in patients with early stages of Parkinson's disease.
Parkinsonian Disorders
The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
Parkinsonian Disorders
The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
Parkinsonian Disorders
The hypothalamus in MPTP-induced parkinsonism.
Parkinsonian Disorders
The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population.
Parkinsonian Disorders
The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions.
Parkinsonian Disorders
The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease.
Parkinsonian Disorders
[Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients]
Parkinsonian Disorders
[Parkinsonism induced by MPTP and free radical generation]
Peptic Ulcer
Treatment of peptic ulcer disease with furazolidone.
Peptic Ulcer
[Intravital histopathological changes in the gastric mucosa and the activity of certain cytoplasmic enzymes (cholinesterase, monoamine oxidase, histaminase) and acetylcholine in peptic ulcer and chronic gastritis]
Peripheral Arterial Disease
Preliminary observations on the role of monoamine oxidase inhibitors in the therapy of peripheral arterial disease.
Peripheral Vascular Diseases
THE PLACE OF MONOAMINE OXIDASE INHIBITOR IN OCCLUSIVE PERIPHERAL VASCULAR DISEASE.
Pharyngeal Neoplasms
Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx.
Pharyngeal Neoplasms
The influence of monoamine oxidase variants on the risk of betel quid-associated oral and pharyngeal cancer.
Phenylketonurias
Is monoamine oxydase-B a modifying gene and phenylethylamine a harmful compound in phenylketonuria?
Phenylketonurias
Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency.
Phenylketonurias
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Pheochromocytoma
1,4-Benzoquinone as a new inhibitor of monoamine oxidase.
Pheochromocytoma
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Pheochromocytoma
4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase.
Pheochromocytoma
An adrenal mass and increased catecholamines: monoamine oxidase or pheochromocytoma effect?
Pheochromocytoma
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Pheochromocytoma
Cytotoxic, cytoprotective and antioxidant effects of isolated phenolic compounds from fresh ginger.
Pheochromocytoma
Dopamine and iron induce apoptosis in PC12 cells.
Pheochromocytoma
Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells.
Pheochromocytoma
Effect of N-methyl-4-phenylpyridinium ion on monoamine oxidase in a clonal rat pheochromocytoma cell line, PC12h.
Pheochromocytoma
Ganglioside GM1 causes expression of type B monoamine oxidase in a rat clonal pheochromocytoma cell line, PC12h.
Pheochromocytoma
Hypertensive emergencies. Etiology and management.
Pheochromocytoma
Inhibition of monoamine oxidase by metaiodobenzylguanidine, a new radiodiagnostic agent.
Pheochromocytoma
Inhibition of type A monoamine oxidase by methylquinolines and structurally related compounds.
Pheochromocytoma
Metabolism and storage of catecholamines in rats with pheochromocytoma implants.
Pheochromocytoma
Monoamine oxidase a down-regulation contributes to high metanephrine concentration in pheochromocytoma.
Pheochromocytoma
Monoamine oxidase in rat and bovine endocrine tissues.
Pheochromocytoma
Monoamine oxidase types A and B in the human adrenal gland and pheochromocytoma.
Pheochromocytoma
N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Pheochromocytoma
Oxidation of 1-amino-4-phenyl-1,2,3,6-tetrahydropyridine, a 1-amino analog of MPTP, by type A and B monoamine oxidase.
Pheochromocytoma
Serotonin metabolism and platelet monoamine oxidase activity in patients with medullary carcinoma of the thyroid and pheochromocytoma.
Pheochromocytoma
The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
Photophobia
MAOA and TNF-? gene polymorphisms are associated with photophobia but not osmophobia in patients with migraine.
Photosensitivity Disorders
Photosensitizing effects of Photofrin II on the site-selected mitochondrial enzymes adenylate kinase and monoamine oxidase.
Pick Disease of the Brain
Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.
Pituitary Neoplasms
Densities of I2-imidazoline receptors, imidazoline receptor proteins, and MAO-B sites in human gliomas and pituitary adenomas.
Pituitary Neoplasms
Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.
Pituitary Neoplasms
Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl.
Pituitary Neoplasms
Positron emission tomography in acromegaly and other pituitary adenoma patients.
Pneumococcal Infections
[Change in activity of 5-oxytryptophan decarboxylase and monoamine oxidase in rat organs in experimental pneumococcal infection]
Pneumococcal Infections
[EFFECT OF INDOPAN, A MONOAMINE OXIDASE INHIBITOR, ON THE TETRACYCLINE SENSITIVITY OF WHITE MICE AND RATS WITH PNEUMOCOCCAL INFECTION.]
Pneumoconiosis
[Monoamine oxidase activity in pneumoconiosis]
Pneumonia
Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.
Polycystic Ovary Syndrome
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Prader-Willi Syndrome
Is monoamine oxidase activity elevated in Prader-Willi syndrome?
Pre-Eclampsia
A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes.
Pre-Eclampsia
Dopamine in the Pathophysiology of Preeclampsia and Gestational Hypertension: Monoamine Oxidase (MAO) and Catechol-O-methyl Transferase (COMT) as Possible Mechanisms.
Pre-Eclampsia
Monoamine oxidase expression and activity in human placentae from pre-eclamptic and normotensive pregnancies.
Pre-Eclampsia
Semicarbazide-sensitive amine oxidase in pre-eclampsia: no relation with markers of endothelial cell activation.
Pre-Eclampsia
Serotonin metabolism in the fetus in preeclampsia.
Pre-Eclampsia
The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies.
Pre-Eclampsia
Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies.
Pre-Eclampsia
[Blood plasma dopamine beta-hydroxylase and monoamine oxidase activity in pregnancy toxemias]
Pre-Eclampsia
[Concentration of serotonin (5-HT) and monoamine oxidase activity in the placentas of women with pregnancy toxemias]
Pre-Eclampsia
[Determination in Warburg apparatus of the monoamine oxidase activity of the placenta in normal pregnancy and in preeclampsia]
Pre-Eclampsia
[Levels of serotonin in plasma and activity of monoamine oxidase in serum and blood platelets of women with EPH gestosis]
Pre-Eclampsia
[Study on serotonin metabolism in toxemia of pregnancy]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Effect of phenelzine on the proliferation, apoptosis and histone methylation and acetylation of Molt-4 cells].
Pregnancy, Ectopic
Ketamine induction and monoamine oxidase inhibitors.
Pregnancy, High-Risk
Monoamine oxidase activity in the term human placenta.
Premenstrual Dysphoric Disorder
Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder.
Premenstrual Dysphoric Disorder
Transcription factor AP-2 and monoaminergic functions in the central nervous system.
Prolactinoma
Erythrocyte catechol-O-methyltransferase, platelet monoamine oxidase, and platelet phenol sulfotransferase activities in patients with prolactin-secreting pituitary adenomas.
Prostatic Hyperplasia
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Prostatic Neoplasms
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.
Prostatic Neoplasms
Antidepressants protect bones from metastatic prostate cancer.
Prostatic Neoplasms
Application of novel pH sensitive isoniazid-heptamethine carbocyanine dye conjugates against prostate cancer cells.
Prostatic Neoplasms
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Prostatic Neoplasms
Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1? signaling.
Prostatic Neoplasms
Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.
Prostatic Neoplasms
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Prostatic Neoplasms
Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells.
Prostatic Neoplasms
Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer.
Prostatic Neoplasms
Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats.
Prostatic Neoplasms
Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells.
Prostatic Neoplasms
Kava root extracts hinder prostate cancer development and tumorigenesis by involvement of dual inhibition of MAO-A and LSD1.
Prostatic Neoplasms
MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Prostatic Neoplasms
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Prostatic Neoplasms
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Prostatic Neoplasms
Monoamine oxidase-A targeting probe for prostate cancer imaging and inhibition of metastasis.
Prostatic Neoplasms
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell.
Prostatic Neoplasms
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Prostatic Neoplasms
Regulation of monoamine oxidase A (MAO-A) expression, activity, and function in IL-13-stimulated monocytes and A549 lung carcinoma cells.
Prostatic Neoplasms
Repurposing antitubercular agent isoniazid for treatment of prostate cancer.
Prostatic Neoplasms
Serotonin synthesis and metabolism-related molecules in a human prostate cancer cell line.
Prostatic Neoplasms
Targeting monoamine oxidase A in advanced prostate cancer.
Prostatic Neoplasms
The effects of tranylcypromine on osteoclastogenesis in vitro and in vivo.
Prostatic Neoplasms
The Monoamine Oxidase A gene promoter repeat and prostate cancer risk.
Prostatic Neoplasms
The significance of monoamine oxidase-A expression in high grade prostate cancer.
Protein Deficiency
Protein malnourishment: a predisposing factor in acrylamide toxicity in pregnant rats.
Psoriasis
Monoamine- and diamine oxidase activities in psoriasis.
Psychomotor Agitation
Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs.
Pulmonary Arterial Hypertension
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Pulmonary Disease, Chronic Obstructive
Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells.
Pulmonary Disease, Chronic Obstructive
The involvement of serotonin metabolism in cigarette smoke-induced oxidative stress in rat lung in vivo.
Pulmonary Disease, Chronic Obstructive
[Comparative clinical studies of the hemodynamic parameters by anesthesia combination with Nalbuphin (Nubain) and Fentanyl]
Pulmonary Edema
A role for serotonin in alpha-naphthylthiourea-induced pulmonary edema.
Pulmonary Edema
[Influence of monoamine oxidase inhibitors on acute pulmonary edema induced by inhalation of ozone]
Purpura
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Purpura, Thrombocytopenic
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Purpura, Thrombocytopenic, Idiopathic
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Reflex, Abnormal
Phenelzine toxicity responsive to dantrolene.
Renal Insufficiency
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Renal Insufficiency
[Comparative clinical studies of the hemodynamic parameters by anesthesia combination with Nalbuphin (Nubain) and Fentanyl]
Renal Insufficiency, Chronic
Increased serum renalase in peritoneal dialysis patients: Is it related to cardiovascular disease risk?
Renal Insufficiency, Chronic
Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition.
Renal Insufficiency, Chronic
Semicarbazide-sensitive amine oxidase and kidney disease.
Reperfusion Injury
Cardiomyocytes-specific deletion of monoamine oxidase B reduces irreversible myocardial ischemia/reperfusion injury.
Reperfusion Injury
Elevated semicarbazide-sensitive amine oxidase (SSAO) activity in lung with ischemia-reperfusion injury: protective effect of ischemic preconditioning plus SSAO inhibition.
Reperfusion Injury
Flavonoids and Anthranquinones as Xanthine Oxidase and Monoamine Oxidase Inhibitors: A New Approach Towards Inflammation and Oxidative Stress.
Reperfusion Injury
Inhibition of semicarbazide-sensitive amine oxidase attenuates myocardial ischemia-reperfusion injury in an in vivo rat model.
Reperfusion Injury
Monoamine oxidase inhibition prevents ischemia reperfusion damage in rat kidneys.
Reperfusion Injury
Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury.
Reperfusion Injury
Synthesis and identification of a novel derivative of salidroside as a selective, competitive inhibitor of monoamine oxidase B with enhanced neuroprotective properties.
Restless Legs Syndrome
Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia.
Restless Legs Syndrome
Evidence for a genetic association between monoamine oxidase A and restless legs syndrome.
Restless Legs Syndrome
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Restless Legs Syndrome
The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Retinal Detachment
[Monoamine oxidase activity in retinal detachment]
Retinitis Pigmentosa
Studies on retinitis pigmentosa. I. Monoamine oxidase and sulfate conjugation in the experimental degeneration of the retina.
Reye Syndrome
Absence of diffusible inhibitor of glutamate dehydrogenase in the hepatocytes of Reye syndrome patients.
Reye Syndrome
Hepatic monoamine oxidase deficiency in Reye syndrome.
Reye Syndrome
Platelet-monoamine oxidase activity in Reye's syndrome.
Reye Syndrome
Quantitative evaluation of the extent of hepatic enzyme changes in Reye syndrome compared with normal liver or with non-Reye liver disorders: objective criteria for animal models.
Reye Syndrome
Salicylate and mitochondrial monoamine oxidase function in Reye's syndrome.
Rhabdomyolysis
[Hyperthermia and rhabdomyolysis caused by a monoamine oxidase inhibitor]
Rheumatic Diseases
The use of psychotropic drugs in rheumatology.
Rheumatic Diseases
[Activity of serum monoamine oxidase in rheumatism]
Rheumatic Diseases
[Concentration of catecholamines, their precursors, vanilmandelic acid and monoamine oxidase in patients with rheumatism in the active phase]
Rheumatic Fever
[Activity of serum monoamine oxidase in rheumatic fever and rheumatoid arthritis]
Rheumatic Heart Disease
[Monoamine oxidase activity in rheumatic heart disease associated with symptomatic hypertension]
Sarcoma
[The vehaviour of monoaminooxydase (MAO) activity in tumours. I. MAO activity measurement in experimental tumours (author's transl)]
Sarcoma 37
[Monoamine oxidase activity in cell nuclei and nuclear fractions of mouse liver under normal conditions and during development of ascitic sarcoma 37]
Sarcoma, Avian
[Activity of monoamine oxidase and diamine oxidase in a culture of chick fibroblasts infected with Rous sarcoma virus]
Sarcoma, Kaposi
HISTOCHEMISTRY OF KAPOSI'S SARCOMA. II. CHOLINESTERASES, MONOAMINE OXIDASE, AND ADENOSINE TRIPHOSPHATASE.
Schistosomiasis mansoni
Serum enzyme tests in hepatosplenic schistosomiasis.
Scrapie
Alteration of free radical metabolism in the brain of mice infected with scrapie agent.
Seizures
(+/-)-4-Aryl-4,5-dihydro-3H-1,3-benzodiazepines. 1. Synthesis and evaluation of (+/-)-4,5-dihydro-2,3-dimethyl-4-phenyl-3H-1,3-benzodiazepine and analogues as potential antidepressant agents.
Seizures
Abstracts of the 5th joint meeting of the german, austrian, and swiss sections of the international league against epilepsy basle, may 16-19, 2007.
Seizures
Anti-convulsant activity of diazepam and clonidine on metaldehyde-induced seizures in mice: effects on brain gamma-amino butyric acid concentrations and monoamine oxidase activity.
Seizures
Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR-9s).
Seizures
Anticonvulsant efficacy of L-deprenyl (selegiline) during chronic treatment in mice: continuous versus discontinuous administration.
Seizures
Bupropion sustained release. A therapeutic review of Zyban.
Seizures
Can disulfiram (Antabuse) be safely co-administered with the monoamine oxidase inhibitor (MAOI) antidepressants? Despite the ability of the major metabolite of disulfiram (diethyldithiocarbamate) to inhibit the enzyme dopamine beta-hydroxylase and a report of the induction in rats of central motor disturbances, convulsions, and death following the co-administration of tranylcypromine, there appears to be surprisingly little in the literature that directly addresses this question.
Seizures
Catechol-O-methyl transferase and monoamine oxidase activities in brains of mice susceptible and resistant to audiogenic seizures.
Seizures
Chronic administration of citalopram inhibited El mouse convulsions and decreased monoamine oxidase-A activity.
Seizures
Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.
Seizures
Combined inhibition of serotonin uptake and oxidative deamination attenuates audiogenic seizures in DBA/2J mice.
Seizures
Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury.
Seizures
Do SSRIs prolong seizure duration during ECT?
Seizures
Effect of postnatal anoxia on seizure susceptibility in rats: bicuculline-induced seizures and pretreatment with iproniazid.
Seizures
Effect of pretreatment with monoamine oxidase inhibitors or (+)-amphetamine on leptazol convulsions in mice and rats.
Seizures
Electroconvulsive shock increases endogenous monoamine oxidase inhibitor activity in brain and cerebrospinal fluid.
Seizures
Expression pattern of NMDA receptors reveals antiepileptic potential of apigenin 8-C-glucoside and chlorogenic acid in pilocarpine induced epileptic mice.
Seizures
Flumazenil and seizures: analysis of 43 cases.
Seizures
General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
Seizures
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
Seizures
In vivo monoamine oxidase inhibition measured by potentiation of tryptamine convulsions in rats.
Seizures
Increase of brain endogenous monoamine oxidase inhibitory activity (tribulin) in experimental audiogenic seizures in rats: evidence for a monoamine oxidase A inhibiting component of tribulin.
Seizures
Increased monoamine oxidase activity following repeated electroshock seizures.
Seizures
Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase.
Seizures
MAO(A) knockout mice are more susceptible to seizures but show reduced epileptogenesis.
Seizures
MAO-B inhibitor deprenyl and beta-phenylethylamine potentiate [D-ALA2]-Met-enkephalinamide-induced seizures.
Seizures
Medically serious adverse effects of newer antidepressants.
Seizures
New CNS-active 3-methyl-4-substituted methyl-delta 2-isoxazolin-5-ones.
Seizures
Platelet and brain GABA-transaminase and monoamine oxidase activities in patients with complex partial seizures.
Seizures
Search for newer substituted phenoxyacetylethyleneimines as possible CNS, MAO and anticonvulsant agents.
Seizures
Seizures associated with antidepressants: a review.
Seizures
Seizures in a diabetic patient on monoamine oxidase inhibitors.
Seizures
Seizures with neuroleptics and antidepressants.
Seizures
Synthesis of substituted anilino-3-methoxy-4-substituted acetoxy) benzylidenes and their monoamine oxidase inhibitory and anticonvulsant properties.
Seizures
Temporal profile of aminergic neurotransmitter release in striatal dialysates in rats with post-ischemic seizures.
Seizures
The dose-response ratio in electroconvulsive therapy a preliminary study.
Seizures
The effect of monoamine oxidase inhibitor and amine precursors on epileptic seizures.
Seizures
The epidemiology of depression and the evolution of treatment.
Seizures
[Biochemical indices of the sensitivity of cold-adapted animals to hyperoxic exposure]
Seizures
[Effect of a monoamine oxidase inhibitor on the level of seizure readiness and functional asymmetry of the brain]
Seizures
[Effect of benzamide derivatives on convulsions induced by the toxic action of oxygen in rats]
Seizures
[Effect of cold adaptation and brief exposure to cold on the resistance of animals to hypoxic hypoxia]
Seizures
[Histochemical and image-analytic study of the rat locus coeruleus during status epilepticus]
Seizures
[Monoamine oxidase activity and effect of clorgyline on the polyamine level during hyperoxia in rats]
Seizures
[Monoamine oxidase and diamine oxidase activity of the tissues of rats in the convulsive phase of oxygen poisoning]
sepiapterin reductase (l-erythro-7,8-dihydrobiopterin forming) deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Shy-Drager Syndrome
Monoamine oxidase inhibitors and Sinemet in Shy-Drager syndrome.
Shy-Drager Syndrome
[Case of Shy-Drager syndrome with an effective response to a monoamine oxidase inhibitor and cheese therapy--evaluation of catecholamine metabolism]
Skin Diseases
[Blood monoamine oxidase activity and erythrocyte membrane permeability in patients with allergic dermatoses]
Sleep Apnea Syndromes
Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.
Sleep Apnea Syndromes
Sleep apneas are increased in mice lacking monoamine oxidase A.
Sleep Apnea, Central
Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.
Sleep Apnea, Obstructive
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Sleep Deprivation
Activities of monoamine oxidase (MAO) A and B in discrete regions of rat brain after rapid eye movement (REM) sleep deprivation.
Sleep Deprivation
Alterations of blood platelet MAO-B activity and LSD-binding in humans after sleep deprivation and recovery sleep.
Sleep Deprivation
Decreased activity of striatal monoamine oxidase B after rapid eye movement (REM) sleep deprivation in rats.
Sleep Deprivation
Effect of rapid eye movement sleep deprivation on rat brain monoamine oxidases.
Sleep Deprivation
Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study.
Sleep Deprivation
Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats.
Sleep Deprivation
Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.
Sleep Deprivation
Monoamine oxidase activity in platelets before and after sleep deprivation as predictor for antidepressive drug response.
Sleep Deprivation
Possible mechanism of rapid eye movement sleep deprivation induced increase in Na-K ATPase activity.
Sleep Deprivation
Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetine.
Sleep Deprivation
[Rapid eye-movement sleep for five days deprivation causes delayed depressive-like behavior in mice].
Sleep Initiation and Maintenance Disorders
(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Sleep Initiation and Maintenance Disorders
Antidepressants and their effect on sleep.
Sleep Initiation and Maintenance Disorders
Insomnia, platelet serotonin and platelet monoamine oxidase in chronic alcoholism.
Sleep Initiation and Maintenance Disorders
Liquid chromatography-mass spectrometry in-depth analysis and in silico verification of the potential active ingredients of Baihe Dihuang decoction in vivo and in vitro.
Sleep Initiation and Maintenance Disorders
Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.
Sleep Initiation and Maintenance Disorders
Management of monoamine oxidase inhibitor-associated insomnia with trazodone.
Sleep Initiation and Maintenance Disorders
The effects of trazodone on sleep disturbances induced by brofaromine.
Sleep Initiation and Maintenance Disorders
Withdrawal phenomena associated with antidepressant and antipsychotic agents.
Sleep Wake Disorders
Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study.
Spinal Cord Injuries
Effect of acetylcholine in rat brain in promoting early recovery of spinal cord injury by inhibiting monoamine oxidase enzyme: A pre-clinical evidence.
Staphylococcal Infections
[Separate and combined action of antibiotics and vitamins on monoamine oxidase activity of the rabbit liver in staphylococcal infection]
Starvation
Effect of acute starvation on monoamine oxidase and Na+,K(+)-ATPase activity in rat brain.
Starvation
Effect of starvation and pattern of feeding upon activities of enzymes catechol-O-methyltransferase and monoamine oxidase in heart and liver of developing rats.
Starvation
Influence of progressive starvation upon brain and adrenal monoaminergic activity in developing rats of two different ages.
Starvation
Serotonergic and tryptaminergic overstimulation on refeeding implicated in "enlightenment" experiences.
Starvation
Variations in mitochondrial monoamine oxidase during progressive starvation in the brain of developing rats.
Stillbirth
Association of dopamine transporter and monoamine oxidase molecular polymorphisms with sudden infant death syndrome and stillbirth: new insights into the serotonin hypothesis.
Stomach Neoplasms
Antidepressants and Gastric Cancer: A Nationwide Population-Based Nested Case-Control Study.
Stomach Neoplasms
Enzyme activities in human gastric cancer and polyps.
Stomach Neoplasms
Monoamine Oxidase A is a Major Mediator of Mitochondrial Homeostasis and Glycolysis in Gastric Cancer Progression.
Stomach Neoplasms
Promotion by nialamide of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Stomach Ulcer
L-deprenyl attenuates stress ulcer formation in rats.
Stomach Ulcer
[Mitochondrial monoamine oxidase in the brain, stomach and liver in experimental gastric ulcer and the change in their activity under the influence of quateron]
Stroke
Alcohol free beer link with strokes.
Stroke
Drug-induced hyperpyrexia. A case report.
Stroke
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
Stroke
Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke.
Stroke
Long-term food restriction, deprenyl, and nimodipine treatment on life expectancy and blood pressure of stroke-prone rats.
Stroke
Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
Stroke
Plasma semicarbazide-sensitive amine oxidase in stroke.
Stroke
Post-Stroke Fatigue May Be Associated with the Promoter Region of a Monoamine Oxidase A Gene Polymorphism.
Stroke
Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats.
Stroke
Safinamide (Newron Pharmaceuticals).
Stupor
Stupor from dextroamphetamineamobarbital and monoamine oxidase inhibitor, phenelzine.
Stuttering
Neurogenic stuttering and lateralized motor deficits induced by tranylcypromine.
Subarachnoid Hemorrhage
Monoamine oxidase inhibitors and subarachnoid hemorrhage.
succinate-semialdehyde dehydrogenase [nad(p)+] deficiency
Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the iNTD registry.
succinate-semialdehyde dehydrogenase [nad(p)+] deficiency
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
Supranuclear Palsy, Progressive
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Supranuclear Palsy, Progressive
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.
Supranuclear Palsy, Progressive
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.
Tachycardia
"Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity.
Tachycardia
Acute myocarditis after massive phenelzine overdose.
Tachycardia
Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study.
Tachycardia
Phenelzine toxicity responsive to dantrolene.
Tachycardia
Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs.
Tachycardia
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.
Tachycardia
St. John's wort: a new alternative for depression?
Tardive Dyskinesia
A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
Tardive Dyskinesia
An inverse correlation between spontaneous eye-blink rate and platelet monoamine oxidase activity.
Tardive Dyskinesia
Enzyme studies in tardive dyskinesia. I. One-year biochemical follow-up.
Tardive Dyskinesia
Enzyme studies in tardive dyskinesia. II. Familial aspects.
Tardive Dyskinesia
Ex uno multi: subtyping the schizophrenic syndrome.
Tardive Dyskinesia
Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.
Tardive Dyskinesia
Monoamine oxidase inhibitors antagonize the acceleration of brain dopamine synthesis induced by neuroleptic drugs in vivo: implications for the treatment of Tardive dyskinesia.
Tardive Dyskinesia
Platelet monoamine oxidase activity and tardive dyskinesia.
Tardive Dyskinesia
Platelet monoamine oxidase and plasma dopamine beta-hydroxylase in tardive dyskinesia.
Tardive Dyskinesia
Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Tauopathies
Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2- production.
Tension-Type Headache
Association analysis of the functional MAOA gene promoter and MAOB gene intron 13 polymorphisms in tension type headache patients.
Tension-Type Headache
Platelet monoamine oxidase activity and headache.
Teratoma
Neurochemical studies in a mouse teratoma with neuroepithelial differentiation. Presence of cyclic AMP, serotonin and enzymes of the serotonergic, adrenergic and cholinergic systems.
Thiamine Deficiency
Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency.
Thrombocytopenia
Linezolid: new preparation. In severe gram-positive infections.
Thrombocytopenia
[Inactivation of serotonin in patients with hemorrhagic fever with kidney syndrome]
Thrombocytosis
Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density.
Thrombosis
Effects of monoamine oxidase inhibitors, glyceryl gualacolate, and ethanol on experimental arterial thrombosis.
Thrombosis
[THE ACTION OF A MONOAMINE OXIDASE INHIBITOR ON THE SIZE OF VENOUS AND ARTERIAL THROMBOSES.]
Thyroid Diseases
Monoamine oxidase activity of the thyroid glands in thyroid disease.
Thyroid Diseases
Ultrastructural localization of thyroid peroxidase, hydrogen peroxide-generating sites, and monoamine oxidase in benign and malignant thyroid diseases.
Thyroid Diseases
[Serum monoamine oxidase in thyroid diseases (author's transl)]
Thyroiditis
Monoamine oxidase (MAO) activity and its forms in normal and pathological human thyroid tissues.
Thyrotoxicosis
Blood platelet monoamine oxidase and acetylcholinesterase in thyrotoxicosis.
Thyrotoxicosis
[Liver and heart mitochondrial monoamine oxidase activity in experimental thyrotoxicosis]
Thyrotoxicosis
[Study of monoamine oxidase activity in the blood plasma in thyrotoxicosis]
Tics
Corrigendum to "gender in obsessive-compulsive disorder: clinical and genetic findings" [Eur. Neuropsychopharmacol. 14 (2004) 105-113].
Tics
Gender in obsessive-compulsive disorder: clinical and genetic findings.
Tonsillitis
[Serotonin and histamine content and the monoamine oxidase and diamine oxidase activities in the palatine tonsil in compensated and decompensated forms of chronic tonsillitis]
Tourette Syndrome
Enzyme activity in Tourette's syndrome.
Tourette Syndrome
Family-based association study between monoamine oxidase A (MAOA) gene promoter VNTR polymorphism and Tourette's syndrome in Chinese Han population.
Tourette Syndrome
Monoamine oxidase and catechol-O-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome.
Toxemia
[Study on serotonin metabolism in toxemia of pregnancy]
Tremor
5-Hydroxytryptamine-mediated behaviour in male and female rats.
Tremor
Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
Tremor
Blockade of central beta-adrenoceptors attenuates tremor induced by 5-hydroxytryptamine (5-HT)-receptor activation in rats.
Tremor
Contrasting local effects of MAO inhibitors on caudate tremor activities.
Tremor
Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications.
Tremor
Drug concentrations in neuropsychiatry: alternative approaches.
Tremor
Drugs for Parkinson's disease.
Tremor
Future directions in the treatment of Parkinson's disease.
Tremor
Harmine tremor after brain monoamine oxidase inhibition in the mouse.
Tremor
Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
Tremor
Morphological and functional studies on the serotoninergic innervation of the inferior olive.
Tremor
Pharmacological characteristics of abnormal behavior induced by harmine with special reference to tremor in mice.
Tremor
The inhibition of A and B forms of MAO in the production of a characteristic behabioural syndrome in rats after 1-tryptophan loading.
Tremor
The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Tuberculosis
Novel pyridazino[4,3-b]indoles with dual inhibitory activity against Mycobacterium tuberculosis and monoamine oxidase.
Tuberculosis
[Biogenic amine deamination in experimental tuberculosis]
Tuberculosis
[IDENTITY OF BEHAVIOR IN VITRO WITH RESPECT TO MYCOBACTERIUM TUBERCULOSIS OF INH AND NIALAMIDE, THYMOANALEPTIC MONOAMINE OXIDASE INHIBITORS (DEDUCTIONS OF BIOLOGICAL AND THERAPEUTIC ORDER).]
Turner Syndrome
The development of mental state attributions in women with X-monosomy, and the role of monoamine oxidase B in the sociocognitive phenotype.
Uremia
[Monoamine oxidase activity in patients with chronic renal failure and in experimental uremia in rats]
Ureteral Obstruction
Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model.
Urinary Bladder Neck Obstruction
Decreased Monoamine Oxidase a Expression and Activity in the Bladders of Rats with Partial Outlet Obstruction.
Urinary Bladder Neoplasms
Mao-a enzyme binding in bladder-cancer characterized with [C-11] harmine in frozen-section autoradiography.
Urinary Bladder, Overactive
Influence of medications and diagnoses on fall risk in psychiatric inpatients.
Urinary Incontinence
A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria.
Uterine Cervical Neoplasms
Invasive Cervical Cancer and Antidepressants: A Nationwide Population-Based Study.
Uterine Inertia
[Activity of mitochondrial monoamine oxidase and catecholamine content in the placenta of women in normal labor and in primary uterine inertia]
Vascular Diseases
Monoamine oxidase inhibitors and vascular disease.
Vascular Diseases
Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta.
Vascular Headaches
[Treatment of vascular headaches with nialamide, a monoamine oxidase inhibitor.]
Vascular Ring
CONTRIBUTION OF MONOAMINE OXIDASES TO VASCULAR OXIDATIVE STRESS IN PATIENTS WITH END-STAGE RENAL DISEASE REQUIRING HEMODIALYSIS.
Vascular Ring
Monoamine oxidase is a source of oxidative stress in obese patients with chronic inflammation 1.
Vasoplegia
Serotonin syndrome after cardiopulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors.
Ventricular Dysfunction
Mitochondrial 4-HNE derived from MAO-A promotes mitoCa2+ overload in chronic postischemic cardiac remodeling.
Ventricular Dysfunction
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Ventricular Dysfunction, Left
Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload.
Ventricular Dysfunction, Left
p53-PGC-1? Pathway Mediates Oxidative Mitochondrial Damage and Cardiomyocyte Necrosis Induced by Monoamine Oxidase-A Upregulation: Role in Chronic Left Ventricular Dysfunction in Mice.
Vertigo
Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.
Virus Diseases
Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections.
Vitamin B 12 Deficiency
[Monoamine oxidase activity in rat liver in vitamin B12 deficiency]
Vitiligo
In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase.
Vitiligo
Increased monoamine oxidase A activity in the epidermis of patients with vitiligo.
Whooping Cough
Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration.
Xanthomatosis, Cerebrotendinous
Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.35
(2-methylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.0013
(2-phenylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.0056
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.00222
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00459
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00405
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00372
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00562
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00025
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00012
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00187
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00126
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0206
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00046
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0522
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00019
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00022
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00258
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00049
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00044
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00133
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
40
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00107
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0299
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0443
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0399
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00054
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0155
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.001
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
Homo sapiens
IC50: 0.001mM, at 0.15 mM kynuramine
0.0000207
(E)-5-(3-chlorostyryl)isatin
Homo sapiens
-
0.000444
(E)-5-(3-fluorostyryl)isatin
Homo sapiens
-
0.0000417
(E)-5-styrylisatin
Homo sapiens
-
0.0000301
(E)-6-styrylisatin
Homo sapiens
-
0.098
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
Homo sapiens
-
0.000447
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0179
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0216
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.117
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0022
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0166
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.000049
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.000184
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.000175
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.000529
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.042
2,4-dimethoxy-5-hydroxybenzaldehyde
Homo sapiens
IC50: 0.042 mM, monoamine oxidase A
0.0624
2,6-dimethoxyphenol
Homo sapiens
IC50: 0.0624 mM, monoamine oxidase A
0.0222
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.036
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
Homo sapiens
-
0.25
2-(aminooxy)-1-phenylethanol
Homo sapiens
-
0.175
2-methoxyphenol
Homo sapiens
IC50: 0.175 mM, monoamine oxidase A
0.15
2-methyl-5-methylaniline
Homo sapiens
IC50: 0.15 mM, monoamine oxidase A
0.131
3,4-dimethoxyaniline
Homo sapiens
IC50: 0.131 mM, monoamine oxidase A
0.000813
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00357
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00317
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0419
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0157
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0214
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.115
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0456
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.0138
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000092
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000458
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00132
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00004
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000023
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0222
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00963
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.024
3-methoxyphenol
Homo sapiens
IC50: 0.024 mM, monoamine oxidase A
0.000578
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.0134
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
Homo sapiens
IC50: 0.0134 mM, monoamine oxidase A
0.13
4-Hydroxy-3-methoxybenzylamine
Homo sapiens
IC50: 0.13 mM, monoamine oxidase A
0.18
4-hydroxy-3-methoxyphenethyl alcohol
Homo sapiens
IC50: 0.18 mM, monoamine oxidase A
0.0302
4-hydroxy-3-methoxyphenyl acetone
Homo sapiens
IC50: 0.0302 mM, monoamine oxidase A
0.142
cis-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.142 mM, monoamine oxidase A
0.038
clorgiline
Homo sapiens
pH and temperature not specified in the publication
-
0.0000044 - 0.0000045
Clorgyline
0.06725
Deprenyl
Homo sapiens
pH and temperature not specified in the publication
0.0247
ethyl 4-hydroxy-3-methoxycinnamate
Homo sapiens
IC50: 0.0247 mM, monoamine oxidase A
0.081
ethyl-4-hydroxy-3-methoxyphenylacetate
Homo sapiens
IC50: 0.081 mM, monoamine oxidase A
0.0344
eugenol
Homo sapiens
IC50: 0.0344 mM, monoamine oxidase A
0.11
eugenol methyl ether
Homo sapiens
IC50: 0.11 mM, monoamine oxidase A
0.252
metanephrine
Homo sapiens
IC50: 0.252 mM, monoamine oxidase A
0.0271
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
Homo sapiens
inhibition of MAO-A
0.361
moclobemide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.09
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
Homo sapiens
IC50: 0.09 mM, at 0.15 mM kynuramine
0.0005
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
Homo sapiens
IC50: 0.0005 mM, at 0.15 mM kynuramine
0.00287
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00042
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.00764
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
10
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
10
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.01
N-phenyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
0.101
o-eugenol
Homo sapiens
IC50: 0.101 mM, monoamine oxidase A
54.35
selegiline
Homo sapiens
pH and temperature not specified in the publication
0.124
trans-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.124 mM, monoamine oxidase A
0.0028
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
Homo sapiens
-
0.002
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.001
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.006
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.015 - 0.039
(+)-6-hydroxytrypargine
0.008 - 0.034
(-)-6-hydroxytrypargine
0.01665 - 0.1374
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
14.86 - 88
(1R,2R)-(-)-psi-ephedrine
1.77 - 234
(1S,2S)-(+)-psi-ephedrine
0.02
(2-methylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.071
(2-phenylprop-2-en-1-yl)hydrazine
Homo sapiens
-
0.00141
(2E)-1,3-diphenylprop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00103
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.01876
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.011
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-(3-hydroxyphenyl)ethanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.02 - 2
(2E)-2-(2,4-dioxo-1,3-thiazolidin-5-ylidene)-N-phenylethanamide
Homo sapiens
-
pH and temperature not specified in the publication
9.95
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carbothioamide
Homo sapiens
pH 7.4, temperature not specified in the publication
-
17.7
(2E)-2-[(5-chloro-2-hydroxy-3-iodophenyl)methylidene]hydrazine-1-carboxamide
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.0077 - 0.00983
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
0.0000051 - 0.00495
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
0.0000044
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00125
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00016
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.000071
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.000031
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.000054
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00547
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-(thiophen-2-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.00142
(2E)-3-chloro-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-3-phenylprop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.000193
(2E)-3-chloro-3-(4-methylphenyl)-2-(6-nitro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)prop-2-enal
Homo sapiens
pH 7.4, 37°C
-
0.05
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00045
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.01882 - 0.663
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
0.0599
(4Z)-1-benzyl-4-[(2E)-(1-phenylethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0253
(4Z)-1-benzyl-4-[(2E)-(cyclopentylmethylidene)hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00066
(4Z)-1-benzyl-4-[(2E)-benzylidenehydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00305
(4Z)-1-benzyl-4-[(2E)-[(2-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0141
(4Z)-1-benzyl-4-[(2E)-[(2-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00014
(4Z)-1-benzyl-4-[(2E)-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00161
(4Z)-1-benzyl-4-[(2E)-[(2-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0005
(4Z)-1-benzyl-4-[(2E)-[(3-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0685
(4Z)-1-benzyl-4-[(2E)-[(3-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00015
(4Z)-1-benzyl-4-[(2E)-[(4-bromophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00018
(4Z)-1-benzyl-4-[(2E)-[(4-chlorophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00031
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxy-3-methoxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00214
(4Z)-1-benzyl-4-[(2E)-[(4-hydroxyphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00138
(4Z)-1-benzyl-4-[(2E)-[(4-methylphenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00102
(4Z)-1-benzyl-4-[(2E)-[(4-nitrophenyl)methylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00014
(4Z)-1-benzyl-4-[(2E)-[1-(2,4-dichlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0764
(4Z)-1-benzyl-4-[(2E)-[1-(4-chlorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00064
(4Z)-1-benzyl-4-[(2E)-[1-(4-fluorophenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0419
(4Z)-1-benzyl-4-[(2E)-[1-(5-chloro-2-hydroxyphenyl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0568
(4Z)-1-benzyl-4-[(2E)-[1-(furan-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.0491
(4Z)-1-benzyl-4-[(2E)-[1-(pyridin-2-yl)ethylidene]hydrazinylidene]-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.00013
(4Z)-4-[(2E)-[1-(2-aminophenyl)ethylidene]hydrazinylidene]-1-benzyl-3,4-dihydro-2lambda6,1-benzothiazine-2,2(1H)-dione
Homo sapiens
pH and temperature not specified in the publication
-
0.027
(5E)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000082
(5E)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000195
(5E)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00607
(5E)-5-(3-bromobenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.03648
(5E)-5-(4-chlorobenzylidene)-3-methyl-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.03165
(5E)-5-(4-hydroxy-2,5-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00249
(5E)-5-(4-hydroxy-3-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.013
(5E)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.02405
(5E)-5-benzylidene-2-imino-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.01051
(5E)-5-benzylidene-3-methyl-2-thioxo-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00102
(5E)-5-[(3,5-dibromo-4-hydroxycyclohexa-1,4-dien-1-yl)methylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.027
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000082
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000195
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.013
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00348 - 0.00527
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00019 - 0.00065
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00137 - 0.00161
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
0.00298 - 0.00828
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
0.00019 - 0.00063
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
0.0001 - 0.00048
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00171 - 0.00219
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
0.00018 - 0.00717
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
0.00044 - 0.0039
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.0000207
(E)-5-(3-chlorostyryl)isatin
Homo sapiens
-
0.000444
(E)-5-(3-fluorostyryl)isatin
Homo sapiens
-
0.0000417
(E)-5-styrylisatin
Homo sapiens
-
0.0000301
(E)-6-styrylisatin
Homo sapiens
-
0.0012 - 0.0125
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.00055 - 0.00439
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
0.00016 - 0.00114
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
0.0991 - 4.03
(R)-amphetamine
0.0244 - 3
(R,S)-amphetamine
0.0022
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
Homo sapiens
-
0.000152 - 0.00372
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
0.0004 - 0.000546
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
0.000414 - 0.0008
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
0.00556 - 0.00697
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
0.000333 - 0.00168
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
0.000455 - 0.00381
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
0.000116 - 0.0037
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
0.00055 - 0.000636
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
0.0000122 - 0.000737
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
0.0000266 - 0.000836
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
0.0000727 - 0.000679
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
0.000231 - 0.00145
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
0.0000355 - 0.000749
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
0.000875
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000343
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00678
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00115 - 0.00672
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
0.0036
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00138
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000872 - 0.00131
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
0.000772 - 0.000824
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
0.00443 - 0.00507
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
0.000538 - 0.00291
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
0.000698 - 0.00114
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
0.000458 - 0.00049
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
0.0000295 - 0.00178
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
0.0000318 - 0.00191
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
0.000592 - 0.00106
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
0.0713
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0534
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0348
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.051
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0137
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0494
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0168
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.00307
1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0139
1-hydroxy-2-(4-methylphenyl)-3-propanoyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0125
1-hydroxy-3-(4-methoxybenzoyl)-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.027
1-hydroxy-3-(4-methoxybenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00732
1-hydroxy-3-(4-methylbenzoyl)pyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0135
1-hydroxy-3-propanoyl-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00087
1-methoxy-2-(4-methoxyphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.00129
1-methoxy-2-(4-methylphenyl)-5,7-dioxo-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.0157
1-methoxy-5,7-dioxo-2-(thiophen-2-yl)-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.00231
1-methoxy-5,7-dioxo-2-phenyl-1,2,3,5,6,7-hexahydropyrrolo[3,4-f]indole-3-carbaldehyde
Homo sapiens
pH 7.4, 37°C
-
0.0208 - 0.0926
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
0.0155
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0846
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.0181
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
Homo sapiens
-
pH 7.4, 37°C, recombinant MAO-B
0.39
2,4-dimethoxy-5-hydroxybenzaldehyde
Homo sapiens
IC50: 0.39 mM
0.5
2,6-dimethoxyphenol
Homo sapiens
IC50: above 0.5 mM, monoamine oxidase B
0.011
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.022
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00094 - 0.05928
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
0.000016 - 0.007229
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
0.000004 - 0.01028
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
0.003925 - 0.005025
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
0.00092 - 0.009612
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
0.000011 - 0.01785
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
0.000027 - 0.01485
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
0.000652 - 0.04575
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
0.000004 - 0.0001752
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
0.007509 - 0.01196
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
0.003689 - 0.02373
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
0.000086 - 0.02415
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
0.000116 - 0.04835
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
0.000284 - 0.05451
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
0.000003 - 0.002318
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
0.00004 - 0.004436
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
0.000164 - 0.001055
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
0.000134 - 0.002019
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
0.000094 - 0.000344
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
0.000296 - 0.007883
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
0.00797
2-(4-methylphenyl)-3-propanoyl-1-(propanoyloxy)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
8.2
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
Homo sapiens
-
0.45
2-(aminooxy)-1-phenylethanol
Homo sapiens
-
0.00388 - 0.00991
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
0.00104 - 0.01062
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
0.00088 - 0.00137
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
0.5
2-methoxyphenol
Homo sapiens
IC50: above 0.5 mM, monoamine oxidase B
0.5
2-methyl-5-methylaniline
Homo sapiens
IC50: above 0.5 mM
0.000143
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000032
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000711 - 0.04124
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
0.00014 - 0.00243
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
0.005477 - 0.008109
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
0.000362 - 0.02088
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
0.000259 - 0.03422
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
0.00006 - 0.0098
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
0.000014 - 0.000051
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
0.000048 - 0.00283
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
0.2729
3-(4-hydroxyphenyl)-2-(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)propanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
11.52
3-(4-hydroxyphenyl)propionic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.000532
3-(4-methoxybenzoyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00982
3-acetyl-1-(acetyloxy)-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00119
3-acetyl-1-(acetyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0356
3-acetyl-1-(acetyloxy)-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0251
3-acetyl-1-hydroxy-2-(4-methoxyphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0471
3-acetyl-1-hydroxy-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.018
3-acetyl-1-hydroxy-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0676
3-acetyl-1-hydroxy-2-phenyl-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.0135
3-benzoyl-1-hydroxy-1H-indole-5,6-dicarboxylic acid
Homo sapiens
pH 7.4, 37°C
-
0.00399
3-benzoyl-1-hydroxypyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00119
3-bromo-1-hydroxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000734
3-bromo-1-hydroxy-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.00105
3-bromo-1-hydroxy-2-phenyl-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000605
3-bromo-1-methoxy-2-(4-methoxyphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.000178
3-bromo-1-methoxy-6-methyl-2-(4-methylphenyl)-2,3-dihydropyrrolo[3,4-f]indole-5,7(1H,6H)-dione
Homo sapiens
pH 7.4, 37°C
-
0.0191
3-butanoyl-1-(butanoyloxy)-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00279
3-butanoyl-1-(butanoyloxy)-2-(thiophen-2-yl)-1H-indole-5,6-dicarbonitrile
Homo sapiens
pH 7.4, 37°C
-
0.00076 - 0.031
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
0.00099 - 0.0077
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
17.75
3-hydroxyphenylacetic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.1759 - 0.259
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
0.00229
3-[(5E)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]propanenitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.6043
3-[(5E)-5-benzylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.056
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00026 - 0.00084
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
0.02681 - 0.0447
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.009446 - 0.08149
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000014 - 0.03796
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000091 - 0.0195
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.0035
4-(2-hydrazinyl-1,3-oxazol-4-yl)benzene-1,2-diol
Homo sapiens
pH 7.4, temperature not specified in the publication
-
0.000477 - 0.006182
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
0.000211 - 0.002911
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
0.000262 - 0.00716
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
0.01313 - 0.03522
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.002411 - 0.01522
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000204 - 0.04356
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000043 - 0.04546
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.002373 - 0.002762
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.005763 - 0.0312
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
0.000847
4-([6-[(4-cyanophenyl)methoxy]-4-oxoquinazolin-3(4H)-yl]methyl)benzonitrile
Homo sapiens
pH and temperature not specified in the publication
-
0.0089
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
Homo sapiens
IC50: 0.0089 mM, monoamine oxidase B
0.382
4-Hydroxy-3-methoxybenzylamine
Homo sapiens
IC50: 0.382 mM, monoamine oxidase B
20.28
4-hydroxyphenylacetic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.047
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.056
4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000046 - 0.004327
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
0.000053 - 0.004837
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
0.000221 - 0.000644
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
0.000026 - 0.03103
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
0.000061 - 0.006994
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
0.0158
4-[[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]methyl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
-
0.00238
5-(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000225
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.01606
5-(4-hydroxy-3,5-dimethylbenzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00225
5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.000298
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000832
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.000048
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.0009 - 0.0365
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
0.00089 - 0.00234
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
0.00099
5-nitroindazole
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.0008
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-1,3-thiazolidine-2,4-dione ammoniate (1:1)
Homo sapiens
-
pH and temperature not specified in the publication
0.3089
5-[(4-acetylcyclohexa-1,4-dien-1-yl)methyl]-2-imino-1,3-thiazolidin-4-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00252
6-nitroindazole
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.0414
6-[(3-iodophenyl)methoxy]-3-[(3-iodophenyl)methyl]quinazolin-4(3H)-one
Homo sapiens
pH and temperature not specified in the publication
-
0.00635
6-[(3-iodophenyl)methoxy]quinazolin-4(3H)-one
Homo sapiens
pH and temperature not specified in the publication
-
0.000685
6-[(4-fluorophenyl)methoxy]-3-[(4-fluorophenyl)methyl]quinazolin-4(3H)-one
Homo sapiens
pH and temperature not specified in the publication
-
0.0278
7-nitroindazole
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00207
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.00124 - 0.00177
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000068 - 0.00094
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000107 - 0.00067
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000542 - 0.00107
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.00101 - 0.00315
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
0.000032 - 0.00011
benzhydrylidene-prop-2-ynyl-amine
0.00889 - 0.0116
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
0.362
cis-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.362 mM, monoamine oxidase B
0.0000012 - 20.27
Clorgyline
0.06135
clorogyline
Homo sapiens
pH and temperature not specified in the publication
-
0.0295
cyanidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.113 - 0.152
cyanidin-3,5-diglucoside
0.0359 - 0.0464
cyanidin-3-O-beta-D-galactoside
0.0343
cyanidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0332 - 0.0351
cyanidin-3-O-beta-D-rutinoside
0.0348 - 0.038
delphinidin
0.0294 - 0.0314
delphinidin-3-O-beta-D-glucoside
0.0057
ethyl 4-hydroxy-3-methoxycinnamate
Homo sapiens
IC50: 0.0057 mM, monoamine oxidase B
0.288
eugenol
Homo sapiens
IC50: 0.288 mM, monoamine oxidase B
0.269
eugenol methyl ether
Homo sapiens
IC50: 0.269 mM, monoamine oxidase B
0.00656 - 0.00754
Iproniazide
0.0371
ladostigil
Homo sapiens
isoform MAO-B, at pH 8.0 and 37°C
0.0616 - 0.0733
malvidin 3-O,5-O-di-beta-D-glucoside
0.0341 - 0.0393
malvidin-3-O-beta-D-galactoside
0.0368 - 0.0478
malvidin-3-O-beta-D-glucoside
0.0016
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
Homo sapiens
inhibition of MAO-B
0.00234 - 0.00536
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
0.3614
moclobemide
Homo sapiens
-
MAO-A, pH not specified in the publication, temperature not specified in the publication
0.00384 - 0.15
N-(2-methyl-1H-indol-5-yl)benzamide
0.00696 - 0.0694
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
0.00000108
N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000000386
N-(3,4-dichlorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000000586
N-(3,4-dichlorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000144
N-(3,4-dichlorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000152
N-(3,4-difluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00000159
N-(3,4-difluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.0000384
N-(3,4-difluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000662
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000000679
N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.00808
N-(3-chloro-4-fluorophenyl)-2-methyl-2H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.000202
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000038
N-benzyl-N-methylprop-2-yn-1-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00401 - 0.1088
N-benzylprop-2-yn-1-amine
0.000117
N-phenyl-1H-indazole-5-carboxamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.0000022
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.5
o-eugenol
Homo sapiens
IC50: above 0.5 mM, monoamine oxidase B
0.000188
Pargyline
Homo sapiens
isoform MAO-B, at pH 8.0 and 37°C
0.0268 - 0.0426
pelargonidin
0.1173 - 0.242
pelargonidin 3-O,5-O-di-beta-D-glucoside
0.0381 - 0.0407
peonidin-3-O-beta-D-glucoside
0.0315 - 0.0432
petunidin
0.0005
pioglitazone
Homo sapiens
pH and temperature not specified in the publication
0.000017 - 0.0687
R-(-)-deprenyl
0.000048 - 0.039
safinamide
0.033
selegiline
Homo sapiens
pH and temperature not specified in the publication
0.000006
sembragiline
Homo sapiens
pH and temperature not specified in the publication
-
4.16
syringic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.338
trans-2,4,5-trimethoxypropenylbenzene
Homo sapiens
IC50: 0.338 mM, monoamine oxidase B
3.89
vanillic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00065
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
Homo sapiens
-
0.00229
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
Homo sapiens
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.09
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.0245
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
0.081
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
Homo sapiens
-
additional information
additional information
-
0.0000044
Clorgyline
Homo sapiens
pH 7.4, temperature not specified in the publication
0.0000045
Clorgyline
Homo sapiens
pH and temperature not specified in the publication
45
safinamide
Homo sapiens
isoform MAO-A, at pH 7.4, temperature not specified in the publication
223.5
safinamide
Homo sapiens
pH and temperature not specified in the publication
0.00392
toloxatone
Homo sapiens
pH 7.4, 37°C
0.00392
toloxatone
Homo sapiens
pH and temperature not specified in the publication
0.015
(+)-6-hydroxytrypargine
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.039
(+)-6-hydroxytrypargine
Homo sapiens
-
pH 7.4, 37°C, MAO-A
0.008
(-)-6-hydroxytrypargine
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.034
(-)-6-hydroxytrypargine
Homo sapiens
-
pH 7.4, 37°C, MAO-A
0.01665
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.1374
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
14.86
(1R,2R)-(-)-psi-ephedrine
Homo sapiens
-
IC50 for soluble enzyme: 5.35 mM, IC50 for immobilized enzyme: 14.86 mM, monoamine oxidase A
88
(1R,2R)-(-)-psi-ephedrine
Homo sapiens
-
IC50 for soluble enzyme: 5.03 mM, IC50 for immobilized enzyme: 88 mM, monoamine oxidase B
1.77
(1S,2S)-(+)-psi-ephedrine
Homo sapiens
-
IC50 for soluble enzyme: 0.88 mM, IC50 for immobilized enzyme: 1.77 mM, monoamine oxidase A
234
(1S,2S)-(+)-psi-ephedrine
Homo sapiens
-
IC50 for soluble enzyme: 10 mM, IC50 for immobilized enzyme: 234 mM, monoamine oxidase B
0.0077
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00983
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0000051
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-B
0.00495
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.4, 37°C, MAO-A
0.01882
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.663
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00348
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00527
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00019
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00065
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00137
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00161
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00298
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00828
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00019
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00063
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.0001
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00048
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00171
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00219
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00018
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00717
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00044
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0039
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-A
0.0012
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0125
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00055
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00439
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00016
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00114
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.0991
(R)-amphetamine
Homo sapiens
-
IC50 for soluble enzyme: 0.0311 mM, IC50 for immobilized enzyme: 0.0991 mM, monoamine oxidase A
4.03
(R)-amphetamine
Homo sapiens
-
IC50 for soluble enzyme: 0.246 mM, IC50 for immobilized enzyme: 4.03 mM, monoamine oxidase B
0.0244
(R,S)-amphetamine
Homo sapiens
-
IC50 for soluble enzyme: 0.0031 mM, IC50 for immobilized enzyme: 0.0244 mM, monoamine oxidase A
3
(R,S)-amphetamine
Homo sapiens
-
IC50 for soluble enzyme: 0.0625 mM, IC50 for immobilized enzyme: 3 mM, monoamine oxidase B
0.000152
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00372
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0004
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.000546
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.000414
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.0008
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00556
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00697
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000333
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00168
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000455
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00381
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000116
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.0037
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00055
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000636
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.0000122
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000737
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.0000266
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000836
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.0000727
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000679
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000231
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00145
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.0000355
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000749
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00115
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00672
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000872
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00131
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000772
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000824
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00443
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00507
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000538
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00291
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000698
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00114
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.000458
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00049
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.0000295
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00178
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.0000318
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.00191
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.000592
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
Homo sapiens
-
MAO A, pH 7.4, 37°C
0.00106
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
Homo sapiens
-
MAO B, pH 7.4, 37°C
0.0208
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.0926
1-methyl-N-(2-methyl-1H-indol-5-yl)-1lambda4-pyridine-3-carboxamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.00094
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.05928
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000016
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.007229
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000004
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.01028
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.003925
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.005025
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00092
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.009612
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000011
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.01785
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000027
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.01485
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000652
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.04575
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000004
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.0001752
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.007509
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.01196
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.003689
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.02373
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000086
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.02415
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000116
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.04835
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000284
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.05451
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000003
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.002318
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00004
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.004436
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000164
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.001055
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000134
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.002019
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000094
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000344
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000296
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.007883
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00388
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00991
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00104
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.01062
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00088
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00137
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000711
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.04124
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00014
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00243
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.005477
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.008109
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000362
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.02088
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000259
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.03422
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00006
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0098
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.000014
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000051
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000048
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00283
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00076
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.031
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00099
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0077
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-A
0.1759
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
Homo sapiens
pH 7.4, 37°C, MAO-B
0.259
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00026
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00084
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.02681
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.0447
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.009446
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.08149
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000014
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.03796
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000091
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.0195
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000477
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.006182
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000211
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.002911
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000262
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00716
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.01313
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.03522
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.002411
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.01522
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000204
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.04356
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000043
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.04546
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.002373
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.002762
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.005763
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.0312
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000046
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.004327
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000053
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.004837
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000221
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.000644
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000026
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.03103
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.000061
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.006994
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.0009
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.0365
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00089
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00234
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00124
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.00177
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.000068
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00094
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.000107
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00067
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.000542
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00107
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.00101
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00315
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.000032
benzhydrylidene-prop-2-ynyl-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00011
benzhydrylidene-prop-2-ynyl-amine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00889
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0116
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
Homo sapiens
pH 7.4, 37°C, MAO-A
0.0000012
Clorgyline
Homo sapiens
-
IC50: 1.2 nM
0.0000052
Clorgyline
Homo sapiens
-
MAO-A, pH not specified in the publication, temperature not specified in the publication
0.000014
Clorgyline
Homo sapiens
-
IC50: 0.000014 mM
0.00042
Clorgyline
Homo sapiens
-
IC50: 0.00042 mM
0.0634
Clorgyline
Homo sapiens
-
MAO-B, pH not specified in the publication, temperature not specified in the publication
20.27
Clorgyline
Homo sapiens
pH and temperature not specified in the publication
0.113
cyanidin-3,5-diglucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.152
cyanidin-3,5-diglucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0359
cyanidin-3-O-beta-D-galactoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0464
cyanidin-3-O-beta-D-galactoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0332
cyanidin-3-O-beta-D-rutinoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0351
cyanidin-3-O-beta-D-rutinoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0348
delphinidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.038
delphinidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0294
delphinidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0314
delphinidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.000019
Deprenyl
Homo sapiens
pH 7.4, temperature not specified in the publication
0.0000196
Deprenyl
Homo sapiens
pH and temperature not specified in the publication
0.0023
Deprenyl
Homo sapiens
-
IC50: 0.0023 mM
0.02
Deprenyl
Homo sapiens
-
IC50: 0.020 mM
3.3
Deprenyl
Homo sapiens
-
IC50: 3.3 mM
0.00656
Iproniazide
Homo sapiens
-
MAO-A, pH not specified in the publication, temperature not specified in the publication
0.00754
Iproniazide
Homo sapiens
-
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.008566
isatin
Homo sapiens
inhibition of MAO-B
368.4
isatin
Homo sapiens
pH and temperature not specified in the publication
0.000091
lazabemide
Homo sapiens
pH 7.4, 37°C
0.000091
lazabemide
Homo sapiens
pH and temperature not specified in the publication
0.0187
malvidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0221
malvidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0616
malvidin 3-O,5-O-di-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0733
malvidin 3-O,5-O-di-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0341
malvidin-3-O-beta-D-galactoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0393
malvidin-3-O-beta-D-galactoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0368
malvidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0478
malvidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.00234
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.00536
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.00384
N-(2-methyl-1H-indol-5-yl)benzamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.15
N-(2-methyl-1H-indol-5-yl)benzamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00696
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
Homo sapiens
pH 7.4, 37°C, MAO-B
0.0694
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
Homo sapiens
pH 7.4, 37°C, MAO-A
0.00401
N-benzylprop-2-yn-1-amine
Homo sapiens
-
MAO A, pH not specified in the publication, temperature not specified in the publication
0.1088
N-benzylprop-2-yn-1-amine
Homo sapiens
-
MAO B, pH not specified in the publication, temperature not specified in the publication
0.0268
pelargonidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0426
pelargonidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.1173
pelargonidin 3-O,5-O-di-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.242
pelargonidin 3-O,5-O-di-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0221
peonidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0305
peonidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0381
peonidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0407
peonidin-3-O-beta-D-glucoside
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.0315
petunidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-A
0.0432
petunidin
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, MAO-B
0.000017
R-(-)-deprenyl
Homo sapiens
-
MAO-B, pH not specified in the publication, temperature not specified in the publication
0.0687
R-(-)-deprenyl
Homo sapiens
-
MAO-A, pH not specified in the publication, temperature not specified in the publication
0.000048
safinamide
Homo sapiens
pH 7.4, 37°C
0.00045
safinamide
Homo sapiens
pH and temperature not specified in the publication
0.00518
safinamide
Homo sapiens
isoform MAO-B, at pH 7.4, temperature not specified in the publication
0.039
safinamide
Homo sapiens
pH and temperature not specified in the publication
additional information
additional information
Homo sapiens
-
inhibition kinetics
-
additional information
additional information
Homo sapiens
pIC50 value of rosiridin for MAO B inhibition is 5.38, the pIC50 value for L-deprenyl is 7.23 for MAO B inhibition
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Powell, J.F.
Molecular biological studies of monoamine oxidase: structure and function
Biochem. Soc. Trans.
19
199-201
1991
Homo sapiens
brenda
Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.
High-level expression of human liver monoamine oxidase B in Pichia pastoris
Protein Expr. Purif.
20
334-345
2000
Bos taurus, Homo sapiens
brenda
Li, M.; Hubalek, F.; Newton-Vinson, P.; Edmondson, D.E.
High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae
Protein Expr. Purif.
24
152-162
2002
Homo sapiens, Homo sapiens (P21397)
brenda
Nandigama, R.K.; Miller, J.R.; Edmondson, D.E.
Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A
Biochemistry
40
14839-14846
2001
Homo sapiens
brenda
Ramsay, R.R.; Singer, T.P.
The kinetic mechanisms of monoamine oxidases A and B
Biochem. Soc. Trans.
19
219-223
1991
Bos taurus, Homo sapiens
brenda
Tipton, M.F.; Houslay, M.D.; Garrett, N.J.
Rapid screening assay for revertants derived from MSV-transformed cells
Nature
246
213-214
1973
Homo sapiens
brenda
Norstrand, I.F.; Glantz, M.D.
Purification and properties of human liver monoamine oxidase
Arch. Biochem. Biophys.
158
1-11
1973
Homo sapiens
brenda
Dennick, R.G.; Mayer, R.J.
Purification and immunochemical characterization of monoamine oxidase from rat and human liver
Biochem. J.
161
167-174
1977
Homo sapiens, Rattus norvegicus
brenda
Pearce, L.B.; Roth, J.A.
Human brain monoamine oxidase: solubilization and kinetics of inhibition by octylglucoside
Arch. Biochem. Biophys.
224
464-472
1983
Homo sapiens
brenda
Weyler, W.; Salach, J.I.
Purification and properties of mitochondrial monoamine oxidase type A from human placenta
J. Biol. Chem.
260
13199-13207
1985
Homo sapiens
brenda
Balsa, M.D.; Gomez, N.; Unzeta, M.
Characterization of monoamine oxidase activity present in human granulocytes and lymphocytes
Biochim. Biophys. Acta
992
140-144
1989
Homo sapiens
brenda
Ramsay, R.R.
Kinetic mechanism of monoamine oxidase A
Biochemistry
30
4624-4629
1991
Homo sapiens
brenda
Roth, J.A.; Eddy, B.J.
Kinetic properties of membrane-bound and Triton X-100-solubilized human brain monoamine oxidase
Arch. Biochem. Biophys.
205
260-266
1980
Homo sapiens
brenda
Gottowik, J.; Cesura, A.M.; Malherbe, P.; Lang, G.; Da Prada, M.
Characterization of wild-type and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line
FEBS Lett.
317
152-156
1993
Homo sapiens
brenda
Zhou, B.P.; Lewis, D.A.; Kwan, S.W.; Kirksey, T.J.; Abell, C.W.
Mutagenesis at a highly conserved tyrosine in monoamine oxidase B affects FAD incorporation and catalytic activity
Biochemistry
34
9526-9531
1995
Homo sapiens
brenda
Sablin, S.O.; Ramsay, R.R.
Monoamine oxidase contains a redox-active disulfide
J. Biol. Chem.
273
14074-14076
1998
Homo sapiens
brenda
Herraiz, T.; Chaparro, C.
Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors
Biochem. Biophys. Res. Commun.
326
378-386
2005
Homo sapiens
brenda
Ramsay, R.R.; Hunter, D.J.
Inhibitors alter the spectrum and redox properties of monoamine oxidase A
Biochim. Biophys. Acta
1601
178-184
2002
Homo sapiens
brenda
Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F.
Structure and mechanism of monoamine oxidase
Curr. Med. Chem.
11
1983-1993
2004
Homo sapiens
brenda
Ucar, G.
Substrate specificities of monoamine oxidase isoforms
FABAD J. Pharm. Sci.
27
149-156
2002
Homo sapiens, Rattus norvegicus
-
brenda
Binda, C.; Hubalek, F.; Li, M.; Edmondson, D.E.; Mattevi, A.
Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane
FEBS Lett.
564
225-228
2004
Homo sapiens (P27338), Homo sapiens
brenda
Ramonet, D.; Rodriguez, M.; Saura, J.; Lizcano, J.M.; Romera, M.; Unzeta, M.; Finch, C.; Billett, E.; Mahy, N.
Localization of monoamine oxidase A and B and semicarbazide-sensitive amine oxidase in human peripheral tissues
Inflammopharmacology
11
111-117
2003
Homo sapiens
brenda
Geha, R.M.; Chen, K.; Wouters, J.; Ooms, F.; Shih, J.C.
Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling
J. Biol. Chem.
277
17209-17216
2002
Homo sapiens
brenda
Markoglou, N.; Hsuesh, R.; Wainer, I.W.
Immobilized enzyme reactors based upon the flavoenzymes monoamine oxidase A and B
J. Chromatogr. B
804
295-302
2004
Homo sapiens
brenda
Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D.E.; Mattevi, A.
Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class
J. Med. Chem.
47
1767-1774
2004
Homo sapiens (P27338)
brenda
Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A.
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Nat. Struct. Biol.
9
22-26
2002
Homo sapiens (P27338), Homo sapiens
brenda
Dittmann, K.; Riese, U.; Hamburger, M.
HPLC-based bioactivity profiling of plant extracts: a kinetic assay for the identification of monoamine oxidase-A inhibitors using human recombinant monoamine oxidase-A
Phytochemistry
65
2885-2891
2004
Homo sapiens
brenda
Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A.
Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures
Proc. Natl. Acad. Sci. USA
100
9750-9755
2003
Homo sapiens
brenda
Ucar, G.; Tas, C.; Tuemer, A.
Monoamine oxidase inhibitory activities of the scorpion Mesobuthus gibbosus (Buthidae) venom peptides
Toxicon
45
43-52
2005
Homo sapiens, Rattus norvegicus
brenda
Jones, T.Z.; Fleming, P.; Eyermann, C.J.; Gravestock, M.B.; Ramsay, R.R.
Orientation of oxazolidinones in the active site of monoamine oxidase
Biochem. Pharmacol.
70
407-416
2005
Homo sapiens (P21397)
brenda
Li, M.; Binda, C.; Mattevi, A.; Edmondson, D.E.
Functional role of the "aromatic cage" in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins
Biochemistry
45
4775-4784
2006
Homo sapiens (P27338), Homo sapiens
brenda
Vintem, A.P.; Price, N.T.; Silverman, R.B.; Ramsay, R.R.
Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines
Bioorg. Med. Chem.
13
3487-3495
2005
Homo sapiens (P21397)
brenda
Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M.
Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity
Bioorg. Med. Chem.
13
4777-4788
2005
Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Rimoldi, J.M.; Puppali, S.G.; Isin, E.; Bissel, P.; Khalil, A.; Castagnoli, N.
A novel and selective monoamine oxidase B substrate
Bioorg. Med. Chem.
13
5808-5813
2005
Papio hamadryas, Homo sapiens (P21397)
brenda
Novaroli, L.; Reist, M.; Favre, E.; Carotti, A.; Catto, M.; Carrupt, P.A.
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening
Bioorg. Med. Chem.
13
6212-6217
2005
Homo sapiens (P27338), Homo sapiens
brenda
Toprakci, M.; Yelekci, K.
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds
Bioorg. Med. Chem. Lett.
15
4438-4446
2005
Homo sapiens (P27338)
brenda
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.
Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N-bis[2-oxo-2H-benzopyran]-3-carboxamides
Bioorg. Med. Chem. Lett.
16
4135-4140
2006
Homo sapiens (P21397), Homo sapiens (P27338), Bos taurus (P21398), Bos taurus (P56560)
brenda
Hubalek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E.
Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors
J. Biol. Chem.
280
15761-15766
2005
Equus caballus, Ovis aries, Rattus norvegicus (P19643), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens, Bos taurus (P56560), Bos taurus, Mus musculus (Q8BW75), Mus musculus
brenda
Ou, X.M.; Chen, K.; Shih, J.C.
Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1
J. Biol. Chem.
281
21512-21525
2006
Homo sapiens
brenda
Herraiz, T.; Chaparro, C.
Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee
Life Sci.
78
795-802
2006
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Lewitzka, U.; Mueller-Oerlinghausen, B.; Felber, W.; Brunner, J.; Hawellek, B.; Rujescu, D.; Ising, M.; Lauterbach, E.; Broocks, A.; Bondy, B.; Rao, M.L.; Frahnert, C.; Heuser, I.; Hohagen, F.; Maier, W.; Bronisch, T.
Is MAO-B activity in platelets associated with the occurrence of suicidality and behavioural personality traits in depressed patients?
Acta Psychiatr. Scand.
117
41-49
2008
Homo sapiens (P27338), Homo sapiens
brenda
Nilsson, K.W.; Sjoeberg, R.L.; Wargelius, H.L.; Leppert, J.; Lindstroem, L.; Oreland, L.
The monoamine oxidase A (MAO-A) gene, family function and maltreatment as predictors of destructive behaviour during male adolescent alcohol consumption
Addiction
102
389-398
2007
Homo sapiens (P21397), Homo sapiens
brenda
Bortolato, M.; Chen, K.; Shih, J.C.
Monoamine oxidase inactivation: From pathophysiology to therapeutics
Adv. Drug Deliv. Rev.
60
1527-1533
2008
Homo sapiens (P21397), Homo sapiens (P27338), Mus musculus (Q64133)
brenda
Berggren, U.; Eriksson, M.; Fahlke, C.; Blennow, K.; Balldin, J.
Different effects of smoking or use of smokeless tobacco on platelet MAO-B activity in type 1 alcohol-dependent subjects
Alcohol Alcohol.
42
267-271
2007
Homo sapiens (P27338), Homo sapiens
brenda
Pombo, S.; Levy, P.; Bicho, M.; Ismail, F.; Cardoso, J.M.
Neuropsychological function and platelet monoamine oxidase activity levels in type I alcoholic patients
Alcohol Alcohol.
43
423-430
2008
Homo sapiens (P27338), Homo sapiens
brenda
Rodriguez-Revenga, L.; Madrigal, I.; Alkhalidi, L.S.; Armengol, L.; Gonzalez, E.; Badenas, C.; Estivill, X.; Mila, M.
Contiguous deletion of the NDP, MAOA, MAOB, and EFHC2 genes in a patient with Norrie disease, severe psychomotor retardation and myoclonic epilepsy
Am. J. Med. Genet. A
143A
916-920
2007
Homo sapiens, Homo sapiens (P21397)
brenda
Li, J.; Kang, C.; Zhang, H.; Wang, Y.; Zhou, R.; Wang, B.; Guan, L.; Yang, L.; Faraone, S.V.
Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder
Am. J. Med. Genet. B Neuropsychiatr. Genet.
144B
430-433
2007
Homo sapiens (P21397), Homo sapiens
brenda
Li, J.; Wang, Y.; Hu, S.; Zhou, R.; Yu, X.; Wang, B.; Guan, L.; Yang, L.; Zhang, F.; Faraone, S.V.
The monoamine oxidase B gene exhibits significant association to ADHD
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147
370-374
2008
Homo sapiens (P21397), Homo sapiens
brenda
Li, D.; He, L.
Meta-study on association between the monoamine oxidase A gene (MAOA) and schizophrenia
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147B
174-178
2008
Homo sapiens (P21397), Homo sapiens
brenda
Prichard, Z.; Mackinnon, A.; Jorm, A.F.; Easteal, S.
No evidence for interaction between MAOA and childhood adversity for antisocial behavior
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147B
228-232
2008
Homo sapiens (P21397)
brenda
Philibert, R.A.; Gunter, T.D.; Beach, S.R.; Brody, G.H.; Madan, A.
MAOA methylation is associated with nicotine and alcohol dependence in women
Am. J. Med. Genet. B Neuropsychiatr. Genet.
147B
565-570
2008
Homo sapiens (P21397), Homo sapiens
brenda
Gao, X.; Scott, W.K.; Wang, G.; Mayhew, G.; Li, Y.J.; Vance, J.M.; Martin, E.R.
Gene-gene interaction between FGF20 and MAOB in Parkinson disease
Ann. Hum. Genet.
72
157-162
2008
Homo sapiens (P27338)
brenda
Palaska, E.; Aydin, F.; Ucar, G.; Erol, D.
Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole derivatives
Arch. Pharm.
341
209-215
2008
Rattus norvegicus (P21396), Homo sapiens (P27338), Homo sapiens
brenda
Lin, Y.M.; Davamani, F.; Yang, W.C.; Lai, T.J.; Sun, H.S.
Association analysis of monoamine oxidase A gene and bipolar affective disorder in Han Chinese
Behav. Brain Funct.
4
21
2008
Homo sapiens (P21397), Homo sapiens
brenda
Harkcom, W.T.; Bevan, D.R.
Molecular docking of inhibitors into monoamine oxidase B
Biochem. Biophys. Res. Commun.
360
401-406
2007
Homo sapiens (P27338)
brenda
Upadhyay, A.K.; Wang, J.; Edmondson, D.E.
Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms
Biochemistry
47
526-536
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Bour, S.; Daviaud, D.; Gres, S.; Lefort, C.; Prevot, D.; Zorzano, A.; Wabitsch, M.; Saulnier-Blache, J.S.; Valet, P.; Carpene, C.
Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes
Biochimie
89
916-925
2007
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Brummett, B.H.; Boyle, S.H.; Siegler, I.C.; Kuhn, C.M.; Surwit, R.S.; Garrett, M.E.; Collins, A.; Ashley-Koch, A.; Williams, R.B.
HPA axis function in male caregivers: Effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR)
Biol. Psychol.
79
250-255
2008
Homo sapiens (P21397)
brenda
Bissel, P.; Khalil, A.; Rimoldi, J.M.; Igarashi, K.; Edmondson, D.; Miller, A.; Castagnoli, N.
Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)- and (1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane
Bioorg. Med. Chem.
16
3557-3564
2008
Homo sapiens (P27338), Homo sapiens
brenda
Xu, X.; Brookes, K.; Chen, C.; Huang, Y.; Wu, Y.; Asherson, P.
Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples
BMC Psychiatry
7
10
2007
Homo sapiens (P21397), Homo sapiens
brenda
Malmberg, K.; Wargelius, H.L.; Lichtenstein, P.; Oreland, L.; Larsson, J.O.
ADHD and disruptive behavior scores - associations with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents
BMC Psychiatry
8
28
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Wu, Y.H.; Fischer, D.F.; Swaab, D.F.
A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimers disease patients
Brain Res.
1167
13-19
2007
Homo sapiens (P21397), Homo sapiens
brenda
Cerasa, A.; Gioia, M.C.; Fera, F.; Passamonti, L.; Liguori, M.; Lanza, P.; Muglia, M.; Magariello, A.; Quattrone, A.
Ventro-lateral prefrontal activity during working memory is modulated by MAO A genetic variation
Brain Res.
1201
114-121
2008
Homo sapiens (P21397)
brenda
Chen, J.J.; Swope, D.M.; Dashtipour, K.
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinsons disease
Clin. Ther.
29
1825-1849
2007
Homo sapiens (P27338), Homo sapiens
brenda
Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P.
Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target
Curr. Med. Chem.
15
1827-1839
2008
Rattus norvegicus, Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Zhao, H.; Nolley, R.; Chen, Z.; Reese, S.W.; Peehl, D.M.
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells
Differentiation
76
820-830
2008
Homo sapiens (P21397)
brenda
Nilsson, K.W.; Wargelius, H.L.; Sjoeberg, R.L.; Leppert, J.; Oreland, L.
The MAO-A gene, platelet MAO-B activity and psychosocial environment in adolescent female alcohol-related problem behaviour
Drug Alcohol Depend.
93
51-62
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Huang, S.Y.; Lin, M.T.; Shy, M.J.; Lin, W.W.; Lin, F.Y.; Lu, R.B.
Neither single-marker nor haplotype analyses support an association between monoamine oxidase A gene and bipolar disorder
Eur. Arch. Psychiatry Clin. Neurosci.
258
350-356
2008
Homo sapiens (P21397)
brenda
De Luca, V.; Tharmaligam, S.; Strauss, J.; Kennedy, J.L.
5-ht2c receptor and mao-a interaction analysis: no association with suicidal behaviour in bipolar patients
Eur. Arch. Psychiatry Clin. Neurosci.
258
428-433
2008
Homo sapiens (P21397), Homo sapiens
brenda
Reif, A.; Scarpini, E.; Venturelli, E.; Toepner, T.; Fenoglio, C.; Lesch, K.P.; Galimberti, D.
The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia
Eur. J. Neurol.
15
637-639
2008
Homo sapiens (P21397), Homo sapiens
brenda
Izumi, T.; Iwamoto, N.; Kitaichi, Y.; Kato, A.; Inoue, T.; Koyama, T.
Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats
Eur. J. Pharmacol.
565
105-112
2007
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Ballesteros, J.; Maeztu, A.I.; Callado, L.F.; Meana, J.J.; Gutierrez, M.
Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death
Eur. Neuropsychopharmacol.
18
55-61
2008
Homo sapiens (P27338)
brenda
Arrojo, M.; Baca-Garcia, E.; Perez-Rodriguez, M.M.; Dolengevich-Segal, H.; Navio-Acosta, M.; Rodriguez-Salgado, B.; Saiz-Ruiz, J.
Platelet monoamine oxidase activity in obsessive-compulsive disorder
Eur. Psychiatry
22
525-529
2007
Homo sapiens
brenda
Akkermann, K.; Paaver, M.; Nordquist, N.; Oreland, L.; Harro, J.
Association of 5-HTT gene polymorphism, platelet MAO activity, and drive for thinness in a population-based sample of adolescent girls
Int. J. Eat. Disord.
41
399-404
2008
Homo sapiens
brenda
Herraiz, T.
Identification and occurrence of beta-carboline alkaloids in raisins and inhibition of monoamine oxidase (MAO)
J. Agric. Food Chem.
55
8534-8540
2007
Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Kay, C.W.; El Mkami, H.; Molla, G.; Pollegioni, L.; Ramsay, R.R.
Characterization of the covalently bound anionic flavin radical in monoamine oxidase A by electron paramagnetic resonance
J. Am. Chem. Soc.
129
16091-16097
2007
Homo sapiens (P21397)
brenda
Leonetti, F.; Capaldi, C.; Pisani, L.; Nicolotti, O.; Muncipinto, G.; Stefanachi, A.; Cellamare, S.; Caccia, C.; Carotti, A.
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase
J. Med. Chem.
50
4909-4916
2007
Homo sapiens (P27338)
brenda
Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A.
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs
J. Med. Chem.
50
5848-5852
2007
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cardia, M.C.; Distinto, S.
Selective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivatives
J. Med. Chem.
50
707-712
2007
Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Akyuez, M.A.; Erdem, S.S.; Edmondson, D.E.
The aromatic cage in the active site of monoamine oxidase B: effect on the structural and electronic properties of bound benzylamine and p-nitrobenzylamine
J. Neural Transm.
114
693-698
2007
Homo sapiens (P27338)
brenda
Cruz, F.; Edmondson, D.E.
Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks
J. Neural Transm.
114
699-702
2007
Homo sapiens (P21397), Homo sapiens
brenda
Nordquist, N.; Oreland, L.
Monoallelic expression of MAO-A in skin fibroblasts
J. Neural Transm.
114
713-716
2007
Homo sapiens (P21397)
brenda
Wang, J.; Edmondson, D.E.
Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-As
J. Neural Transm.
114
721-724
2007
Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens
brenda
Alia-Klein, N.; Goldstein, R.Z.; Kriplani, A.; Logan, J.; Tomasi, D.; Williams, B.; Telang, F.; Shumay, E.; Biegon, A.; Craig, I.W.; Henn, F.; Wang, G.J.; Volkow, N.D.; Fowler, J.S.
Brain monoamine oxidase A activity predicts trait aggression
J. Neurosci.
28
5099-5104
2008
Homo sapiens (P21397), Homo sapiens
brenda
ORourke, A.M.; Wang, E.Y.; Miller, A.; Podar, E.M.; Scheyhing, K.; Huang, L.; Kessler, C.; Gao, H.; Ton-Nu, H.T.; Macdonald, M.T.; Jones, D.S.; Linnik, M.D.
Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity
J. Pharmacol. Exp. Ther.
324
867-875
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Baler, R.D.; Volkow, N.D.; Fowler, J.S.; Benveniste, H.
Is fetal brain monoamine oxidase inhibition the missing link between maternal smoking and conduct disorders?
J. Psychiatry Neurosci.
33
187-195
2008
Homo sapiens (P21397), Homo sapiens
brenda
Gabilondo, A.M.; Hostalot, C.; Garibi, J.M.; Meana, J.J.; Callado, L.F.
Monoamine oxidase B activity is increased in human gliomas
Neurochem. Int.
52
230-234
2008
Homo sapiens (P27338), Homo sapiens
brenda
Cicin-Sain, L.; Matosic, A.; Mokrovic, G.; Balija, M.; Marusic, S.; Jernej, B.
Platelet monoamine oxidase kinetics, alcoholism subtypes and cigarette smoking
Neuropsychobiology
56
138-145
2007
Homo sapiens (P27338), Homo sapiens
brenda
Kersting, A.; Kroker, K.; Horstmann, J.; Baune, B.T.; Hohoff, C.; Mortensen, L.S.; Neumann, L.C.; Arolt, V.; Domschke, K.
Association of MAO-A variant with complicated grief in major depression
Neuropsychobiology
56
191-196
2007
Homo sapiens (P21397), Homo sapiens
brenda
Sjoeberg, R.L.; Ducci, F.; Barr, C.S.; Newman, T.K.; Dellosso, L.; Virkkunen, M.; Goldman, D.
A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior
Neuropsychopharmacology
33
425-430
2008
Homo sapiens (P21397), Homo sapiens
brenda
Frazzetto, G.; Di Lorenzo, G.; Carola, V.; Proietti, L.; Sokolowska, E.; Siracusano, A.; Gross, C.; Troisi, A.
Early trauma and increased risk for physical aggression during adulthood: the moderating role of MAOA genotype
PLoS ONE
2
e486
2007
Homo sapiens (P21397), Homo sapiens
brenda
Mallajosyula, J.K.; Kaur, D.; Chinta, S.J.; Rajagopalan, S.; Rane, A.; Nicholls, D.G.; Di Monte, D.A.; Macarthur, H.; Andersen, J.K.
MAO-B elevation in mouse brain astrocytes results in Parkinsons pathology
PLoS ONE
3
e1616
2008
Homo sapiens (P27338), Homo sapiens
brenda
Culpepper, L.; Kovalick, L.J.
A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression
Prim. Care Companion J. Clin. Psychiatry
10
25-30
2008
Homo sapiens
brenda
Tadic, A.; Rujescu, D.; Mueller, M.J.; Kohnen, R.; Stassen, H.H.; Dahmen, N.; Szegedi, A.
A monoamine oxidase B gene variant and short-term antidepressant treatment response
Prog. Neuropsychopharmacol. Biol. Psychiatry
31
1370-1377
2007
Homo sapiens (P27338), Homo sapiens
brenda
Muck-Seler, D.; Sagud, M.; Mustapic, M.; Nedic, G.; Babic, A.; Mihaljevic Peles, A.; Jakovljevic, M.; Pivac, N.
The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression
Prog. Neuropsychopharmacol. Biol. Psychiatry
32
1195-1198
2008
Homo sapiens (P27338), Homo sapiens
brenda
Domschke, K.; Hohoff, C.; Mortensen, L.S.; Roehrs, T.; Deckert, J.; Arolt, V.; Baune, B.T.
Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression
Prog. Neuropsychopharmacol. Biol. Psychiatry
32
224-228
2008
Homo sapiens (P21397), Homo sapiens
brenda
Lee, B.C.; Yang, J.W.; Lee, S.H.; Kim, S.H.; Joe, S.H.; Jung, I.K.; Choi, I.G.; Ham, B.J.
An interaction between the norepinephrine transporter and monoamine oxidase A polymorphisms, and novelty-seeking personality traits in Korean females
Prog. Neuropsychopharmacol. Biol. Psychiatry
32
238-242
2008
Homo sapiens (P21397)
brenda
Alia-Klein, N.; Kriplani, A.; Pradhan, K.; Ma, J.Y.; Logan, J.; Williams, B.; Craig, I.W.; Telang, F.; Tomasi, D.; Goldstein, R.Z.; Wang, G.J.; Volkow, N.D.; Fowler, J.S.
The MAO-A genotype does not modulate resting brain metabolism in adults
Psychiatry Res.
164
73-76
2008
Homo sapiens (P21397)
brenda
Guersoy, S.; Erdal, E.; Sezgin, M.; Barlas, I.O.; Aydeniz, A.; Alasehirli, B.; Sahin, G.
Which genotype of MAO gene that the patients have are likely to be most susceptible to the symptoms of fibromyalgia?
Rheumatol. Int.
28
307-311
2008
Homo sapiens (P21397), Homo sapiens
brenda
Lecht, S.; Haroutiunian, S.; Hoffman, A.; Lazarovici, P.
Rasagiline - a novel MAO B inhibitor in Parkinsons disease therapy
Ther. Clin. Risk Manag.
3
467-474
2007
Homo sapiens (P27338), Homo sapiens
brenda
Buckholtz, J.W.; Meyer-Lindenberg, A.
MAOA and the neurogenetic architecture of human aggression
Trends Neurosci.
31
120-129
2008
Homo sapiens (P21397)
brenda
Upadhyay, A.K.; Borbat, P.P.; Wang, J.; Freed, J.H.; Edmondson, D.E.
Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-D-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy
Biochemistry
47
1554-1566
2008
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; Edmondson, D.E.
Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B
Biochemistry
47
5616-5625
2008
Homo sapiens, Homo sapiens (P27338)
brenda
Upadhyay, A.K.; Edmondson, D.E.
Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B
Biochemistry
48
3928-3935
2009
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Gooden, D.M.; Schmidt, D.M.; Pollock, J.A.; Kabadi, A.M.; McCafferty, D.G.
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B
Bioorg. Med. Chem. Lett.
18
3047-3051
2008
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Van der Walt, E.M.; Milczek, E.M.; Malan, S.F.; Edmondson, D.E.; Castagnoli, N.; Bergh, J.J.; Petzer, J.P.
Inhibition of monoamine oxidase by (E)-styrylisatin analogues
Bioorg. Med. Chem. Lett.
19
2509-2513
2009
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Zhao, H.; Flamand, V.; Peehl, D.M.
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells
BMC Med. Genomics
2
55
2009
Homo sapiens
brenda
Wu, J.B.; Chen, K.; Li, Y.; Lau, Y.F.; Shih, J.C.
Regulation of monoamine oxidase A by the SRY gene on the Y chromosome
FASEB J.
23
4029-4038
2009
Homo sapiens (P21397), Homo sapiens
brenda
Dunn, R.V.; Marshall, K.R.; Munro, A.W.; Scrutton, N.S.
The pH dependence of kinetic isotope effects in monoamine oxidase A indicates stabilization of the neutral amine in the enzyme-substrate complex
FEBS J.
275
3850-3858
2008
Homo sapiens (P21397)
brenda
Wang, J.; Harris, J.; Mousseau, D.D.; Edmondson, D.E.
Mutagenic probes of the role of Ser209 on the cavity shaping loop of human monoamine oxidase A
FEBS J.
276
4569-4581
2009
Homo sapiens (P21397), Homo sapiens
brenda
van Diermen, D.; Marston, A.; Bravo, J.; Reist, M.; Carrupt, P.A.; Hostettmann, K.
Monoamine oxidase inhibition by Rhodiola rosea L. roots
J. Ethnopharmacol.
122
397-401
2009
Homo sapiens (P27338)
brenda
Milczek, E.M.; Bonivento, D.; Binda, C.; Mattevi, A.; McDonald, I.A.; Edmondson, D.E.
Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B
J. Med. Chem.
51
8019-8026
2008
Homo sapiens (P27338), Homo sapiens
brenda
Yoo, H.J.; Lee, S.K.; Park, M.; Cho, I.H.; Hyun, S.H.; Lee, J.C.; Yang, S.Y.; Kim, S.A.
Family- and population-based association studies of monoamine oxidase A and autism spectrum disorders in Korean
Neurosci. Res.
63
172-176
2009
Homo sapiens
brenda
Petzer, J.P.; Castagnoli, N.; Schwarzschild, M.A.; Chen, J.F.; Van der Schyf, C.J.
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinsons disease
Neurotherapeutics
6
141-151
2009
Mus musculus, Homo sapiens (P27338)
brenda
van der Vegt, E.J.; Oostra, B.A.; Arias-Vasquez, A.; van der Ende, J.; Verhulst, F.C.; Tiemeier, H.
High activity of monoamine oxidase A is associated with externalizing behaviour in maltreated and nonmaltreated adoptees
Psychiatr. Genet.
19
209-211
2009
Homo sapiens
brenda
Saidemberg, D.M.; Ferreira, M.A.; Takahashi, T.N.; Gomes, P.C.; Cesar-Tognoli, L.M.; da Silva-Filho, L.C.; Tormena, C.F.; da Silva, G.V.; Palma, M.S.
Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I
Toxicon
54
717-724
2009
Homo sapiens
brenda
Ravikumar, K.; Sridhar, B.
Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B
Acta Crystallogr. Sect. C
66
o317-o320
2010
Homo sapiens
brenda
Shen, H.W.; Wu, C.; Jiang, X.L.; Yu, A.M.
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics
Biochem. Pharmacol.
80
122-128
2010
Homo sapiens, Mus musculus
brenda
Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A.
Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases
Biochemistry
48
4220-4230
2009
Bos taurus, Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Jia, Z.; Wei, S.; Zhu, Q.
Monoamine oxidase inhibitors: benzylidene-prop-2-ynyl-amines analogues
Biol. Pharm. Bull.
33
725-728
2010
Homo sapiens
brenda
Alcaro, S.; Gaspar, A.; Ortuso, F.; Milhazes, N.; Orallo, F.; Uriarte, E.; Yanez, M.; Borges, F.
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B
Bioorg. Med. Chem. Lett.
20
2709-2712
2010
Homo sapiens
brenda
Geldenhuys, W.J.; Darvesh, A.S.; Funk, M.O.; Van der Schyf, C.J.; Carroll, R.T.
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening
Bioorg. Med. Chem. Lett.
20
5295-5298
2010
Homo sapiens (P27338), Homo sapiens
brenda
Strydom, B.; Malan, S.F.; Castagnoli, N.; Bergh, J.J.; Petzer, J.P.
Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues
Bioorg. Med. Chem.
18
1018-1028
2010
Homo sapiens, Papio anubis
brenda
Luehr, S.; Vilches-Herrera, M.; Fierro, A.; Ramsay, R.R.; Edmondson, D.E.; Reyes-Parada, M.; Cassels, B.K.; Iturriaga-Vasquez, P.
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors
Bioorg. Med. Chem.
18
1388-1395
2010
Homo sapiens, Rattus norvegicus
brenda
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Maccioni, E.; Cardia, M.C.; Yanez, M.; Orallo, F.; Alcaro, S.; Ortuso, F.; Cirilli, R.; Ferretti, R.; Distinto, S.; Kirchmair, J.; Langer, T.
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors
Bioorg. Med. Chem.
18
5063-5070
2010
Homo sapiens
brenda
Chimenti, F.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors
Bioorg. Med. Chem.
18
5715-5723
2010
Homo sapiens
brenda
Ke, S.; Qian, X.; Liu, F.; Wang, N.; Yang, Q.; Li, Z.
Novel 4H-1,3,4-oxadiazin-5(6H)-ones with hydrophobic and long alkyl chains: design, synthesis, and bioactive diversity on inhibition of monoamine oxidase, chitin biosynthesis and tumor cell
Eur. J. Med. Chem.
44
2113-2121
2009
Homo sapiens
brenda
Prins, L.H.; Petzer, J.P.; Malan, S.F.
Inhibition of monoamine oxidase by indole and benzofuran derivatives
Eur. J. Med. Chem.
45
4458-4466
2010
Homo sapiens (P27338)
brenda
Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C.; Distinto, S.; Costa, G.; Yanez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D.
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase
Eur. J. Med. Chem.
45
4490-4498
2010
Homo sapiens
brenda
Herraiz, T.; Gonzalez, D.; Ancin-Azpilicueta, C.; Aran, V.J.; Guillen, H.
beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)
Food Chem. Toxicol.
48
839-845
2010
Homo sapiens
brenda
Herraiz, T.; Aran, V.J.; Guillen, H.
Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO)
Free Radic. Res.
43
975-984
2009
Homo sapiens
brenda
Hu, K.; Zhang, L.; Li, X.; Zhao, S.
Rapid screening of monoamine oxidase B inhibitors in natural extracts by capillary electrophoresis after enzymatic reaction at capillary inlet
J. Chromatogr. B
878
3156-3160
2010
Homo sapiens
brenda
Goren, T.; Adar, L.; Sasson, N.; Weiss, Y.M.
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline
J. Clin. Pharmacol.
50
1420-1428
2010
Homo sapiens
brenda
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins
J. Med. Chem.
52
1935-1942
2009
Homo sapiens
brenda
Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.
Chalcones: a valid scaffold for monoamine oxidases inhibitors
J. Med. Chem.
52
2818-2824
2009
Homo sapiens
brenda
Dreiseitel, A.; Korte, G.; Schreier, P.; Oehme, A.; Locher, S.; Domani, M.; Hajak, G.; Sand, P.G.
Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B
Pharmacol. Res.
59
306-311
2009
Homo sapiens
brenda
Ramsay, R.R.; Olivieri, A.; Holt, A.
An improved approach to steady-state analysis of monoamine oxidases
J. Neural Transm.
118
1003-1019
2011
Homo sapiens (P27338)
brenda
McDonald, G.R.; Olivieri, A.; Ramsay, R.R.;, Holt, A.
On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B
Pharmacol. Res.
62
475-488
2010
Homo sapiens (P27338), Homo sapiens
brenda
Carroll, R.T.; Dluzen, D.E.; Stinnett, H.; Awale, P.S.; Funk, M.O.; Geldenhuys, W.J.
Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B
Bioorg. Med. Chem. Lett.
21
4798-4803
2011
Homo sapiens
brenda
Milczek, E.M.; Binda, C.; Rovida, S.; Mattevi, A.; Edmondson, D.E.
The gating residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition
FEBS J.
278
4860-4869
2011
Homo sapiens
brenda
Mathew, B.; Mathew, G.E.; Ucar, G.; Baysal, I.; Suresh, J.; Vilapurathu, J.K.; Prakasan, A.; Suresh, J.K.; Thomas, A.
Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors Synthesis, biochemistry and molecular docking studies
Bioorg. Chem.
62
22-29
2015
Homo sapiens (P27338), Homo sapiens
brenda
Sun, Y.; Chen, J.; Chen, X.; Huang, L.; Li, X.
Inhibition of cholinesterase and monoamine oxidase-B activity by tacrine-homoisoflavonoid hybrids
Bioorg. Med. Chem.
21
7406-7417
2013
Homo sapiens (P27338), Homo sapiens
brenda
Tzvetkov, N.T.; Stammler, H.G.; Neumann, B.; Hristova, S.; Antonov, L.; Gastreich, M.
Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors
Eur. J. Med. Chem.
127
470-492
2017
Rattus norvegicus (P19643), Rattus norvegicus (P21396), Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Bonaiuto, E.; Milelli, A.; Cozza, G.; Tumiatti, V.; Marchetti, C.; Agostinelli, E.; Fimognari, C.; Hrelia, P.; Minarini, A.; Di Paolo, M.L.
Novel polyamine analogues from substrates towards potential inhibitors of monoamine oxidases
Eur. J. Med. Chem.
70
88-101
2013
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Dasgupta, S.; Mukherjee, S.; Mukhopadhyay, B.P.; Banerjee, A.; Mishra, D.K.
Recognition dynamics of dopamine to human monoamine oxidase B role of Leu171/Gln206 and conserved water molecules in the active site cavity
J. Biomol. Struct. Dyn.
24
1-24
2017
Homo sapiens (P27338), Homo sapiens
brenda
Chaudhuri, A.D.; Yelamanchili, S.V.; Fox, H.S.
MicroRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1
PLoS ONE
8
e79579
2013
Homo sapiens
brenda
Qazi, S.; Naz, A.; Hameed, A.; Osra, F.; Jalil, S.; Iqbal, J.; Shah, S.; Mirza, A.
Semicarbazones, thiosemicarbazone, thiazole and oxazole analogues as monoamine oxidase inhibitors Synthesis, characterization, biological evaluation, molecular docking, and kinetic studies
Bioorg. Chem.
115
116165
2021
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Ahmad, S.; Zaib, S.; Jalil, S.; Shafiq, M.; Ahmad, M.; Sultan, S.; Iqbal, M.; Aslam, S.; Iqbal, J.
Synthesis, characterization, monoamine oxidase inhibition, molecular docking and dynamic simulations of novel 2,1-benzothiazine-2,2-dioxide derivatives
Bioorg. Chem.
80
498-510
2018
Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Qhobosheane, M.; Legoabe, L.; Petzer, A.; Petzer, J.
The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone
Bioorg. Chem.
85
60-65
2019
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Cheng, K.; Li, S.; Lv, X.; Tian, Y.; Kong, H.; Huang, X.; Duan, Y.; Han, J.; Xie, Z.; Liao, C.
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure
Bioorg. Med. Chem. Lett.
29
1012-1018
2019
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Chirkova, Z.; Kabanova, M.; Filimonov, S.; Abramov, I.; Petzer, A.; Engelbrecht, I.; Petzer, J.; Yu Suponitsky, K.; Veselovsky, A.
An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4-f]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives
Drug Dev. Res.
79
81-93
2018
Homo sapiens (P21397), Homo sapiens (P27338)
brenda
Herraiz, T.; Flores, A.; Fernandez, L.
Analysis of monoamine oxidase (MAO) enzymatic activity by high-performance liquid chromatography-diode array detection combined with an assay of oxidation with a peroxidase and its application to MAO inhibitors from foods and plants
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
1073
136-144
2018
Homo sapiens (P21397), Homo sapiens (P27338), Homo sapiens
brenda
Reis, J.; Manzella, N.; Cagide, F.; Mialet-Perez, J.; Uriarte, E.; Parini, A.; Borges, F.; Binda, C.
Tight-binding inhibition of human monoamine oxidase B by chromone analogs a kinetic, crystallographic, and biological analysis
J. Med. Chem.
61
4203-4212
2018
Homo sapiens (P27338), Homo sapiens
brenda
Yang, D.; Wang, R.; Zhu, J.; Cao, Q.; Qin, J.; Zhu, H.; Qian, S.
Synthesis, crystal structures, molecular docking, vitro monoamine oxidase-B inhibitory activity of transition metal complexes with 2-{4-[bis (4-fluorophenyl)methyl]piperazin-1-yl} acetic acid
J. Mol. Struct.
1128
493-498
2017
Rattus norvegicus (P19643), Homo sapiens (P27338)
-
brenda
Ramsay, R.; Albreht, A.
Kinetics, mechanism, and inhibition of monoamine oxidase
J. Neural Transm.
125
1659-1683
2018
Homo sapiens (P21397), Homo sapiens (P27338)
brenda